id	sid	tid	token	lemma	pos
njb-27	1	1	nepal	nepal	ADJ
njb-27	1	2	journal	journal	NOUN
njb-27	1	3	of	of	ADP
njb-27	1	4	biotechnology	biotechnology	NOUN
njb-27	1	5	.	.	PUNCT
njb-27	2	1	d	d	X
njb-27	2	2	e	e	PROPN
njb-27	2	3	c	c	PROPN
njb-27	2	4	.	.	PUNCT
njb-27	3	1	2	2	NUM
njb-27	3	2	0	0	NUM
njb-27	3	3	1	1	NUM
njb-27	3	4	6	6	NUM
njb-27	3	5	vol	vol	NOUN
njb-27	3	6	.	.	PROPN
njb-27	4	1	4	4	NUM
njb-27	4	2	,	,	PUNCT
njb-27	4	3	no	no	NOUN
njb-27	4	4	.	.	NOUN
njb-27	4	5	1	1	NUM
njb-27	4	6	:	:	SYM
njb-27	4	7	18	18	NUM
njb-27	4	8	-	-	SYM
njb-27	4	9	25	25	NUM
njb-27	4	10	issn	issn	PROPN
njb-27	4	11	2091	2091	NUM
njb-27	4	12	-	-	SYM
njb-27	4	13	1130(print)/issn	1130(print)/issn	NUM
njb-27	4	14	2467	2467	NUM
njb-27	4	15	-	-	SYM
njb-27	4	16	9319	9319	NUM
njb-27	4	17	(	(	PUNCT
njb-27	4	18	online	online	ADJ
njb-27	4	19	)	)	PUNCT
njb-27	4	20	original	original	ADJ
njb-27	4	21	research	research	NOUN
njb-27	4	22	article	article	NOUN
njb-27	4	23	©	©	PROPN
njb-27	4	24	njb	njb	PROPN
njb-27	4	25	,	,	PUNCT
njb-27	4	26	biotechnology	biotechnology	NOUN
njb-27	4	27	society	society	NOUN
njb-27	4	28	of	of	ADP
njb-27	4	29	nepal	nepal	ADJ
njb-27	4	30	18	18	NUM
njb-27	4	31	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	4	32	detection	detection	NOUN
njb-27	4	33	of	of	ADP
njb-27	4	34	latent	latent	ADJ
njb-27	4	35	hiv-1	hiv-1	PUNCT
njb-27	4	36	infection	infection	NOUN
njb-27	4	37	and	and	CCONJ
njb-27	4	38	drug	drug	NOUN
njb-27	4	39	resistant	resistant	ADJ
njb-27	4	40	mutation	mutation	NOUN
njb-27	4	41	testing	testing	NOUN
njb-27	4	42	in	in	ADP
njb-27	4	43	nepal	nepal	NOUN
njb-27	4	44	:	:	PUNCT
njb-27	4	45	hiv-1	hiv-1	PUNCT
njb-27	4	46	env	env	NOUN
njb-27	4	47	v3	v3	PROPN
njb-27	4	48	dna	dna	PROPN
njb-27	4	49	sequence	sequence	NOUN
njb-27	4	50	and	and	CCONJ
njb-27	4	51	rt	rt	PROPN
njb-27	4	52	gene	gene	NOUN
njb-27	4	53	(	(	PUNCT
njb-27	4	54	m184v	m184v	PROPN
njb-27	4	55	)	)	PUNCT
njb-27	4	56	mutation	mutation	NOUN
njb-27	4	57	rupendra	rupendra	X
njb-27	4	58	shrestha1,2	shrestha1,2	PROPN
njb-27	4	59	*	*	PROPN
njb-27	4	60	,	,	PUNCT
njb-27	4	61	sundar	sundar	PROPN
njb-27	4	62	khadka1,2	khadka1,2	PROPN
njb-27	4	63	,	,	PUNCT
njb-27	4	64	susbin	susbin	PROPN
njb-27	4	65	raj	raj	PROPN
njb-27	5	1	wagle1,2	wagle1,2	PROPN
njb-27	5	2	,	,	PUNCT
njb-27	5	3	alisha	alisha	PROPN
njb-27	5	4	sapkota1,2	sapkota1,2	PROPN
njb-27	5	5	1department	1department	NUM
njb-27	5	6	of	of	ADP
njb-27	5	7	laboratory	laboratory	NOUN
njb-27	5	8	medicine	medicine	NOUN
njb-27	5	9	,	,	PUNCT
njb-27	5	10	nobel	nobel	PROPN
njb-27	5	11	college	college	PROPN
njb-27	5	12	,	,	PUNCT
njb-27	5	13	sinamangal	sinamangal	ADJ
njb-27	5	14	,	,	PUNCT
njb-27	5	15	kathmandu	kathmandu	NOUN
njb-27	5	16	,	,	PUNCT
njb-27	5	17	nepal	nepal	ADJ
njb-27	5	18	.	.	PUNCT
njb-27	6	1	2center	2center	NUM
njb-27	6	2	for	for	ADP
njb-27	6	3	molecular	molecular	ADJ
njb-27	6	4	dynamics	dynamic	NOUN
njb-27	6	5	nepal	nepal	ADJ
njb-27	6	6	(	(	PUNCT
njb-27	6	7	cmdn	cmdn	PROPN
njb-27	6	8	)	)	PUNCT
njb-27	6	9	,	,	PUNCT
njb-27	6	10	thapathali-11	thapathali-11	X
njb-27	6	11	,	,	PUNCT
njb-27	6	12	kathmandu	kathmandu	NOUN
njb-27	6	13	,	,	PUNCT
njb-27	6	14	nepal	nepal	ADJ
njb-27	6	15	.	.	PUNCT
njb-27	7	1	abstract	abstract	ADJ
njb-27	7	2	hiv-1	hiv-1	PUNCT
njb-27	7	3	resistance	resistance	NOUN
njb-27	7	4	to	to	ADP
njb-27	7	5	antiretroviral	antiretroviral	ADJ
njb-27	7	6	therapy	therapy	NOUN
njb-27	7	7	(	(	PUNCT
njb-27	7	8	art	art	NOUN
njb-27	7	9	)	)	PUNCT
njb-27	7	10	is	be	AUX
njb-27	7	11	a	a	DET
njb-27	7	12	crucial	crucial	ADJ
njb-27	7	13	issue	issue	NOUN
njb-27	7	14	,	,	PUNCT
njb-27	7	15	despite	despite	SCONJ
njb-27	7	16	various	various	ADJ
njb-27	7	17	effective	effective	ADJ
njb-27	7	18	drugs	drug	NOUN
njb-27	7	19	are	be	AUX
njb-27	7	20	available	available	ADJ
njb-27	7	21	for	for	ADP
njb-27	7	22	the	the	DET
njb-27	7	23	treatment	treatment	NOUN
njb-27	7	24	.	.	PUNCT
njb-27	8	1	although	although	SCONJ
njb-27	8	2	the	the	DET
njb-27	8	3	viral	viral	ADJ
njb-27	8	4	rna	rna	NOUN
njb-27	8	5	is	be	AUX
njb-27	8	6	suppressed	suppress	VERB
njb-27	8	7	below	below	ADP
njb-27	8	8	the	the	DET
njb-27	8	9	detection	detection	NOUN
njb-27	8	10	limit	limit	NOUN
njb-27	8	11	(	(	PUNCT
njb-27	8	12	<	<	X
njb-27	8	13	50	50	NUM
njb-27	8	14	copies	copy	NOUN
njb-27	8	15	/	/	SYM
njb-27	8	16	ml	ml	PROPN
njb-27	8	17	)	)	PUNCT
njb-27	8	18	with	with	ADP
njb-27	8	19	the	the	DET
njb-27	8	20	use	use	NOUN
njb-27	8	21	of	of	ADP
njb-27	8	22	potent	potent	ADJ
njb-27	8	23	antiviral	antiviral	ADJ
njb-27	8	24	drugs	drug	NOUN
njb-27	8	25	,	,	PUNCT
njb-27	8	26	the	the	DET
njb-27	8	27	mutation	mutation	NOUN
njb-27	8	28	can	can	AUX
njb-27	8	29	be	be	AUX
njb-27	8	30	archived	archive	VERB
njb-27	8	31	in	in	ADP
njb-27	8	32	the	the	DET
njb-27	8	33	cellular	cellular	ADJ
njb-27	8	34	reservoir	reservoir	NOUN
njb-27	8	35	as	as	ADP
njb-27	8	36	proviral	proviral	ADJ
njb-27	8	37	dna	dna	PROPN
njb-27	8	38	.	.	PUNCT
njb-27	9	1	the	the	DET
njb-27	9	2	detection	detection	NOUN
njb-27	9	3	of	of	ADP
njb-27	9	4	proviral	proviral	ADJ
njb-27	9	5	dna	dna	NOUN
njb-27	9	6	and	and	CCONJ
njb-27	9	7	mutation	mutation	NOUN
njb-27	9	8	screening	screening	NOUN
njb-27	9	9	in	in	ADP
njb-27	9	10	hiv	hiv	PROPN
njb-27	9	11	1	1	NUM
njb-27	9	12	rna	rna	NOUN
njb-27	9	13	for	for	ADP
njb-27	9	14	genotypic	genotypic	ADJ
njb-27	9	15	resistance	resistance	NOUN
njb-27	9	16	is	be	AUX
njb-27	9	17	the	the	DET
njb-27	9	18	sole	sole	ADJ
njb-27	9	19	basis	basis	NOUN
njb-27	9	20	for	for	ADP
njb-27	9	21	monitoring	monitor	VERB
njb-27	9	22	the	the	DET
njb-27	9	23	effectiveness	effectiveness	NOUN
njb-27	9	24	of	of	ADP
njb-27	9	25	art	art	NOUN
njb-27	9	26	.	.	PUNCT
njb-27	10	1	our	our	PRON
njb-27	10	2	study	study	NOUN
njb-27	10	3	aim	aim	VERB
njb-27	10	4	to	to	PART
njb-27	10	5	access	access	VERB
njb-27	10	6	the	the	DET
njb-27	10	7	extent	extent	NOUN
njb-27	10	8	of	of	ADP
njb-27	10	9	latent	latent	ADJ
njb-27	10	10	hiv	hiv	PROPN
njb-27	10	11	infections	infection	NOUN
njb-27	10	12	by	by	ADP
njb-27	10	13	detecting	detect	VERB
njb-27	10	14	env	env	NOUN
njb-27	10	15	v3	v3	PROPN
njb-27	10	16	dna	dna	PROPN
njb-27	10	17	and	and	CCONJ
njb-27	10	18	also	also	ADV
njb-27	10	19	testing	testing	NOUN
njb-27	10	20	of	of	ADP
njb-27	10	21	m184v	m184v	PROPN
njb-27	10	22	(	(	PUNCT
njb-27	10	23	meth184val	meth184val	ADJ
njb-27	10	24	;	;	PUNCT
njb-27	10	25	atg	atg	PROPN
njb-27	10	26	gtg	gtg	PROPN
njb-27	10	27	substitution	substitution	NOUN
njb-27	10	28	at	at	ADP
njb-27	10	29	184th	184th	PROPN
njb-27	10	30	codon	codon	PROPN
njb-27	10	31	)	)	PUNCT
njb-27	10	32	specific	specific	ADJ
njb-27	10	33	mutations	mutation	NOUN
njb-27	10	34	in	in	ADP
njb-27	10	35	hiv-1	hiv-1	PUNCT
njb-27	10	36	rt	rt	PROPN
njb-27	10	37	gene	gene	NOUN
njb-27	10	38	to	to	PART
njb-27	10	39	monitor	monitor	VERB
njb-27	10	40	the	the	DET
njb-27	10	41	effectiveness	effectiveness	NOUN
njb-27	10	42	of	of	ADP
njb-27	10	43	art	art	NOUN
njb-27	10	44	.	.	PUNCT
njb-27	11	1	the	the	DET
njb-27	11	2	hiv-1	hiv-1	PUNCT
njb-27	11	3	env	env	NOUN
njb-27	11	4	v3	v3	PROPN
njb-27	11	5	dna	dna	PROPN
njb-27	11	6	sequence	sequence	NOUN
njb-27	11	7	was	be	AUX
njb-27	11	8	amplified	amplify	VERB
njb-27	11	9	using	use	VERB
njb-27	11	10	multiple	multiple	ADJ
njb-27	11	11	upstream	upstream	ADJ
njb-27	11	12	and	and	CCONJ
njb-27	11	13	downstream	downstream	ADJ
njb-27	11	14	primes	prime	NOUN
njb-27	11	15	to	to	PART
njb-27	11	16	show	show	VERB
njb-27	11	17	the	the	DET
njb-27	11	18	latent	latent	ADJ
njb-27	11	19	hiv	hiv	PROPN
njb-27	11	20	infections	infection	NOUN
njb-27	11	21	,	,	PUNCT
njb-27	11	22	whereas	whereas	SCONJ
njb-27	11	23	polymerase	polymerase	NOUN
njb-27	11	24	chain	chain	NOUN
njb-27	11	25	reaction	reaction	NOUN
njb-27	11	26	restriction	restriction	NOUN
njb-27	11	27	fragment	fragment	ADJ
njb-27	11	28	digestion	digestion	NOUN
njb-27	11	29	assay	assay	NOUN
njb-27	11	30	(	(	PUNCT
njb-27	11	31	pcr	pcr	NOUN
njb-27	11	32	-	-	NOUN
njb-27	11	33	rfda	rfda	NOUN
njb-27	11	34	)	)	PUNCT
njb-27	11	35	was	be	AUX
njb-27	11	36	used	use	VERB
njb-27	11	37	for	for	ADP
njb-27	11	38	testing	testing	NOUN
njb-27	11	39	m184v	m184v	VERB
njb-27	11	40	mutation	mutation	NOUN
njb-27	11	41	in	in	ADP
njb-27	11	42	hiv-1	hiv-1	PUNCT
njb-27	11	43	rt	rt	PROPN
njb-27	11	44	gene	gene	NOUN
njb-27	11	45	.	.	PUNCT
njb-27	12	1	in	in	ADP
njb-27	12	2	the	the	DET
njb-27	12	3	study	study	NOUN
njb-27	12	4	,	,	PUNCT
njb-27	12	5	out	out	ADP
njb-27	12	6	of	of	ADP
njb-27	12	7	15	15	NUM
njb-27	12	8	hiv	hiv	PROPN
njb-27	12	9	infected	infect	VERB
njb-27	12	10	patient	patient	ADJ
njb-27	12	11	blood	blood	NOUN
njb-27	12	12	samples	sample	NOUN
njb-27	12	13	,	,	PUNCT
njb-27	12	14	12	12	NUM
njb-27	12	15	shows	show	VERB
njb-27	12	16	amplification	amplification	NOUN
njb-27	12	17	of	of	ADP
njb-27	12	18	env	env	NOUN
njb-27	12	19	v3	v3	PROPN
njb-27	12	20	dna	dna	PROPN
njb-27	12	21	,	,	PUNCT
njb-27	12	22	confirming	confirm	VERB
njb-27	12	23	the	the	DET
njb-27	12	24	latent	latent	ADJ
njb-27	12	25	hiv	hiv	PROPN
njb-27	12	26	infections	infection	NOUN
njb-27	12	27	while	while	SCONJ
njb-27	12	28	3	3	NUM
njb-27	12	29	were	be	AUX
njb-27	12	30	negative	negative	ADJ
njb-27	12	31	for	for	ADP
njb-27	12	32	env	env	NOUN
njb-27	12	33	v3	v3	PROPN
njb-27	12	34	dna	dna	PROPN
njb-27	12	35	.	.	PUNCT
njb-27	13	1	hiv-1	hiv-1	CCONJ
njb-27	13	2	rt	rt	PROPN
njb-27	13	3	gene	gene	PROPN
njb-27	13	4	tested	test	VERB
njb-27	13	5	for	for	ADP
njb-27	13	6	m184v	m184v	ADJ
njb-27	13	7	mutation	mutation	NOUN
njb-27	13	8	in	in	ADP
njb-27	13	9	all	all	DET
njb-27	13	10	15	15	NUM
njb-27	13	11	samples	sample	NOUN
njb-27	13	12	showed	show	VERB
njb-27	13	13	wild	wild	ADJ
njb-27	13	14	type	type	NOUN
njb-27	13	15	after	after	ADP
njb-27	13	16	analysis	analysis	NOUN
njb-27	13	17	using	use	VERB
njb-27	13	18	pcr	pcr	PROPN
njb-27	13	19	-	-	PUNCT
njb-27	13	20	rfda	rfda	PROPN
njb-27	13	21	.	.	PUNCT
njb-27	14	1	after	after	ADP
njb-27	14	2	digestion	digestion	NOUN
njb-27	14	3	with	with	ADP
njb-27	14	4	cviaii	cviaii	PROPN
njb-27	14	5	,	,	PUNCT
njb-27	14	6	three	three	NUM
njb-27	14	7	bands	band	NOUN
njb-27	14	8	were	be	AUX
njb-27	14	9	observed	observe	VERB
njb-27	14	10	in	in	ADP
njb-27	14	11	wild	wild	ADJ
njb-27	14	12	type	type	NOUN
njb-27	14	13	whereas	whereas	SCONJ
njb-27	14	14	in	in	ADP
njb-27	14	15	mutant	mutant	ADJ
njb-27	14	16	only	only	ADV
njb-27	14	17	two	two	NUM
njb-27	14	18	bands	band	NOUN
njb-27	14	19	.	.	PUNCT
njb-27	15	1	although	although	SCONJ
njb-27	15	2	the	the	DET
njb-27	15	3	study	study	NOUN
njb-27	15	4	shows	show	VERB
njb-27	15	5	negative	negative	ADJ
njb-27	15	6	for	for	ADP
njb-27	15	7	the	the	DET
njb-27	15	8	m184v	m184v	ADJ
njb-27	15	9	resistance	resistance	NOUN
njb-27	15	10	mutation	mutation	PROPN
njb-27	15	11	,	,	PUNCT
njb-27	15	12	screening	screening	NOUN
njb-27	15	13	of	of	ADP
njb-27	15	14	various	various	ADJ
njb-27	15	15	panels	panel	NOUN
njb-27	15	16	of	of	ADP
njb-27	15	17	drug	drug	NOUN
njb-27	15	18	resistance	resistance	NOUN
njb-27	15	19	mutations	mutation	NOUN
njb-27	15	20	should	should	AUX
njb-27	15	21	be	be	AUX
njb-27	15	22	performed	perform	VERB
njb-27	15	23	in	in	ADP
njb-27	15	24	recently	recently	ADV
njb-27	15	25	infected	infect	VERB
njb-27	15	26	hiv1	hiv1	PROPN
njb-27	15	27	patients	patient	NOUN
njb-27	15	28	for	for	ADP
njb-27	15	29	planning	plan	VERB
njb-27	15	30	the	the	DET
njb-27	15	31	effective	effective	ADJ
njb-27	15	32	art	art	NOUN
njb-27	15	33	strategy	strategy	NOUN
njb-27	15	34	.	.	PUNCT
njb-27	16	1	the	the	DET
njb-27	16	2	data	datum	NOUN
njb-27	16	3	is	be	AUX
njb-27	16	4	not	not	PART
njb-27	16	5	enough	enough	ADJ
njb-27	16	6	to	to	PART
njb-27	16	7	compare	compare	VERB
njb-27	16	8	the	the	DET
njb-27	16	9	overall	overall	ADJ
njb-27	16	10	scenario	scenario	NOUN
njb-27	16	11	of	of	ADP
njb-27	16	12	the	the	DET
njb-27	16	13	nepal	nepal	ADJ
njb-27	16	14	thus	thus	ADV
njb-27	16	15	warrant	warrant	VERB
njb-27	16	16	urgency	urgency	NOUN
njb-27	16	17	for	for	ADP
njb-27	16	18	large	large	ADJ
njb-27	16	19	scale	scale	NOUN
njb-27	16	20	study	study	NOUN
njb-27	16	21	with	with	ADP
njb-27	16	22	standard	standard	ADJ
njb-27	16	23	genotypic	genotypic	NOUN
njb-27	16	24	tools	tool	NOUN
njb-27	16	25	.	.	PUNCT
njb-27	17	1	keywords	keyword	NOUN
njb-27	17	2	:	:	PUNCT
njb-27	17	3	hiv-1	hiv-1	PUNCT
njb-27	17	4	,	,	PUNCT
njb-27	17	5	antiretroviral	antiretroviral	ADJ
njb-27	17	6	therapy	therapy	NOUN
njb-27	17	7	,	,	PUNCT
njb-27	17	8	resistance	resistance	NOUN
njb-27	17	9	mutation	mutation	PROPN
njb-27	17	10	,	,	PUNCT
njb-27	17	11	env	env	NOUN
njb-27	17	12	v3	v3	PROPN
njb-27	17	13	dna	dna	PROPN
njb-27	17	14	,	,	PUNCT
njb-27	17	15	rt	rt	PROPN
njb-27	17	16	gene	gene	NOUN
njb-27	17	17	.	.	PUNCT
njb-27	18	1	*	*	PUNCT
njb-27	18	2	corresponding	correspond	VERB
njb-27	18	3	author	author	NOUN
njb-27	18	4	e	e	NOUN
njb-27	18	5	-	-	NOUN
njb-27	18	6	mail	mail	NOUN
njb-27	18	7	:	:	PUNCT
njb-27	18	8	dph.rupendra@gmail.com	dph.rupendra@gmail.com	PROPN
njb-27	18	9	introduction	introduction	NOUN
njb-27	18	10	hiv	hiv	PROPN
njb-27	18	11	/	/	SYM
njb-27	18	12	aids	aids	PROPN
njb-27	18	13	is	be	AUX
njb-27	18	14	the	the	DET
njb-27	18	15	gradually	gradually	ADV
njb-27	18	16	increasing	increase	VERB
njb-27	18	17	global	global	ADJ
njb-27	18	18	epidemic	epidemic	NOUN
njb-27	18	19	threat	threat	NOUN
njb-27	18	20	with	with	ADP
njb-27	18	21	an	an	DET
njb-27	18	22	estimated	estimate	VERB
njb-27	18	23	36.7	36.7	NUM
njb-27	18	24	million	million	NUM
njb-27	18	25	hiv	hiv	PROPN
njb-27	18	26	positive	positive	ADJ
njb-27	18	27	people	people	NOUN
njb-27	18	28	worldwide	worldwide	ADV
njb-27	18	29	.	.	PUNCT
njb-27	19	1	among	among	ADP
njb-27	19	2	them	they	PRON
njb-27	19	3	5.1	5.1	NUM
njb-27	19	4	million	million	NUM
njb-27	19	5	people	people	NOUN
njb-27	19	6	are	be	AUX
njb-27	19	7	in	in	ADP
njb-27	19	8	asia	asia	PROPN
njb-27	19	9	including	include	VERB
njb-27	19	10	3,00,000	3,00,000	NUM
njb-27	19	11	newly	newly	ADV
njb-27	19	12	infected	infect	VERB
njb-27	19	13	and	and	CCONJ
njb-27	19	14	1,80,000	1,80,000	NUM
njb-27	19	15	aids	aid	NOUN
njb-27	19	16	-	-	PUNCT
njb-27	19	17	related	relate	VERB
njb-27	19	18	deaths	death	NOUN
njb-27	19	19	occurred	occur	VERB
njb-27	19	20	in	in	ADP
njb-27	19	21	asia	asia	PROPN
njb-27	19	22	per	per	ADP
njb-27	19	23	year	year	NOUN
njb-27	19	24	[	[	PUNCT
njb-27	19	25	1	1	NUM
njb-27	19	26	]	]	PUNCT
njb-27	19	27	.	.	PUNCT
njb-27	20	1	till	till	SCONJ
njb-27	20	2	date	date	NOUN
njb-27	20	3	39,249	39,249	NUM
njb-27	20	4	people	people	NOUN
njb-27	20	5	are	be	AUX
njb-27	20	6	estimated	estimate	VERB
njb-27	20	7	to	to	PART
njb-27	20	8	be	be	AUX
njb-27	20	9	living	live	VERB
njb-27	20	10	with	with	ADP
njb-27	20	11	hiv	hiv	PROPN
njb-27	20	12	in	in	ADP
njb-27	20	13	nepal	nepal	ADJ
njb-27	20	14	[	[	X
njb-27	20	15	2	2	NUM
njb-27	20	16	]	]	PUNCT
njb-27	20	17	.	.	PUNCT
njb-27	21	1	the	the	DET
njb-27	21	2	hiv	hiv	PROPN
njb-27	21	3	epidemic	epidemic	NOUN
njb-27	21	4	has	have	AUX
njb-27	21	5	changed	change	VERB
njb-27	21	6	due	due	ADP
njb-27	21	7	to	to	ADP
njb-27	21	8	use	use	NOUN
njb-27	21	9	of	of	ADP
njb-27	21	10	antiretroviral	antiretroviral	ADJ
njb-27	21	11	therapies	therapy	NOUN
njb-27	21	12	(	(	PUNCT
njb-27	21	13	arts	art	NOUN
njb-27	21	14	)	)	PUNCT
njb-27	21	15	that	that	PRON
njb-27	21	16	suppress	suppress	VERB
njb-27	21	17	the	the	DET
njb-27	21	18	hiv-1	hiv-1	PUNCT
njb-27	21	19	rna	rna	NOUN
njb-27	21	20	load	load	NOUN
njb-27	21	21	in	in	ADP
njb-27	21	22	plasma	plasma	NOUN
njb-27	21	23	below	below	ADP
njb-27	21	24	the	the	DET
njb-27	21	25	detection	detection	NOUN
njb-27	21	26	limit	limit	NOUN
njb-27	21	27	(	(	PUNCT
njb-27	21	28	<	<	X
njb-27	21	29	50	50	NUM
njb-27	21	30	copies	copy	NOUN
njb-27	21	31	/	/	SYM
njb-27	21	32	ml	ml	PROPN
njb-27	21	33	)	)	PUNCT
njb-27	21	34	.	.	PUNCT
njb-27	22	1	however	however	ADV
njb-27	22	2	,	,	PUNCT
njb-27	22	3	lifelong	lifelong	ADJ
njb-27	22	4	art	art	NOUN
njb-27	22	5	is	be	AUX
njb-27	22	6	necessary	necessary	ADJ
njb-27	22	7	for	for	ADP
njb-27	22	8	patients	patient	NOUN
njb-27	22	9	with	with	ADP
njb-27	22	10	latent	latent	ADJ
njb-27	22	11	hiv	hiv	PROPN
njb-27	22	12	infections	infection	NOUN
njb-27	22	13	due	due	ADJ
njb-27	22	14	to	to	ADP
njb-27	22	15	decrease	decrease	NOUN
njb-27	22	16	in	in	ADP
njb-27	22	17	level	level	NOUN
njb-27	22	18	of	of	ADP
njb-27	22	19	cd4	cd4	X
njb-27	22	20	+	+	SYM
njb-27	22	21	lymphocytes	lymphocyte	NOUN
njb-27	22	22	[	[	X
njb-27	22	23	3	3	NUM
njb-27	22	24	,	,	PUNCT
njb-27	22	25	4	4	NUM
njb-27	22	26	]	]	PUNCT
njb-27	22	27	.	.	PUNCT
njb-27	23	1	the	the	DET
njb-27	23	2	decrease	decrease	NOUN
njb-27	23	3	in	in	ADP
njb-27	23	4	level	level	NOUN
njb-27	23	5	of	of	ADP
njb-27	23	6	cd4	cd4	X
njb-27	23	7	+	+	SYM
njb-27	23	8	t	t	NOUN
njb-27	23	9	cells	cell	NOUN
njb-27	23	10	caused	cause	VERB
njb-27	23	11	by	by	ADP
njb-27	23	12	hiv	hiv	PROPN
njb-27	23	13	infection	infection	NOUN
njb-27	23	14	leads	lead	VERB
njb-27	23	15	into	into	ADP
njb-27	23	16	aids	aid	NOUN
njb-27	23	17	and	and	CCONJ
njb-27	23	18	cause	cause	VERB
njb-27	23	19	opportunistic	opportunistic	ADJ
njb-27	23	20	infections	infection	NOUN
njb-27	23	21	,	,	PUNCT
njb-27	23	22	like	like	SCONJ
njb-27	23	23	pneumocystis	pneumocystis	NOUN
njb-27	23	24	carinii	carinii	ADJ
njb-27	23	25	pneumonia	pneumonia	NOUN
njb-27	23	26	and	and	CCONJ
njb-27	23	27	kaposi	kaposi	NOUN
njb-27	23	28	’s	’s	PART
njb-27	23	29	sarcoma	sarcoma	NOUN
njb-27	23	30	[	[	X
njb-27	23	31	5	5	NUM
njb-27	23	32	]	]	PUNCT
njb-27	23	33	.	.	PUNCT
njb-27	24	1	more	more	ADJ
njb-27	24	2	than	than	ADP
njb-27	24	3	50	50	NUM
njb-27	24	4	%	%	NOUN
njb-27	24	5	of	of	ADP
njb-27	24	6	the	the	DET
njb-27	24	7	worldwide	worldwide	ADJ
njb-27	24	8	epidemic	epidemic	NOUN
njb-27	24	9	are	be	AUX
njb-27	24	10	due	due	ADJ
njb-27	24	11	to	to	ADP
njb-27	24	12	hiv-1	hiv-1	PUNCT
njb-27	24	13	subtype	subtype	NOUN
njb-27	24	14	c	c	NOUN
njb-27	24	15	and	and	CCONJ
njb-27	24	16	are	be	AUX
njb-27	24	17	prone	prone	ADJ
njb-27	24	18	to	to	ADP
njb-27	24	19	genotypic	genotypic	NOUN
njb-27	24	20	resistance	resistance	NOUN
njb-27	24	21	with	with	ADP
njb-27	24	22	treatment	treatment	NOUN
njb-27	24	23	failure	failure	NOUN
njb-27	24	24	.	.	PUNCT
njb-27	25	1	hiv-1	hiv-1	PUNCT
njb-27	25	2	has	have	VERB
njb-27	25	3	a	a	DET
njb-27	25	4	higher	high	ADJ
njb-27	25	5	rate	rate	NOUN
njb-27	25	6	of	of	ADP
njb-27	25	7	replication	replication	NOUN
njb-27	25	8	with	with	ADP
njb-27	25	9	lack	lack	NOUN
njb-27	25	10	of	of	ADP
njb-27	25	11	3	3	NUM
njb-27	25	12	’	'	PUNCT
njb-27	25	13	to	to	ADP
njb-27	25	14	5	5	NUM
njb-27	25	15	’	'	PUNCT
njb-27	25	16	proof	proof	NOUN
njb-27	25	17	reading	read	VERB
njb-27	25	18	mechanism	mechanism	NOUN
njb-27	25	19	and	and	CCONJ
njb-27	25	20	highly	highly	ADV
njb-27	25	21	error	error	NOUN
njb-27	25	22	-	-	PUNCT
njb-27	25	23	prone	prone	ADJ
njb-27	25	24	to	to	PART
njb-27	25	25	reverse	reverse	VERB
njb-27	25	26	transcriptase	transcriptase	NOUN
njb-27	26	1	[	[	X
njb-27	26	2	6	6	NUM
njb-27	26	3	-	-	SYM
njb-27	26	4	8	8	NUM
njb-27	26	5	]	]	PUNCT
njb-27	26	6	.	.	PUNCT
njb-27	27	1	the	the	DET
njb-27	27	2	selection	selection	NOUN
njb-27	27	3	of	of	ADP
njb-27	27	4	drug	drug	NOUN
njb-27	27	5	specific	specific	ADJ
njb-27	27	6	resistance	resistance	NOUN
njb-27	27	7	mutation	mutation	NOUN
njb-27	27	8	in	in	ADP
njb-27	27	9	viral	viral	ADJ
njb-27	27	10	genome	genome	NOUN
njb-27	27	11	is	be	AUX
njb-27	27	12	due	due	ADJ
njb-27	27	13	to	to	ADP
njb-27	27	14	treatment	treatment	NOUN
njb-27	27	15	failure	failure	NOUN
njb-27	27	16	and	and	CCONJ
njb-27	27	17	those	those	DET
njb-27	27	18	mutations	mutation	NOUN
njb-27	27	19	may	may	AUX
njb-27	27	20	be	be	AUX
njb-27	27	21	archived	archive	VERB
njb-27	27	22	into	into	ADP
njb-27	27	23	the	the	DET
njb-27	27	24	cellular	cellular	ADJ
njb-27	27	25	reservoir	reservoir	NOUN
njb-27	27	26	(	(	PUNCT
njb-27	27	27	proviral	proviral	ADJ
njb-27	27	28	dna	dna	PROPN
njb-27	27	29	)	)	PUNCT
njb-27	27	30	.	.	PUNCT
njb-27	28	1	thus	thus	ADV
njb-27	28	2	,	,	PUNCT
njb-27	28	3	mutations	mutation	NOUN
njb-27	28	4	can	can	AUX
njb-27	28	5	be	be	AUX
njb-27	28	6	detected	detect	VERB
njb-27	28	7	in	in	ADP
njb-27	28	8	proviral	proviral	ADJ
njb-27	28	9	dna	dna	PROPN
njb-27	28	10	even	even	ADV
njb-27	28	11	if	if	SCONJ
njb-27	28	12	hiv	hiv	PROPN
njb-27	28	13	rna	rna	PROPN
njb-27	28	14	is	be	AUX
njb-27	28	15	below	below	ADP
njb-27	28	16	detection	detection	NOUN
njb-27	28	17	limit	limit	NOUN
njb-27	28	18	[	[	X
njb-27	28	19	9	9	NUM
njb-27	28	20	]	]	PUNCT
njb-27	28	21	.	.	PUNCT
njb-27	29	1	hiv1	hiv1	PROPN
njb-27	29	2	resistance	resistance	NOUN
njb-27	29	3	to	to	ADP
njb-27	29	4	art	art	NOUN
njb-27	29	5	is	be	AUX
njb-27	29	6	a	a	DET
njb-27	29	7	major	major	ADJ
njb-27	29	8	problem	problem	NOUN
njb-27	29	9	which	which	PRON
njb-27	29	10	is	be	AUX
njb-27	29	11	due	due	ADJ
njb-27	29	12	to	to	ADP
njb-27	29	13	suboptimum	suboptimum	PROPN
njb-27	29	14	treatment	treatment	NOUN
njb-27	29	15	and	and	CCONJ
njb-27	29	16	transmission	transmission	NOUN
njb-27	29	17	of	of	ADP
njb-27	29	18	resistant	resistant	ADJ
njb-27	29	19	variant	variant	NOUN
njb-27	29	20	at	at	ADP
njb-27	29	21	the	the	DET
njb-27	29	22	time	time	NOUN
njb-27	29	23	of	of	ADP
njb-27	29	24	infection	infection	NOUN
njb-27	30	1	[	[	PUNCT
njb-27	30	2	10	10	NUM
njb-27	30	3	-	-	SYM
njb-27	30	4	12	12	NUM
njb-27	30	5	]	]	PUNCT
njb-27	30	6	.	.	PUNCT
njb-27	31	1	resistance	resistance	NOUN
njb-27	31	2	mutation	mutation	PROPN
njb-27	31	3	is	be	AUX
njb-27	31	4	associated	associate	VERB
njb-27	31	5	with	with	ADP
njb-27	31	6	high	high	ADJ
njb-27	31	7	replicative	replicative	ADJ
njb-27	31	8	activities	activity	NOUN
njb-27	31	9	of	of	ADP
njb-27	31	10	the	the	DET
njb-27	31	11	viral	viral	ADJ
njb-27	31	12	genome	genome	NOUN
njb-27	31	13	during	during	ADP
njb-27	31	14	therapy	therapy	NOUN
njb-27	31	15	.	.	PUNCT
njb-27	32	1	several	several	ADJ
njb-27	32	2	drugs	drug	NOUN
njb-27	32	3	have	have	AUX
njb-27	32	4	been	be	AUX
njb-27	32	5	approved	approve	VERB
njb-27	32	6	for	for	ADP
njb-27	32	7	the	the	DET
njb-27	32	8	treatment	treatment	NOUN
njb-27	32	9	of	of	ADP
njb-27	32	10	hiv-1	hiv-1	PUNCT
njb-27	32	11	infection	infection	NOUN
njb-27	32	12	such	such	ADJ
njb-27	32	13	as	as	ADP
njb-27	32	14	nucleotide	nucleotide	NOUN
njb-27	32	15	and	and	CCONJ
njb-27	32	16	nucleoside	nucleoside	NOUN
njb-27	32	17	reverse	reverse	ADJ
njb-27	32	18	transcriptase	transcriptase	NOUN
njb-27	32	19	inhibitors	inhibitor	NOUN
njb-27	32	20	(	(	PUNCT
njb-27	32	21	nrtis	nrtis	PROPN
njb-27	32	22	)	)	PUNCT
njb-27	32	23	,	,	PUNCT
njb-27	32	24	protease	protease	NOUN
njb-27	32	25	inhibitors	inhibitor	NOUN
njb-27	32	26	(	(	PUNCT
njb-27	32	27	pis	pis	PROPN
njb-27	32	28	)	)	PUNCT
njb-27	32	29	,	,	PUNCT
njb-27	32	30	nonnucleoside	nonnucleoside	PROPN
njb-27	32	31	rt	rt	PROPN
njb-27	32	32	inhibitors	inhibitor	NOUN
njb-27	32	33	(	(	PUNCT
njb-27	32	34	nnrtis	nnrtis	NOUN
njb-27	32	35	)	)	PUNCT
njb-27	32	36	,	,	PUNCT
njb-27	32	37	and	and	CCONJ
njb-27	32	38	fusion	fusion	NOUN
njb-27	32	39	inhibitors	inhibitor	NOUN
njb-27	32	40	.	.	PUNCT
njb-27	33	1	however	however	ADV
njb-27	33	2	,	,	PUNCT
njb-27	33	3	drug	drug	NOUN
njb-27	33	4	resistance	resistance	NOUN
njb-27	33	5	mutations	mutation	NOUN
njb-27	33	6	in	in	ADP
njb-27	33	7	hiv-1	hiv-1	CCONJ
njb-27	33	8	remain	remain	VERB
njb-27	33	9	crucial	crucial	ADJ
njb-27	33	10	,	,	PUNCT
njb-27	33	11	even	even	ADV
njb-27	33	12	though	though	SCONJ
njb-27	33	13	effective	effective	ADJ
njb-27	33	14	(	(	PUNCT
njb-27	33	15	art	art	NOUN
njb-27	33	16	)	)	PUNCT
njb-27	33	17	is	be	AUX
njb-27	33	18	available	available	ADJ
njb-27	33	19	in	in	ADP
njb-27	33	20	the	the	DET
njb-27	33	21	global	global	ADJ
njb-27	33	22	market	market	NOUN
njb-27	33	23	.	.	PUNCT
njb-27	34	1	one	one	NUM
njb-27	34	2	of	of	ADP
njb-27	34	3	the	the	DET
njb-27	34	4	commonly	commonly	ADV
njb-27	34	5	associated	associate	VERB
njb-27	34	6	drug	drug	NOUN
njb-27	34	7	resistance	resistance	NOUN
njb-27	34	8	mutations	mutation	NOUN
njb-27	34	9	in	in	ADP
njb-27	34	10	hiv-1	hiv-1	PUNCT
njb-27	34	11	rt	rt	PROPN
njb-27	34	12	gene	gene	NOUN
njb-27	34	13	is	be	AUX
njb-27	34	14	m184v	m184v	VERB
njb-27	34	15	.	.	PUNCT
njb-27	35	1	the	the	DET
njb-27	35	2	appearance	appearance	NOUN
njb-27	35	3	of	of	ADP
njb-27	35	4	lamivudine	lamivudine	NOUN
njb-27	35	5	nepal	nepal	ADJ
njb-27	35	6	journal	journal	NOUN
njb-27	35	7	of	of	ADP
njb-27	35	8	biotechnology	biotechnology	NOUN
njb-27	35	9	.	.	PUNCT
njb-27	36	1	d	d	X
njb-27	36	2	e	e	PROPN
njb-27	36	3	c	c	PROPN
njb-27	36	4	.	.	PUNCT
njb-27	37	1	2	2	NUM
njb-27	37	2	0	0	NUM
njb-27	37	3	1	1	NUM
njb-27	37	4	6	6	NUM
njb-27	37	5	vol	vol	NOUN
njb-27	37	6	.	.	PROPN
njb-27	38	1	4	4	NUM
njb-27	38	2	,	,	PUNCT
njb-27	38	3	no	no	NOUN
njb-27	38	4	.	.	NOUN
njb-27	38	5	1	1	NUM
njb-27	38	6	:	:	SYM
njb-27	38	7	18	18	NUM
njb-27	38	8	-	-	SYM
njb-27	38	9	25	25	NUM
njb-27	38	10	shrestha	shrestha	NOUN
njb-27	38	11	et	et	X
njb-27	38	12	al	al	PROPN
njb-27	38	13	.	.	PUNCT
njb-27	39	1	©	©	PROPN
njb-27	39	2	njb	njb	PROPN
njb-27	39	3	,	,	PUNCT
njb-27	39	4	biotechnology	biotechnology	NOUN
njb-27	39	5	society	society	NOUN
njb-27	39	6	of	of	ADP
njb-27	39	7	nepal	nepal	ADJ
njb-27	39	8	19	19	NUM
njb-27	39	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	PROPN
njb-27	39	10	(	(	PUNCT
njb-27	39	11	3tc	3tc	NOUN
njb-27	39	12	)	)	PUNCT
njb-27	39	13	resistance	resistance	NOUN
njb-27	39	14	mutation	mutation	PROPN
njb-27	39	15	,	,	PUNCT
njb-27	39	16	m184i	m184i	PROPN
njb-27	39	17	,	,	PUNCT
njb-27	39	18	was	be	AUX
njb-27	39	19	found	find	VERB
njb-27	39	20	to	to	PART
njb-27	39	21	be	be	AUX
njb-27	39	22	transiently	transiently	ADV
njb-27	39	23	proceeded	proceed	VERB
njb-27	39	24	to	to	ADP
njb-27	39	25	the	the	DET
njb-27	39	26	outgrowth	outgrowth	NOUN
njb-27	39	27	of	of	ADP
njb-27	39	28	m184v	m184v	ADJ
njb-27	39	29	substitution	substitution	NOUN
njb-27	39	30	[	[	PUNCT
njb-27	39	31	13	13	NUM
njb-27	39	32	-	-	SYM
njb-27	39	33	15	15	NUM
njb-27	39	34	]	]	PUNCT
njb-27	39	35	.	.	PUNCT
njb-27	40	1	the	the	DET
njb-27	40	2	study	study	NOUN
njb-27	40	3	of	of	ADP
njb-27	40	4	the	the	DET
njb-27	40	5	nucleotide	nucleotide	NOUN
njb-27	40	6	sequences	sequence	NOUN
njb-27	40	7	of	of	ADP
njb-27	40	8	both	both	DET
njb-27	40	9	3tc	3tc	ADJ
njb-27	40	10	-	-	PUNCT
njb-27	40	11	resistant	resistant	ADJ
njb-27	40	12	variants	variant	NOUN
njb-27	40	13	shows	show	VERB
njb-27	40	14	that	that	SCONJ
njb-27	40	15	m184v	m184v	VERB
njb-27	40	16	(	(	PUNCT
njb-27	40	17	gtg	gtg	PROPN
njb-27	40	18	)	)	PUNCT
njb-27	40	19	originates	originate	VERB
njb-27	40	20	from	from	ADP
njb-27	40	21	wild	wild	ADJ
njb-27	40	22	-	-	PUNCT
njb-27	40	23	type	type	NOUN
njb-27	40	24	met	meet	VERB
njb-27	40	25	(	(	PUNCT
njb-27	40	26	atg	atg	PROPN
njb-27	40	27	)	)	PUNCT
njb-27	40	28	but	but	CCONJ
njb-27	40	29	not	not	PART
njb-27	40	30	from	from	ADP
njb-27	40	31	the	the	DET
njb-27	40	32	m184i	m184i	ADJ
njb-27	40	33	variant	variant	NOUN
njb-27	40	34	(	(	PUNCT
njb-27	40	35	ata	ata	X
njb-27	40	36	)	)	PUNCT
njb-27	40	37	[	[	PUNCT
njb-27	40	38	16	16	NUM
njb-27	40	39	]	]	PUNCT
njb-27	40	40	.	.	PUNCT
njb-27	41	1	both	both	DET
njb-27	41	2	variants	variant	NOUN
njb-27	41	3	are	be	AUX
njb-27	41	4	generated	generate	VERB
njb-27	41	5	from	from	ADP
njb-27	41	6	the	the	DET
njb-27	41	7	wildtype	wildtype	PROPN
njb-27	41	8	atg	atg	PROPN
njb-27	41	9	sequence	sequence	NOUN
njb-27	41	10	by	by	ADP
njb-27	41	11	transitional	transitional	ADJ
njb-27	41	12	substitutions	substitution	NOUN
njb-27	41	13	(	(	PUNCT
njb-27	41	14	g	g	NOUN
njb-27	41	15	to	to	ADP
njb-27	41	16	a	a	PRON
njb-27	41	17	for	for	ADP
njb-27	41	18	184i	184i	NOUN
njb-27	41	19	and	and	CCONJ
njb-27	41	20	a	a	PRON
njb-27	41	21	to	to	ADP
njb-27	41	22	g	g	NOUN
njb-27	41	23	for	for	ADP
njb-27	41	24	184v	184v	NOUN
njb-27	41	25	)	)	PUNCT
njb-27	41	26	.	.	PUNCT
njb-27	42	1	the	the	DET
njb-27	42	2	g	g	NOUN
njb-27	42	3	to	to	ADP
njb-27	42	4	a	a	DET
njb-27	42	5	substitution	substitution	NOUN
njb-27	42	6	is	be	AUX
njb-27	42	7	the	the	DET
njb-27	42	8	type	type	NOUN
njb-27	42	9	of	of	ADP
njb-27	42	10	mutation	mutation	NOUN
njb-27	42	11	that	that	PRON
njb-27	42	12	most	most	ADV
njb-27	42	13	commonly	commonly	ADV
njb-27	42	14	occur	occur	VERB
njb-27	42	15	during	during	ADP
njb-27	42	16	replication	replication	NOUN
njb-27	42	17	of	of	ADP
njb-27	42	18	hiv-1	hiv-1	PUNCT
njb-27	42	19	thus	thus	ADV
njb-27	42	20	m184i	m184i	PROPN
njb-27	42	21	appears	appear	VERB
njb-27	42	22	before	before	SCONJ
njb-27	42	23	m184v	m184v	VERB
njb-27	42	24	[	[	PUNCT
njb-27	42	25	17	17	NUM
njb-27	42	26	,	,	PUNCT
njb-27	42	27	18	18	NUM
njb-27	42	28	]	]	PUNCT
njb-27	42	29	.	.	PUNCT
njb-27	43	1	in	in	ADP
njb-27	43	2	addition	addition	NOUN
njb-27	43	3	,	,	PUNCT
njb-27	43	4	there	there	PRON
njb-27	43	5	have	have	AUX
njb-27	43	6	been	be	AUX
njb-27	43	7	no	no	DET
njb-27	43	8	systematic	systematic	ADJ
njb-27	43	9	studies	study	NOUN
njb-27	43	10	of	of	ADP
njb-27	43	11	hiv-1	hiv-1	PUNCT
njb-27	43	12	resistance	resistance	NOUN
njb-27	43	13	mutation	mutation	NOUN
njb-27	43	14	in	in	ADP
njb-27	43	15	nepalese	nepalese	ADJ
njb-27	43	16	population	population	NOUN
njb-27	43	17	.	.	PUNCT
njb-27	44	1	here	here	ADV
njb-27	44	2	,	,	PUNCT
njb-27	44	3	we	we	PRON
njb-27	44	4	performed	perform	VERB
njb-27	44	5	the	the	DET
njb-27	44	6	preliminary	preliminary	ADJ
njb-27	44	7	study	study	NOUN
njb-27	44	8	of	of	ADP
njb-27	44	9	common	common	ADJ
njb-27	44	10	drug	drug	NOUN
njb-27	44	11	resistance	resistance	NOUN
njb-27	44	12	mutation	mutation	PROPN
njb-27	44	13	,	,	PUNCT
njb-27	44	14	m184v	m184v	VERB
njb-27	44	15	using	use	VERB
njb-27	44	16	a	a	DET
njb-27	44	17	basic	basic	ADJ
njb-27	44	18	molecular	molecular	ADJ
njb-27	44	19	tool	tool	NOUN
njb-27	44	20	called	call	VERB
njb-27	44	21	pcr	pcr	PROPN
njb-27	44	22	-	-	NOUN
njb-27	44	23	rfda	rfda	NOUN
njb-27	44	24	and	and	CCONJ
njb-27	44	25	assessed	assess	VERB
njb-27	44	26	the	the	DET
njb-27	44	27	detection	detection	NOUN
njb-27	44	28	of	of	ADP
njb-27	44	29	proviral	proviral	ADJ
njb-27	44	30	dna	dna	PROPN
njb-27	44	31	in	in	ADP
njb-27	44	32	hiv-1	hiv-1	PUNCT
njb-27	44	33	infected	infected	ADJ
njb-27	44	34	patients	patient	NOUN
njb-27	44	35	with	with	ADP
njb-27	44	36	prolonged	prolonged	ADJ
njb-27	44	37	art	art	NOUN
njb-27	44	38	.	.	PUNCT
njb-27	45	1	materials	material	NOUN
njb-27	45	2	and	and	CCONJ
njb-27	45	3	methods	method	NOUN
njb-27	45	4	patients	patient	NOUN
njb-27	45	5	counselling	counselling	NOUN
njb-27	45	6	and	and	CCONJ
njb-27	45	7	collection	collection	NOUN
njb-27	45	8	of	of	ADP
njb-27	45	9	samples	sample	NOUN
njb-27	45	10	individual	individual	ADJ
njb-27	45	11	patient	patient	NOUN
njb-27	45	12	counselling	counselling	NOUN
njb-27	45	13	was	be	AUX
njb-27	45	14	performed	perform	VERB
njb-27	45	15	on	on	ADP
njb-27	45	16	the	the	DET
njb-27	45	17	background	background	NOUN
njb-27	45	18	of	of	ADP
njb-27	45	19	hiv	hiv	PROPN
njb-27	45	20	/	/	SYM
njb-27	45	21	aids	aid	NOUN
njb-27	45	22	,	,	PUNCT
njb-27	45	23	diagnosis	diagnosis	NOUN
njb-27	45	24	,	,	PUNCT
njb-27	45	25	monitoring	monitoring	NOUN
njb-27	45	26	,	,	PUNCT
njb-27	45	27	treatment	treatment	NOUN
njb-27	45	28	,	,	PUNCT
njb-27	45	29	drug	drug	NOUN
njb-27	45	30	resistant	resistant	ADJ
njb-27	45	31	and	and	CCONJ
njb-27	45	32	genotype	genotype	NOUN
njb-27	45	33	testing	testing	NOUN
njb-27	45	34	.	.	PUNCT
njb-27	46	1	a	a	DET
njb-27	46	2	questionnaire	questionnaire	NOUN
njb-27	46	3	was	be	AUX
njb-27	46	4	performed	perform	VERB
njb-27	46	5	with	with	ADP
njb-27	46	6	regards	regard	NOUN
njb-27	46	7	to	to	ADP
njb-27	46	8	drug	drug	NOUN
njb-27	46	9	use	use	NOUN
njb-27	46	10	,	,	PUNCT
njb-27	46	11	sexual	sexual	ADJ
njb-27	46	12	behavior	behavior	NOUN
njb-27	46	13	and	and	CCONJ
njb-27	46	14	travel	travel	VERB
njb-27	46	15	history	history	NOUN
njb-27	46	16	.	.	PUNCT
njb-27	47	1	15	15	NUM
njb-27	47	2	samples	sample	NOUN
njb-27	47	3	were	be	AUX
njb-27	47	4	collected	collect	VERB
njb-27	47	5	from	from	ADP
njb-27	47	6	hiv-1	hiv-1	PUNCT
njb-27	47	7	infected	infected	ADJ
njb-27	47	8	patients	patient	NOUN
njb-27	47	9	undergoing	undergo	VERB
njb-27	47	10	long	long	ADJ
njb-27	47	11	term	term	NOUN
njb-27	47	12	art	art	NOUN
njb-27	47	13	commonly	commonly	ADV
njb-27	47	14	with	with	ADP
njb-27	47	15	2	2	NUM
njb-27	47	16	-	-	SYM
njb-27	47	17	3	3	NUM
njb-27	47	18	nrtis	nrtis	PROPN
njb-27	47	19	and	and	CCONJ
njb-27	47	20	1	1	NUM
njb-27	47	21	-	-	SYM
njb-27	47	22	2	2	NUM
njb-27	47	23	pis	pis	NOUN
njb-27	47	24	or	or	CCONJ
njb-27	47	25	an	an	DET
njb-27	47	26	nnrti	nnrti	NOUN
njb-27	47	27	for	for	ADP
njb-27	47	28	at	at	ADV
njb-27	47	29	least	least	ADV
njb-27	47	30	3	3	NUM
njb-27	47	31	4	4	NUM
njb-27	47	32	years	year	NOUN
njb-27	47	33	recruited	recruit	VERB
njb-27	47	34	in	in	ADP
njb-27	47	35	sparsha	sparsha	PROPN
njb-27	47	36	nepal	nepal	PROPN
njb-27	47	37	,	,	PUNCT
njb-27	47	38	sanepa	sanepa	ADJ
njb-27	47	39	,	,	PUNCT
njb-27	47	40	kathmandu	kathmandu	NOUN
njb-27	47	41	was	be	AUX
njb-27	47	42	included	include	VERB
njb-27	47	43	.	.	PUNCT
njb-27	48	1	out	out	ADP
njb-27	48	2	of	of	ADP
njb-27	48	3	15	15	NUM
njb-27	48	4	cases	case	NOUN
njb-27	48	5	,	,	PUNCT
njb-27	48	6	only	only	ADV
njb-27	48	7	two	two	NUM
njb-27	48	8	were	be	AUX
njb-27	48	9	clinically	clinically	ADV
njb-27	48	10	approved	approve	VERB
njb-27	48	11	as	as	ADP
njb-27	48	12	art	art	NOUN
njb-27	48	13	resistance	resistance	NOUN
njb-27	48	14	and	and	CCONJ
njb-27	48	15	viral	viral	ADJ
njb-27	48	16	loads	load	NOUN
njb-27	48	17	of	of	ADP
njb-27	48	18	each	each	DET
njb-27	48	19	patients	patient	NOUN
njb-27	48	20	are	be	AUX
njb-27	48	21	shown	show	VERB
njb-27	48	22	in	in	ADP
njb-27	48	23	table	table	NOUN
njb-27	48	24	1	1	NUM
njb-27	48	25	.	.	PUNCT
njb-27	49	1	data	datum	NOUN
njb-27	49	2	were	be	AUX
njb-27	49	3	collected	collect	VERB
njb-27	49	4	as	as	ADP
njb-27	49	5	a	a	DET
njb-27	49	6	part	part	NOUN
njb-27	49	7	of	of	ADP
njb-27	49	8	a	a	DET
njb-27	49	9	continuing	continue	VERB
njb-27	49	10	study	study	NOUN
njb-27	49	11	of	of	ADP
njb-27	49	12	antiretroviral	antiretroviral	ADJ
njb-27	49	13	treatment	treatment	NOUN
njb-27	49	14	at	at	ADP
njb-27	49	15	the	the	DET
njb-27	49	16	time	time	NOUN
njb-27	49	17	of	of	ADP
njb-27	49	18	primary	primary	NOUN
njb-27	49	19	hiv-1	hiv-1	CCONJ
njb-27	49	20	infection	infection	NOUN
njb-27	49	21	,	,	PUNCT
njb-27	49	22	which	which	PRON
njb-27	49	23	was	be	AUX
njb-27	49	24	approved	approve	VERB
njb-27	49	25	by	by	ADP
njb-27	49	26	the	the	DET
njb-27	49	27	department	department	NOUN
njb-27	49	28	of	of	ADP
njb-27	49	29	laboratory	laboratory	NOUN
njb-27	49	30	medicine	medicine	NOUN
njb-27	49	31	,	,	PUNCT
njb-27	49	32	research	research	NOUN
njb-27	49	33	committee	committee	PROPN
njb-27	49	34	of	of	ADP
njb-27	49	35	nobel	nobel	PROPN
njb-27	49	36	college	college	PROPN
njb-27	49	37	and	and	CCONJ
njb-27	49	38	chief	chief	NOUN
njb-27	49	39	of	of	ADP
njb-27	49	40	sparsha	sparsha	PROPN
njb-27	49	41	nepal	nepal	PROPN
njb-27	49	42	.	.	PUNCT
njb-27	50	1	extraction	extraction	NOUN
njb-27	50	2	of	of	ADP
njb-27	50	3	nucleic	nucleic	ADJ
njb-27	50	4	acid	acid	NOUN
njb-27	50	5	the	the	DET
njb-27	50	6	nucleic	nucleic	ADJ
njb-27	50	7	acid	acid	NOUN
njb-27	50	8	extraction	extraction	NOUN
njb-27	50	9	procedure	procedure	NOUN
njb-27	50	10	was	be	AUX
njb-27	50	11	performed	perform	VERB
njb-27	50	12	in	in	ADP
njb-27	50	13	biosafety	biosafety	NOUN
njb-27	50	14	cabinet	cabinet	NOUN
njb-27	50	15	(	(	PUNCT
njb-27	50	16	bsl-2	bsl-2	X
njb-27	50	17	)	)	PUNCT
njb-27	50	18	.	.	PUNCT
njb-27	51	1	hiv-1	hiv-1	PUNCT
njb-27	51	2	rna	rna	NOUN
njb-27	51	3	was	be	AUX
njb-27	51	4	extracted	extract	VERB
njb-27	51	5	using	use	VERB
njb-27	51	6	precision	precision	NOUN
njb-27	51	7	qiaamp	qiaamp	NOUN
njb-27	51	8	viral	viral	ADJ
njb-27	51	9	rna	rna	NOUN
njb-27	51	10	mini	mini	NOUN
njb-27	51	11	kit	kit	NOUN
njb-27	51	12	(	(	PUNCT
njb-27	51	13	qiagen	qiagen	PROPN
njb-27	51	14	,	,	PUNCT
njb-27	51	15	hilden	hilden	PROPN
njb-27	51	16	,	,	PUNCT
njb-27	51	17	germany	germany	PROPN
njb-27	51	18	)	)	PUNCT
njb-27	51	19	while	while	SCONJ
njb-27	51	20	dna	dna	PROPN
njb-27	51	21	was	be	AUX
njb-27	51	22	extracted	extract	VERB
njb-27	51	23	using	use	VERB
njb-27	51	24	shine	shine	ADJ
njb-27	51	25	gene	gene	NOUN
njb-27	51	26	whole	whole	ADJ
njb-27	51	27	blood	blood	NOUN
njb-27	51	28	dna	dna	NOUN
njb-27	51	29	extraction	extraction	NOUN
njb-27	51	30	kit	kit	NOUN
njb-27	51	31	(	(	PUNCT
njb-27	51	32	wuhe	wuhe	PROPN
njb-27	51	33	road	road	PROPN
njb-27	51	34	,	,	PUNCT
njb-27	51	35	minhang	minhang	PROPN
njb-27	51	36	district	district	PROPN
njb-27	51	37	,	,	PUNCT
njb-27	51	38	shanghai	shanghai	PROPN
njb-27	51	39	,	,	PUNCT
njb-27	51	40	china	china	PROPN
njb-27	51	41	)	)	PUNCT
njb-27	51	42	as	as	ADP
njb-27	51	43	per	per	ADP
njb-27	51	44	manufacturer	manufacturer	NOUN
njb-27	51	45	's	's	PART
njb-27	51	46	instructions	instruction	NOUN
njb-27	51	47	.	.	PUNCT
njb-27	52	1	proviral	proviral	ADJ
njb-27	52	2	dna	dna	PROPN
njb-27	52	3	detection	detection	NOUN
njb-27	52	4	:	:	PUNCT
njb-27	52	5	nested	nest	VERB
njb-27	52	6	pcr	pcr	NOUN
njb-27	52	7	nested	nest	VERB
njb-27	52	8	pcr	pcr	NOUN
njb-27	52	9	for	for	ADP
njb-27	52	10	hiv-1	hiv-1	PUNCT
njb-27	52	11	env	env	NOUN
njb-27	52	12	gene	gene	NOUN
njb-27	52	13	the	the	DET
njb-27	52	14	nested	nested	ADJ
njb-27	52	15	pcr	pcr	NOUN
njb-27	52	16	was	be	AUX
njb-27	52	17	performed	perform	VERB
njb-27	52	18	in	in	ADP
njb-27	52	19	the	the	DET
njb-27	52	20	env	env	NOUN
njb-27	52	21	v3	v3	PROPN
njb-27	52	22	dna	dna	PROPN
njb-27	52	23	sequences	sequence	NOUN
njb-27	52	24	of	of	ADP
njb-27	52	25	hiv-1	hiv-1	PUNCT
njb-27	52	26	for	for	ADP
njb-27	52	27	the	the	DET
njb-27	52	28	amplification	amplification	NOUN
njb-27	52	29	using	use	VERB
njb-27	52	30	highfidelity	highfidelity	NOUN
njb-27	52	31	pfu	pfu	PROPN
njb-27	52	32	dna	dna	PROPN
njb-27	52	33	polymerase	polymerase	NOUN
njb-27	52	34	.	.	PUNCT
njb-27	53	1	the	the	DET
njb-27	53	2	amplification	amplification	NOUN
njb-27	53	3	was	be	AUX
njb-27	53	4	performed	perform	VERB
njb-27	53	5	as	as	SCONJ
njb-27	53	6	described	describe	VERB
njb-27	53	7	in	in	ADP
njb-27	53	8	previous	previous	ADJ
njb-27	53	9	study	study	NOUN
njb-27	53	10	[	[	PUNCT
njb-27	53	11	19	19	NUM
njb-27	53	12	]	]	PUNCT
njb-27	53	13	.	.	PUNCT
njb-27	54	1	the	the	DET
njb-27	54	2	total	total	ADJ
njb-27	54	3	reaction	reaction	NOUN
njb-27	54	4	volume	volume	NOUN
njb-27	54	5	of	of	ADP
njb-27	54	6	20μl	20μl	ADV
njb-27	54	7	containing	contain	VERB
njb-27	54	8	1x	1x	PROPN
njb-27	54	9	pcr	pcr	NOUN
njb-27	54	10	buffer	buffer	NOUN
njb-27	54	11	,	,	PUNCT
njb-27	54	12	1.5	1.5	NUM
njb-27	54	13	mm	mm	NUM
njb-27	54	14	mgcl2	mgcl2	PROPN
njb-27	54	15	,	,	PUNCT
njb-27	54	16	200	200	NUM
njb-27	54	17	μm	μm	NOUN
njb-27	54	18	dntps	dntps	NOUN
njb-27	54	19	,	,	PUNCT
njb-27	54	20	and	and	CCONJ
njb-27	54	21	0.25	0.25	NUM
njb-27	54	22	u	u	NOUN
njb-27	54	23	of	of	ADP
njb-27	54	24	pfu	pfu	PROPN
njb-27	54	25	enzyme	enzyme	PROPN
njb-27	54	26	and	and	CCONJ
njb-27	54	27	rnase	rnase	PROPN
njb-27	54	28	free	free	ADJ
njb-27	54	29	water	water	NOUN
njb-27	54	30	.	.	PUNCT
njb-27	55	1	the	the	DET
njb-27	55	2	first	first	ADJ
njb-27	55	3	round	round	NOUN
njb-27	55	4	pcr	pcr	NOUN
njb-27	55	5	was	be	AUX
njb-27	55	6	performed	perform	VERB
njb-27	55	7	with	with	ADP
njb-27	55	8	0.5	0.5	NUM
njb-27	55	9	μm	μm	NOUN
njb-27	55	10	of	of	ADP
njb-27	55	11	upstream	upstream	ADJ
njb-27	55	12	primers	primer	NOUN
njb-27	55	13	ja9ae	ja9ae	PROPN
njb-27	55	14	(	(	PUNCT
njb-27	55	15	5’cacagtacaatgcacacatg-3	5’cacagtacaatgcacacatg-3	PROPN
njb-27	55	16	’	'	PUNCT
njb-27	55	17	)	)	PUNCT
njb-27	55	18	,	,	PUNCT
njb-27	55	19	ja9b	ja9b	PROPN
njb-27	55	20	(	(	PUNCT
njb-27	55	21	5’cacagtacaatgtacacatg-3	5’cacagtacaatgtacacatg-3	PROPN
njb-27	55	22	’	'	PUNCT
njb-27	55	23	)	)	PUNCT
njb-27	55	24	,	,	PUNCT
njb-27	55	25	and	and	CCONJ
njb-27	55	26	downstream	downstream	ADJ
njb-27	55	27	primers	primer	NOUN
njb-27	55	28	ja12a	ja12a	NOUN
njb-27	55	29	(	(	PUNCT
njb-27	55	30	5’gcaatagaaaaattctcctc-3	5’gcaatagaaaaattctcctc-3	NUM
njb-27	55	31	’	'	PUNCT
njb-27	55	32	)	)	PUNCT
njb-27	55	33	,	,	PUNCT
njb-27	55	34	ja12b	ja12b	NOUN
njb-27	55	35	(	(	PUNCT
njb-27	55	36	5’acagtagaaaaattcccctc-3	5’acagtagaaaaattcccctc-3	NUM
njb-27	55	37	’	'	PUNCT
njb-27	55	38	)	)	PUNCT
njb-27	55	39	.	.	PUNCT
njb-27	56	1	the	the	DET
njb-27	56	2	reaction	reaction	NOUN
njb-27	56	3	mixture	mixture	NOUN
njb-27	56	4	was	be	AUX
njb-27	56	5	incubated	incubate	VERB
njb-27	56	6	at	at	ADP
njb-27	56	7	95	95	NUM
njb-27	56	8	°	°	NOUN
njb-27	56	9	c	c	NOUN
njb-27	56	10	for	for	ADP
njb-27	56	11	15	15	NUM
njb-27	56	12	minutes	minute	NOUN
njb-27	56	13	,	,	PUNCT
njb-27	56	14	94	94	NUM
njb-27	56	15	°	°	NOUN
njb-27	56	16	c	c	NOUN
njb-27	56	17	for	for	ADP
njb-27	56	18	30	30	NUM
njb-27	56	19	sec	sec	PROPN
njb-27	56	20	,	,	PUNCT
njb-27	56	21	58	58	NUM
njb-27	56	22	°	°	NOUN
njb-27	56	23	c	c	NOUN
njb-27	56	24	for	for	ADP
njb-27	56	25	30	30	NUM
njb-27	56	26	sec	sec	PROPN
njb-27	56	27	,	,	PUNCT
njb-27	56	28	72	72	NUM
njb-27	56	29	°	°	NOUN
njb-27	56	30	c	c	NOUN
njb-27	56	31	for	for	ADP
njb-27	56	32	30	30	NUM
njb-27	56	33	sec	sec	PROPN
njb-27	56	34	and	and	CCONJ
njb-27	56	35	72	72	NUM
njb-27	56	36	°	°	NOUN
njb-27	56	37	c	c	NOUN
njb-27	56	38	for	for	ADP
njb-27	56	39	10	10	NUM
njb-27	56	40	minutes	minute	NOUN
njb-27	56	41	,	,	PUNCT
njb-27	56	42	for	for	ADP
njb-27	56	43	35	35	NUM
njb-27	56	44	pcr	pcr	NOUN
njb-27	56	45	cycles	cycle	NOUN
njb-27	56	46	.	.	PUNCT
njb-27	57	1	1	1	NUM
njb-27	57	2	μl	μl	NOUN
njb-27	57	3	of	of	ADP
njb-27	57	4	the	the	DET
njb-27	57	5	firstround	firstround	NOUN
njb-27	57	6	pcr	pcr	NOUN
njb-27	57	7	product	product	NOUN
njb-27	57	8	was	be	AUX
njb-27	57	9	used	use	VERB
njb-27	57	10	as	as	ADP
njb-27	57	11	template	template	NOUN
njb-27	57	12	for	for	ADP
njb-27	57	13	second	second	ADJ
njb-27	57	14	-	-	PUNCT
njb-27	57	15	round	round	NOUN
njb-27	57	16	pcr	pcr	NOUN
njb-27	57	17	.	.	PUNCT
njb-27	58	1	inner	inner	ADJ
njb-27	58	2	upstream	upstream	ADJ
njb-27	58	3	primers	primer	NOUN
njb-27	58	4	used	use	VERB
njb-27	58	5	were	be	AUX
njb-27	58	6	a	a	DET
njb-27	58	7	mixture	mixture	NOUN
njb-27	58	8	of	of	ADP
njb-27	58	9	0.33	0.33	NUM
njb-27	58	10	μm	μm	NOUN
njb-27	58	11	each	each	PRON
njb-27	58	12	of	of	ADP
njb-27	58	13	ja10ub	ja10ub	PROPN
njb-27	58	14	(	(	PUNCT
njb-27	58	15	5’ctgttaaatggcagtctagc-3	5’ctgttaaatggcagtctagc-3	NUM
njb-27	58	16	’	'	PUNCT
njb-27	58	17	)	)	PUNCT
njb-27	58	18	,	,	PUNCT
njb-27	58	19	ja10uc	ja10uc	PROPN
njb-27	58	20	(	(	PUNCT
njb-27	58	21	5’ctgttaaatggtagtctagc-3	5’ctgttaaatggtagtctagc-3	NUM
njb-27	58	22	’	'	PUNCT
njb-27	58	23	)	)	PUNCT
njb-27	58	24	,	,	PUNCT
njb-27	58	25	and	and	CCONJ
njb-27	58	26	ja10ug	ja10ug	PROPN
njb-27	58	27	(	(	PUNCT
njb-27	58	28	5’-ctgttaaatggcagtttagc-3	5’-ctgttaaatggcagtttagc-3	NUM
njb-27	58	29	’	'	PUNCT
njb-27	58	30	)	)	PUNCT
njb-27	58	31	.	.	PUNCT
njb-27	59	1	inner	inner	ADJ
njb-27	59	2	downstream	downstream	ADJ
njb-27	59	3	primers	primer	NOUN
njb-27	59	4	used	use	VERB
njb-27	59	5	were	be	AUX
njb-27	59	6	different	different	ADJ
njb-27	59	7	for	for	ADP
njb-27	59	8	each	each	DET
njb-27	59	9	reaction	reaction	NOUN
njb-27	59	10	,	,	PUNCT
njb-27	59	11	namely	namely	ADV
njb-27	59	12	,	,	PUNCT
njb-27	59	13	0.33	0.33	NUM
njb-27	59	14	μm	μm	NOUN
njb-27	59	15	each	each	PRON
njb-27	59	16	of	of	ADP
njb-27	59	17	ja11lae	ja11lae	PROPN
njb-27	59	18	(	(	PUNCT
njb-27	59	19	5’aatttctagatcccctcctg-3	5’aatttctagatcccctcctg-3	PROPN
njb-27	59	20	’	'	PUNCT
njb-27	59	21	)	)	PUNCT
njb-27	59	22	,	,	PUNCT
njb-27	59	23	ja11	ja11	PROPN
njb-27	59	24	lb	lb	NOUN
njb-27	59	25	(	(	PUNCT
njb-27	59	26	5’aatttctgggtcccctcctg-3	5’aatttctgggtcccctcctg-3	PROPN
njb-27	59	27	’	'	PUNCT
njb-27	59	28	)	)	PUNCT
njb-27	59	29	,	,	PUNCT
njb-27	59	30	and	and	CCONJ
njb-27	59	31	ja11lc	ja11lc	NUM
njb-27	59	32	(	(	PUNCT
njb-27	59	33	5’aatttctaggtcccctcctg-3	5’aatttctaggtcccctcctg-3	NUM
njb-27	59	34	’	'	PUNCT
njb-27	59	35	)	)	PUNCT
njb-27	59	36	.	.	PUNCT
njb-27	60	1	the	the	DET
njb-27	60	2	reaction	reaction	NOUN
njb-27	60	3	mixture	mixture	NOUN
njb-27	60	4	was	be	AUX
njb-27	60	5	incubated	incubate	VERB
njb-27	60	6	at	at	ADP
njb-27	60	7	95	95	NUM
njb-27	60	8	°	°	NOUN
njb-27	60	9	c	c	NOUN
njb-27	60	10	for	for	ADP
njb-27	60	11	15	15	NUM
njb-27	60	12	minutes	minute	NOUN
njb-27	60	13	,	,	PUNCT
njb-27	60	14	94	94	NUM
njb-27	60	15	°	°	NOUN
njb-27	60	16	c	c	NOUN
njb-27	60	17	for	for	ADP
njb-27	60	18	30	30	NUM
njb-27	60	19	sec	sec	PROPN
njb-27	60	20	,	,	PUNCT
njb-27	60	21	50	50	NUM
njb-27	60	22	°	°	NOUN
njb-27	60	23	c	c	NOUN
njb-27	60	24	for	for	ADP
njb-27	60	25	30	30	NUM
njb-27	60	26	sec	sec	PROPN
njb-27	60	27	,	,	PUNCT
njb-27	60	28	72	72	NUM
njb-27	60	29	°	°	NOUN
njb-27	60	30	c	c	NOUN
njb-27	60	31	for	for	ADP
njb-27	60	32	30	30	NUM
njb-27	60	33	sec	sec	PROPN
njb-27	60	34	and	and	CCONJ
njb-27	60	35	72	72	NUM
njb-27	60	36	°	°	NOUN
njb-27	60	37	c	c	NOUN
njb-27	60	38	for	for	ADP
njb-27	60	39	10	10	NUM
njb-27	60	40	minutes	minute	NOUN
njb-27	60	41	,	,	PUNCT
njb-27	60	42	for	for	ADP
njb-27	60	43	35	35	NUM
njb-27	60	44	pcr	pcr	NOUN
njb-27	60	45	cycles	cycle	NOUN
njb-27	60	46	.	.	PUNCT
njb-27	61	1	the	the	DET
njb-27	61	2	final	final	ADJ
njb-27	61	3	pcr	pcr	NOUN
njb-27	61	4	product	product	NOUN
njb-27	61	5	was	be	AUX
njb-27	61	6	resolved	resolve	VERB
njb-27	61	7	in	in	ADP
njb-27	61	8	1.7	1.7	NUM
njb-27	61	9	%	%	NOUN
njb-27	61	10	agarose	agarose	NOUN
njb-27	61	11	gel	gel	NOUN
njb-27	61	12	electrophoresis	electrophoresis	NOUN
njb-27	61	13	and	and	CCONJ
njb-27	61	14	image	image	NOUN
njb-27	61	15	was	be	AUX
njb-27	61	16	captured	capture	VERB
njb-27	61	17	using	use	VERB
njb-27	61	18	gel	gel	NOUN
njb-27	61	19	documentation	documentation	NOUN
njb-27	61	20	.	.	PUNCT
njb-27	62	1	hiv-1	hiv-1	PUNCT
njb-27	62	2	rna	rna	NOUN
njb-27	62	3	mutational	mutational	ADJ
njb-27	62	4	(	(	PUNCT
njb-27	62	5	m184v	m184v	PROPN
njb-27	62	6	)	)	PUNCT
njb-27	62	7	analysis	analysis	NOUN
njb-27	62	8	:	:	PUNCT
njb-27	62	9	pcr	pcr	PROPN
njb-27	62	10	-	-	PUNCT
njb-27	62	11	rfda	rfda	PROPN
njb-27	62	12	rt	rt	PROPN
njb-27	62	13	gene	gene	NOUN
njb-27	62	14	amplification	amplification	NOUN
njb-27	62	15	:	:	PUNCT
njb-27	62	16	nested	nest	VERB
njb-27	62	17	pcr	pcr	NOUN
njb-27	62	18	the	the	DET
njb-27	62	19	amplification	amplification	NOUN
njb-27	62	20	of	of	ADP
njb-27	62	21	hiv-1	hiv-1	PUNCT
njb-27	62	22	rt	rt	PROPN
njb-27	62	23	gene	gene	NOUN
njb-27	62	24	was	be	AUX
njb-27	62	25	performed	perform	VERB
njb-27	62	26	using	use	VERB
njb-27	62	27	nested	nest	VERB
njb-27	62	28	primer	primer	NOUN
njb-27	62	29	pairs	pair	NOUN
njb-27	62	30	which	which	PRON
njb-27	62	31	were	be	AUX
njb-27	62	32	reported	report	VERB
njb-27	62	33	in	in	ADP
njb-27	62	34	previous	previous	ADJ
njb-27	62	35	study	study	NOUN
njb-27	62	36	[	[	PUNCT
njb-27	62	37	20	20	NUM
njb-27	62	38	]	]	PUNCT
njb-27	62	39	.	.	PUNCT
njb-27	63	1	the	the	DET
njb-27	63	2	isolated	isolated	ADJ
njb-27	63	3	hiv-1	hiv-1	PUNCT
njb-27	63	4	rna	rna	NOUN
njb-27	63	5	was	be	AUX
njb-27	63	6	subjected	subject	VERB
njb-27	63	7	to	to	ADP
njb-27	63	8	onestep	onestep	PROPN
njb-27	63	9	rt	rt	PROPN
njb-27	63	10	-	-	PUNCT
njb-27	63	11	pcr	pcr	PROPN
njb-27	63	12	(	(	PUNCT
njb-27	63	13	qiagen	qiagen	PROPN
njb-27	63	14	,	,	PUNCT
njb-27	63	15	hilden	hilden	PROPN
njb-27	63	16	,	,	PUNCT
njb-27	63	17	germany	germany	PROPN
njb-27	63	18	)	)	PUNCT
njb-27	63	19	.	.	PUNCT
njb-27	64	1	the	the	DET
njb-27	64	2	rt	rt	PROPN
njb-27	64	3	-	-	PUNCT
njb-27	64	4	pcr	pcr	PROPN
njb-27	64	5	product	product	NOUN
njb-27	64	6	was	be	AUX
njb-27	64	7	then	then	ADV
njb-27	64	8	used	use	VERB
njb-27	64	9	as	as	ADP
njb-27	64	10	templates	template	NOUN
njb-27	64	11	for	for	ADP
njb-27	64	12	second	second	ADJ
njb-27	64	13	round	round	NOUN
njb-27	64	14	pcr	pcr	PROPN
njb-27	64	15	.	.	PUNCT
njb-27	65	1	the	the	DET
njb-27	65	2	qiagen	qiagen	PROPN
njb-27	65	3	nepal	nepal	ADJ
njb-27	65	4	journal	journal	NOUN
njb-27	65	5	of	of	ADP
njb-27	65	6	biotechnology	biotechnology	NOUN
njb-27	65	7	.	.	PUNCT
njb-27	66	1	d	d	X
njb-27	66	2	e	e	PROPN
njb-27	66	3	c	c	PROPN
njb-27	66	4	.	.	PUNCT
njb-27	67	1	2	2	NUM
njb-27	67	2	0	0	NUM
njb-27	67	3	1	1	NUM
njb-27	67	4	6	6	NUM
njb-27	67	5	vol	vol	NOUN
njb-27	67	6	.	.	PROPN
njb-27	68	1	4	4	NUM
njb-27	68	2	,	,	PUNCT
njb-27	68	3	no	no	NOUN
njb-27	68	4	.	.	NOUN
njb-27	68	5	1	1	NUM
njb-27	68	6	:	:	SYM
njb-27	68	7	18	18	NUM
njb-27	68	8	-	-	SYM
njb-27	68	9	25	25	NUM
njb-27	68	10	shrestha	shrestha	NOUN
njb-27	68	11	et	et	X
njb-27	68	12	al	al	PROPN
njb-27	68	13	.	.	PUNCT
njb-27	69	1	©	©	PROPN
njb-27	69	2	njb	njb	PROPN
njb-27	69	3	,	,	PUNCT
njb-27	69	4	biotechnology	biotechnology	NOUN
njb-27	69	5	society	society	NOUN
njb-27	69	6	of	of	ADP
njb-27	69	7	nepal	nepal	ADJ
njb-27	69	8	20	20	NUM
njb-27	69	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	69	10	onestep	onestep	NOUN
njb-27	69	11	rt	rt	PROPN
njb-27	69	12	-	-	PUNCT
njb-27	69	13	pcr	pcr	PROPN
njb-27	69	14	was	be	AUX
njb-27	69	15	performed	perform	VERB
njb-27	69	16	as	as	SCONJ
njb-27	69	17	recommended	recommend	VERB
njb-27	69	18	by	by	ADP
njb-27	69	19	the	the	DET
njb-27	69	20	manufacturer	manufacturer	NOUN
njb-27	69	21	.	.	PUNCT
njb-27	70	1	the	the	DET
njb-27	70	2	total	total	ADJ
njb-27	70	3	volume	volume	NOUN
njb-27	70	4	of	of	ADP
njb-27	70	5	50μl	50μl	ADJ
njb-27	70	6	reaction	reaction	NOUN
njb-27	70	7	was	be	AUX
njb-27	70	8	carried	carry	VERB
njb-27	70	9	out	out	ADP
njb-27	70	10	containing	contain	VERB
njb-27	70	11	rnase	rnase	PROPN
njb-27	70	12	free	free	ADJ
njb-27	70	13	water	water	NOUN
njb-27	70	14	,	,	PUNCT
njb-27	70	15	1x	1x	PROPN
njb-27	70	16	onestep	onestep	PROPN
njb-27	70	17	rt	rt	PROPN
njb-27	70	18	-	-	PUNCT
njb-27	70	19	pcr	pcr	PROPN
njb-27	70	20	buffer	buffer	NOUN
njb-27	70	21	,	,	PUNCT
njb-27	70	22	200	200	NUM
njb-27	70	23	μm	μm	NOUN
njb-27	70	24	dntp	dntp	ADJ
njb-27	70	25	mix	mix	NOUN
njb-27	70	26	,	,	PUNCT
njb-27	70	27	0.6	0.6	NUM
njb-27	70	28	μm	μm	NOUN
njb-27	70	29	of	of	ADP
njb-27	70	30	each	each	DET
njb-27	70	31	primers	primer	NOUN
njb-27	70	32	a1	a1	PROPN
njb-27	70	33	(	(	PUNCT
njb-27	70	34	5’aattttcccattagccctatt-3	5’aattttcccattagccctatt-3	NUM
njb-27	70	35	’	'	PUNCT
njb-27	70	36	)	)	PUNCT
njb-27	70	37	and	and	CCONJ
njb-27	70	38	ne1	ne1	PROPN
njb-27	70	39	(	(	PUNCT
njb-27	70	40	5’tatgtcattgacagtccagct-3	5’tatgtcattgacagtccagct-3	PROPN
njb-27	70	41	’	'	PUNCT
njb-27	70	42	)	)	PUNCT
njb-27	70	43	,	,	PUNCT
njb-27	70	44	2μl	2μl	NOUN
njb-27	70	45	of	of	ADP
njb-27	70	46	onestep	onestep	PROPN
njb-27	70	47	rt	rt	PROPN
njb-27	70	48	-	-	PUNCT
njb-27	70	49	pcr	pcr	PROPN
njb-27	70	50	enzyme	enzyme	NOUN
njb-27	70	51	mix	mix	NOUN
njb-27	70	52	,	,	PUNCT
njb-27	70	53	5	5	NUM
njb-27	70	54	units	unit	NOUN
njb-27	70	55	rnase	rnase	PROPN
njb-27	70	56	inhibitor	inhibitor	NOUN
njb-27	70	57	and	and	CCONJ
njb-27	70	58	2	2	NUM
njb-27	70	59	μg	μg	NOUN
njb-27	70	60	viral	viral	ADJ
njb-27	70	61	rna	rna	NOUN
njb-27	70	62	for	for	ADP
njb-27	70	63	reversetranscriptase	reversetranscriptase	NOUN
njb-27	70	64	gene	gene	NOUN
njb-27	70	65	.	.	PUNCT
njb-27	71	1	the	the	DET
njb-27	71	2	reaction	reaction	NOUN
njb-27	71	3	was	be	AUX
njb-27	71	4	incubated	incubate	VERB
njb-27	71	5	at	at	ADP
njb-27	71	6	48	48	NUM
njb-27	71	7	°	°	NOUN
njb-27	71	8	c	c	NOUN
njb-27	71	9	for	for	ADP
njb-27	71	10	20	20	NUM
njb-27	71	11	minutes	minute	NOUN
njb-27	71	12	(	(	PUNCT
njb-27	71	13	reverse	reverse	ADJ
njb-27	71	14	transcription	transcription	NOUN
njb-27	71	15	)	)	PUNCT
njb-27	71	16	followed	follow	VERB
njb-27	71	17	by	by	ADP
njb-27	71	18	94	94	NUM
njb-27	71	19	°	°	NOUN
njb-27	71	20	c	c	NOUN
njb-27	71	21	for	for	ADP
njb-27	71	22	4	4	NUM
njb-27	71	23	minutes	minute	NOUN
njb-27	71	24	,	,	PUNCT
njb-27	71	25	94	94	NUM
njb-27	71	26	°	°	NOUN
njb-27	71	27	c	c	NOUN
njb-27	71	28	for	for	ADP
njb-27	71	29	30	30	NUM
njb-27	71	30	sec	sec	PROPN
njb-27	71	31	,	,	PUNCT
njb-27	71	32	52	52	NUM
njb-27	71	33	°	°	NOUN
njb-27	71	34	c	c	NOUN
njb-27	71	35	for	for	ADP
njb-27	71	36	30	30	NUM
njb-27	71	37	sec	sec	PROPN
njb-27	71	38	,	,	PUNCT
njb-27	71	39	72	72	NUM
njb-27	71	40	°	°	NOUN
njb-27	71	41	c	c	NOUN
njb-27	71	42	for	for	ADP
njb-27	71	43	30	30	NUM
njb-27	71	44	sec	sec	PROPN
njb-27	71	45	,	,	PUNCT
njb-27	71	46	and	and	CCONJ
njb-27	71	47	72	72	NUM
njb-27	71	48	°	°	NOUN
njb-27	71	49	c	c	NOUN
njb-27	71	50	for	for	ADP
njb-27	71	51	10	10	NUM
njb-27	71	52	minutes	minute	NOUN
njb-27	71	53	,	,	PUNCT
njb-27	71	54	for	for	ADP
njb-27	71	55	35	35	NUM
njb-27	71	56	pcr	pcr	NOUN
njb-27	71	57	cycles	cycle	NOUN
njb-27	71	58	.	.	PUNCT
njb-27	72	1	the	the	DET
njb-27	72	2	second	second	ADJ
njb-27	72	3	round	round	NOUN
njb-27	72	4	pcr	pcr	NOUN
njb-27	72	5	was	be	AUX
njb-27	72	6	done	do	VERB
njb-27	72	7	by	by	ADP
njb-27	72	8	using	use	VERB
njb-27	72	9	a	a	DET
njb-27	72	10	qiagen	qiagen	NOUN
njb-27	72	11	master	master	NOUN
njb-27	72	12	mix	mix	NOUN
njb-27	72	13	with	with	ADP
njb-27	72	14	5	5	NUM
njb-27	72	15	µl	µl	NOUN
njb-27	72	16	of	of	ADP
njb-27	72	17	the	the	DET
njb-27	72	18	first	first	ADJ
njb-27	72	19	rt	rt	PROPN
njb-27	72	20	-	-	PUNCT
njb-27	72	21	pcr	pcr	PROPN
njb-27	72	22	product	product	NOUN
njb-27	72	23	and	and	CCONJ
njb-27	72	24	primers	primer	NOUN
njb-27	72	25	nna	nna	PROPN
njb-27	72	26	(	(	PUNCT
njb-27	72	27	5’aagccaggaatggatggccca-3	5’aagccaggaatggatggccca-3	NUM
njb-27	72	28	,	,	PUNCT
njb-27	72	29	)	)	PUNCT
njb-27	72	30	and	and	CCONJ
njb-27	72	31	e	e	X
njb-27	72	32	(	(	PUNCT
njb-27	72	33	5’ccatttatcaggatggagttc-3	5’ccatttatcaggatggagttc-3	PROPN
njb-27	72	34	’	'	PUNCT
njb-27	72	35	)	)	PUNCT
njb-27	72	36	.	.	PUNCT
njb-27	73	1	the	the	DET
njb-27	73	2	reaction	reaction	NOUN
njb-27	73	3	mixture	mixture	NOUN
njb-27	73	4	was	be	AUX
njb-27	73	5	incubated	incubate	VERB
njb-27	73	6	at	at	ADP
njb-27	73	7	95	95	NUM
njb-27	73	8	°	°	NOUN
njb-27	73	9	c	c	NOUN
njb-27	73	10	for	for	ADP
njb-27	73	11	15	15	NUM
njb-27	73	12	minutes	minute	NOUN
njb-27	73	13	,	,	PUNCT
njb-27	73	14	94	94	NUM
njb-27	73	15	°	°	NOUN
njb-27	73	16	c	c	NOUN
njb-27	73	17	for	for	ADP
njb-27	73	18	30	30	NUM
njb-27	73	19	sec	sec	PROPN
njb-27	73	20	,	,	PUNCT
njb-27	73	21	50	50	NUM
njb-27	73	22	°	°	NOUN
njb-27	73	23	c	c	NOUN
njb-27	73	24	for	for	ADP
njb-27	73	25	30	30	NUM
njb-27	73	26	sec	sec	PROPN
njb-27	73	27	,	,	PUNCT
njb-27	73	28	72	72	NUM
njb-27	73	29	°	°	NOUN
njb-27	73	30	c	c	NOUN
njb-27	73	31	for	for	ADP
njb-27	73	32	45	45	NUM
njb-27	73	33	sec	sec	PROPN
njb-27	73	34	and	and	CCONJ
njb-27	73	35	72	72	NUM
njb-27	73	36	°	°	NOUN
njb-27	73	37	c	c	NOUN
njb-27	73	38	for	for	ADP
njb-27	73	39	10	10	NUM
njb-27	73	40	minutes	minute	NOUN
njb-27	73	41	,	,	PUNCT
njb-27	73	42	for	for	ADP
njb-27	73	43	30	30	NUM
njb-27	73	44	pcr	pcr	NOUN
njb-27	73	45	cycles	cycle	NOUN
njb-27	73	46	.	.	PUNCT
njb-27	74	1	m184v	m184v	VERB
njb-27	74	2	mutation	mutation	NOUN
njb-27	74	3	testing	testing	NOUN
njb-27	74	4	:	:	PUNCT
njb-27	74	5	restriction	restriction	NOUN
njb-27	74	6	fragment	fragment	ADJ
njb-27	74	7	digestion	digestion	NOUN
njb-27	74	8	assay	assay	NOUN
njb-27	74	9	(	(	PUNCT
njb-27	74	10	rfda	rfda	PROPN
njb-27	74	11	)	)	PUNCT
njb-27	74	12	the	the	DET
njb-27	74	13	amplified	amplified	PROPN
njb-27	74	14	rt	rt	PROPN
njb-27	74	15	gene	gene	NOUN
njb-27	74	16	was	be	AUX
njb-27	74	17	tested	test	VERB
njb-27	74	18	for	for	ADP
njb-27	74	19	m184v	m184v	ADJ
njb-27	74	20	mutation	mutation	NOUN
njb-27	74	21	by	by	ADP
njb-27	74	22	digestion	digestion	NOUN
njb-27	74	23	approach	approach	NOUN
njb-27	74	24	called	call	VERB
njb-27	74	25	rfda	rfda	PROPN
njb-27	74	26	.	.	PUNCT
njb-27	75	1	the	the	DET
njb-27	75	2	rfda	rfda	PROPN
njb-27	75	3	was	be	AUX
njb-27	75	4	performed	perform	VERB
njb-27	75	5	using	use	VERB
njb-27	75	6	restriction	restriction	NOUN
njb-27	75	7	enzymes	enzyme	NOUN
njb-27	75	8	cviaii	cviaii	PROPN
njb-27	75	9	.	.	PUNCT
njb-27	76	1	the	the	DET
njb-27	76	2	total	total	ADJ
njb-27	76	3	volume	volume	NOUN
njb-27	76	4	of	of	ADP
njb-27	76	5	50μl	50μl	ADJ
njb-27	76	6	reaction	reaction	NOUN
njb-27	76	7	was	be	AUX
njb-27	76	8	performed	perform	VERB
njb-27	76	9	containing	contain	VERB
njb-27	76	10	1x	1x	NUM
njb-27	76	11	nebuffer	nebuffer	NOUN
njb-27	76	12	,	,	PUNCT
njb-27	76	13	10	10	NUM
njb-27	76	14	units	unit	NOUN
njb-27	76	15	’	'	PUNCT
njb-27	76	16	cviaii	cviaii	PROPN
njb-27	76	17	restriction	restriction	NOUN
njb-27	76	18	enzyme	enzyme	PROPN
njb-27	76	19	,	,	PUNCT
njb-27	76	20	and	and	CCONJ
njb-27	76	21	1μg	1μg	PROPN
njb-27	76	22	rt	rt	PROPN
njb-27	76	23	-	-	PUNCT
njb-27	76	24	pcr	pcr	PROPN
njb-27	76	25	product	product	NOUN
njb-27	76	26	at	at	ADP
njb-27	76	27	25oc	25oc	NOUN
njb-27	76	28	for	for	ADP
njb-27	76	29	1	1	NUM
njb-27	76	30	hour	hour	NOUN
njb-27	76	31	.	.	PUNCT
njb-27	77	1	the	the	DET
njb-27	77	2	digested	digest	VERB
njb-27	77	3	product	product	NOUN
njb-27	77	4	was	be	AUX
njb-27	77	5	resolved	resolve	VERB
njb-27	77	6	in	in	ADP
njb-27	77	7	1.7	1.7	NUM
njb-27	77	8	%	%	NOUN
njb-27	77	9	agarose	agarose	NOUN
njb-27	77	10	gel	gel	NOUN
njb-27	77	11	electrophoresis	electrophoresis	NOUN
njb-27	77	12	and	and	CCONJ
njb-27	77	13	image	image	NOUN
njb-27	77	14	were	be	AUX
njb-27	77	15	captured	capture	VERB
njb-27	77	16	using	use	VERB
njb-27	77	17	gel	gel	NOUN
njb-27	77	18	documentation	documentation	NOUN
njb-27	77	19	.	.	PUNCT
njb-27	78	1	results	result	NOUN
njb-27	78	2	in	in	ADP
njb-27	78	3	the	the	DET
njb-27	78	4	present	present	ADJ
njb-27	78	5	study	study	NOUN
njb-27	78	6	,	,	PUNCT
njb-27	78	7	detection	detection	NOUN
njb-27	78	8	of	of	ADP
njb-27	78	9	proviral	proviral	ADJ
njb-27	78	10	dna	dna	NOUN
njb-27	78	11	by	by	ADP
njb-27	78	12	amplification	amplification	NOUN
njb-27	78	13	of	of	ADP
njb-27	78	14	env	env	NOUN
njb-27	78	15	v3	v3	PROPN
njb-27	78	16	dna	dna	PROPN
njb-27	78	17	sequences	sequence	NOUN
njb-27	78	18	was	be	AUX
njb-27	78	19	done	do	VERB
njb-27	78	20	by	by	ADP
njb-27	78	21	nested	nested	ADJ
njb-27	78	22	pcr	pcr	PROPN
njb-27	78	23	while	while	SCONJ
njb-27	78	24	testing	testing	NOUN
njb-27	78	25	of	of	ADP
njb-27	78	26	resistance	resistance	NOUN
njb-27	78	27	mutation	mutation	NOUN
njb-27	78	28	in	in	ADP
njb-27	78	29	the	the	DET
njb-27	78	30	hiv-1	hiv-1	PUNCT
njb-27	78	31	rt	rt	PROPN
njb-27	78	32	(	(	PUNCT
njb-27	78	33	met	meet	VERB
njb-27	78	34	184	184	NUM
njb-27	78	35	val	val	PROPN
njb-27	78	36	)	)	PUNCT
njb-27	78	37	gene	gene	NOUN
njb-27	78	38	was	be	AUX
njb-27	78	39	performed	perform	VERB
njb-27	78	40	by	by	ADP
njb-27	78	41	pcr	pcr	NOUN
njb-27	78	42	and	and	CCONJ
njb-27	78	43	rfda	rfda	PROPN
njb-27	78	44	.	.	PUNCT
njb-27	79	1	individual	individual	ADJ
njb-27	79	2	band	band	NOUN
njb-27	79	3	,	,	PUNCT
njb-27	79	4	resulting	result	VERB
njb-27	79	5	from	from	ADP
njb-27	79	6	final	final	ADJ
njb-27	79	7	pcr	pcr	NOUN
njb-27	79	8	product	product	NOUN
njb-27	79	9	and	and	CCONJ
njb-27	79	10	enzyme	enzyme	NOUN
njb-27	79	11	digested	digest	VERB
njb-27	79	12	product	product	NOUN
njb-27	79	13	was	be	AUX
njb-27	79	14	compared	compare	VERB
njb-27	79	15	with	with	ADP
njb-27	79	16	art	art	NOUN
njb-27	79	17	resistance	resistance	NOUN
njb-27	79	18	strain	strain	NOUN
njb-27	79	19	and	and	CCONJ
njb-27	79	20	molecular	molecular	ADJ
njb-27	79	21	size	size	NOUN
njb-27	79	22	marker	marker	NOUN
njb-27	79	23	(	(	PUNCT
njb-27	79	24	100bp	100bp	PROPN
njb-27	79	25	)	)	PUNCT
njb-27	79	26	.	.	PUNCT
njb-27	80	1	the	the	DET
njb-27	80	2	results	result	NOUN
njb-27	80	3	are	be	AUX
njb-27	80	4	tabulated	tabulate	VERB
njb-27	80	5	and	and	CCONJ
njb-27	80	6	is	be	AUX
njb-27	80	7	shown	show	VERB
njb-27	80	8	in	in	ADP
njb-27	80	9	table	table	NOUN
njb-27	80	10	1	1	NUM
njb-27	80	11	.	.	PUNCT
njb-27	80	12	table	table	NOUN
njb-27	80	13	1	1	NUM
njb-27	80	14	:	:	PUNCT
njb-27	80	15	patient	patient	NOUN
njb-27	80	16	’s	’s	PART
njb-27	80	17	information	information	NOUN
njb-27	80	18	,	,	PUNCT
njb-27	80	19	art	art	NOUN
njb-27	80	20	and	and	CCONJ
njb-27	80	21	genotypic	genotypic	NOUN
njb-27	80	22	testing	testing	NOUN
njb-27	80	23	in	in	ADP
njb-27	80	24	the	the	DET
njb-27	80	25	study	study	NOUN
njb-27	80	26	population	population	NOUN
njb-27	80	27	n-15	n-15	CCONJ
njb-27	80	28	code	code	NOUN
njb-27	80	29	gender	gender	NOUN
njb-27	80	30	/	/	SYM
njb-27	80	31	age	age	NOUN
njb-27	80	32	art	art	NOUN
njb-27	80	33	used	use	VERB
njb-27	80	34	viral	viral	ADJ
njb-27	80	35	load	load	NOUN
njb-27	80	36	copies	copy	NOUN
njb-27	80	37	/	/	SYM
njb-27	80	38	ml	ml	PROPN
njb-27	80	39	env	env	VERB
njb-27	80	40	v3	v3	PROPN
njb-27	80	41	dna	dna	PROPN
njb-27	80	42	m184v	m184v	VERB
njb-27	80	43	mutation	mutation	NOUN
njb-27	80	44	patient	patient	NOUN
njb-27	80	45	status	status	NOUN
njb-27	80	46	hrm1	hrm1	PROPN
njb-27	80	47	male/36	male/36	VERB
njb-27	80	48	yrs	yrs	PROPN
njb-27	80	49	azt	azt	PROPN
njb-27	80	50	,	,	PUNCT
njb-27	80	51	3tc	3tc	NOUN
njb-27	80	52	,	,	PUNCT
njb-27	80	53	nfv	nfv	INTJ
njb-27	80	54	1500	1500	NUM
njb-27	80	55	positive	positive	ADJ
njb-27	80	56	negative	negative	ADJ
njb-27	80	57	critical	critical	ADJ
njb-27	80	58	hrm2	hrm2	PROPN
njb-27	80	59	male/33	male/33	VERB
njb-27	80	60	yrs	yrs	PROPN
njb-27	80	61	azt	azt	PROPN
njb-27	80	62	,	,	PUNCT
njb-27	80	63	3tc	3tc	NOUN
njb-27	80	64	,	,	PUNCT
njb-27	80	65	efz	efz	NOUN
njb-27	80	66	1500	1500	NUM
njb-27	80	67	positive	positive	ADJ
njb-27	80	68	negative	negative	ADJ
njb-27	80	69	critical	critical	ADJ
njb-27	80	70	hrm3	hrm3	PROPN
njb-27	80	71	male/26yrs	male/26yrs	PROPN
njb-27	80	72	azt	azt	PROPN
njb-27	80	73	,	,	PUNCT
njb-27	80	74	3tc	3tc	NOUN
njb-27	80	75	,	,	PUNCT
njb-27	80	76	nfv	nfv	INTJ
njb-27	80	77	1500	1500	NUM
njb-27	80	78	positive	positive	ADJ
njb-27	80	79	negative	negative	ADJ
njb-27	80	80	critical	critical	ADJ
njb-27	80	81	hrm4	hrm4	PROPN
njb-27	80	82	male/35yrs	male/35yr	NOUN
njb-27	80	83	azt	azt	PROPN
njb-27	80	84	,	,	PUNCT
njb-27	80	85	3tc	3tc	NOUN
njb-27	80	86	,	,	PUNCT
njb-27	80	87	nfv	nfv	INTJ
njb-27	80	88	1000	1000	NUM
njb-27	80	89	positive	positive	ADJ
njb-27	80	90	negative	negative	ADJ
njb-27	80	91	expired	expire	VERB
njb-27	80	92	hrm5	hrm5	PROPN
njb-27	80	93	male/23yrs	male/23yrs	PROPN
njb-27	80	94	azt	azt	PROPN
njb-27	80	95	,	,	PUNCT
njb-27	80	96	3tc	3tc	NOUN
njb-27	80	97	,	,	PUNCT
njb-27	80	98	nfv	nfv	INTJ
njb-27	80	99	1000	1000	NUM
njb-27	80	100	positive	positive	ADJ
njb-27	80	101	negative	negative	ADJ
njb-27	80	102	art	art	NOUN
njb-27	80	103	hrm6	hrm6	PROPN
njb-27	80	104	male/32yrs	male/32yrs	PROPN
njb-27	80	105	azt	azt	PROPN
njb-27	80	106	,	,	PUNCT
njb-27	80	107	3tc	3tc	NOUN
njb-27	80	108	,	,	PUNCT
njb-27	80	109	nfv	nfv	INTJ
njb-27	80	110	300	300	NUM
njb-27	80	111	negative	negative	ADJ
njb-27	80	112	negative	negative	ADJ
njb-27	80	113	art	art	NOUN
njb-27	80	114	hrm7	hrm7	PROPN
njb-27	80	115	male/34yrs	male/34yrs	PROPN
njb-27	80	116	azt	azt	PROPN
njb-27	80	117	,	,	PUNCT
njb-27	80	118	3tc	3tc	NOUN
njb-27	80	119	,	,	PUNCT
njb-27	80	120	nfv	nfv	NOUN
njb-27	80	121	800	800	NUM
njb-27	80	122	positive	positive	ADJ
njb-27	80	123	negative	negative	ADJ
njb-27	80	124	art	art	NOUN
njb-27	80	125	hrm8	hrm8	PROPN
njb-27	80	126	male/25yrs	male/25yr	NOUN
njb-27	80	127	azt	azt	PROPN
njb-27	80	128	,	,	PUNCT
njb-27	80	129	3tc	3tc	NOUN
njb-27	80	130	,	,	PUNCT
njb-27	80	131	nfv	nfv	NOUN
njb-27	80	132	800	800	NUM
njb-27	80	133	positive	positive	ADJ
njb-27	80	134	negative	negative	ADJ
njb-27	80	135	art	art	NOUN
njb-27	80	136	hrm9	hrm9	PROPN
njb-27	80	137	male/28yrs	male/28yrs	PROPN
njb-27	80	138	azt	azt	PROPN
njb-27	80	139	,	,	PUNCT
njb-27	80	140	3tc	3tc	NOUN
njb-27	80	141	,	,	PUNCT
njb-27	80	142	efz	efz	NOUN
njb-27	80	143	500	500	NUM
njb-27	80	144	positive	positive	ADJ
njb-27	80	145	negative	negative	ADJ
njb-27	80	146	art	art	NOUN
njb-27	80	147	hrm10	hrm10	X
njb-27	80	148	male/30yrs	male/30yrs	PROPN
njb-27	80	149	azt	azt	PROPN
njb-27	80	150	,	,	PUNCT
njb-27	80	151	3tc	3tc	NOUN
njb-27	80	152	,	,	PUNCT
njb-27	80	153	nfv	nfv	INTJ
njb-27	80	154	250	250	NUM
njb-27	80	155	negative	negative	ADJ
njb-27	80	156	negative	negative	ADJ
njb-27	80	157	art	art	NOUN
njb-27	80	158	hrm11	hrm11	PROPN
njb-27	80	159	male/36yrs	male/36yrs	PROPN
njb-27	80	160	azt	azt	PROPN
njb-27	80	161	,	,	PUNCT
njb-27	80	162	3tc	3tc	NOUN
njb-27	80	163	,	,	PUNCT
njb-27	80	164	nfv	nfv	INTJ
njb-27	80	165	300	300	NUM
njb-27	80	166	negative	negative	ADJ
njb-27	80	167	negative	negative	ADJ
njb-27	80	168	art	art	NOUN
njb-27	80	169	hrm12	hrm12	PROPN
njb-27	80	170	male/25yrs	male/25yrs	PROPN
njb-27	80	171	azt	azt	PROPN
njb-27	80	172	,	,	PUNCT
njb-27	80	173	3tc	3tc	NOUN
njb-27	80	174	,	,	PUNCT
njb-27	80	175	nfv	nfv	NOUN
njb-27	80	176	750	750	NUM
njb-27	80	177	positive	positive	ADJ
njb-27	80	178	negative	negative	ADJ
njb-27	80	179	art	art	PROPN
njb-27	80	180	hrm13	hrm13	PROPN
njb-27	80	181	male/27yrs	male/27yrs	PROPN
njb-27	80	182	azt	azt	PROPN
njb-27	80	183	,	,	PUNCT
njb-27	80	184	3tc	3tc	NOUN
njb-27	80	185	,	,	PUNCT
njb-27	80	186	nfv	nfv	INTJ
njb-27	80	187	400	400	NUM
njb-27	80	188	positive	positive	ADJ
njb-27	80	189	negative	negative	ADJ
njb-27	80	190	art	art	NOUN
njb-27	80	191	hrm14	hrm14	NOUN
njb-27	80	192	female/28yrs	female/28yr	NOUN
njb-27	80	193	azt	azt	PROPN
njb-27	80	194	,	,	PUNCT
njb-27	80	195	3tc	3tc	NOUN
njb-27	80	196	,	,	PUNCT
njb-27	80	197	efz	efz	NOUN
njb-27	80	198	650	650	NUM
njb-27	80	199	positive	positive	ADJ
njb-27	80	200	negative	negative	ADJ
njb-27	80	201	art	art	NOUN
njb-27	80	202	hrm15	hrm15	PROPN
njb-27	80	203	female/33yrs	female/33yrs	PROPN
njb-27	80	204	azt	azt	PROPN
njb-27	80	205	,	,	PUNCT
njb-27	80	206	3tc	3tc	NOUN
njb-27	80	207	,	,	PUNCT
njb-27	80	208	nfv	nfv	INTJ
njb-27	80	209	550	550	NUM
njb-27	80	210	positive	positive	ADJ
njb-27	80	211	negative	negative	ADJ
njb-27	80	212	art	art	NOUN
njb-27	80	213	key	key	NOUN
njb-27	80	214	:	:	PUNCT
njb-27	80	215	hrm	hrm	PROPN
njb-27	80	216	-	-	PUNCT
njb-27	80	217	hiv-1	hiv-1	CCONJ
njb-27	80	218	resistance	resistance	NOUN
njb-27	80	219	mutation	mutation	NOUN
njb-27	80	220	,	,	PUNCT
njb-27	80	221	art	art	NOUN
njb-27	80	222	-	-	PUNCT
njb-27	80	223	anti	anti	NOUN
njb-27	80	224	retroviral	retroviral	ADJ
njb-27	80	225	therapy	therapy	NOUN
njb-27	80	226	,	,	PUNCT
njb-27	80	227	aztzidovudine	aztzidovudine	NOUN
njb-27	80	228	,	,	PUNCT
njb-27	80	229	3tclamivudine	3tclamivudine	NUM
njb-27	80	230	,	,	PUNCT
njb-27	80	231	efv	efv	PROPN
njb-27	80	232	-	-	PUNCT
njb-27	80	233	efavirenz	efavirenz	PROPN
njb-27	80	234	,	,	PUNCT
njb-27	80	235	nfv	nfv	PROPN
njb-27	80	236	nelfinavir	nelfinavir	PROPN
njb-27	80	237	table	table	PROPN
njb-27	80	238	2	2	NUM
njb-27	80	239	:	:	PUNCT
njb-27	80	240	most	most	ADJ
njb-27	80	241	common	common	ADJ
njb-27	80	242	mutations	mutation	NOUN
njb-27	80	243	in	in	ADP
njb-27	80	244	rt	rt	PROPN
njb-27	80	245	gene	gene	PROPN
njb-27	80	246	and	and	CCONJ
njb-27	80	247	specific	specific	ADJ
njb-27	80	248	drugs	drug	NOUN
njb-27	80	249	resistance	resistance	NOUN
njb-27	80	250	.	.	PUNCT
njb-27	81	1	resistance	resistance	NOUN
njb-27	81	2	genes	gene	NOUN
njb-27	81	3	resistance	resistance	NOUN
njb-27	81	4	level	level	NOUN
njb-27	81	5	mutation	mutation	NOUN
njb-27	81	6	gene	gene	NOUN
njb-27	81	7	high	high	ADJ
njb-27	81	8	intermediate	intermediate	ADJ
njb-27	81	9	low	low	ADJ
njb-27	81	10	m184v	m184v	VERB
njb-27	81	11	/	/	SYM
njb-27	81	12	i	i	PRON
njb-27	81	13	rt	rt	PROPN
njb-27	81	14	3tc	3tc	PROPN
njb-27	81	15	,	,	PUNCT
njb-27	81	16	ftc	ftc	PROPN
njb-27	81	17	abc	abc	PROPN
njb-27	81	18	,	,	PUNCT
njb-27	81	19	ddi	ddi	PROPN
njb-27	81	20	k65r	k65r	PROPN
njb-27	81	21	rt	rt	PROPN
njb-27	81	22	abc	abc	PROPN
njb-27	81	23	,	,	PUNCT
njb-27	81	24	ddi	ddi	PROPN
njb-27	81	25	,	,	PUNCT
njb-27	81	26	tnf	tnf	PROPN
njb-27	81	27	,	,	PUNCT
njb-27	81	28	d4	d4	PROPN
njb-27	81	29	t	t	NOUN
njb-27	81	30	3tc	3tc	NOUN
njb-27	81	31	,	,	PUNCT
njb-27	81	32	ftc	ftc	PROPN
njb-27	81	33	m41l	m41l	PROPN
njb-27	82	1	rt	rt	PROPN
njb-27	82	2	azt	azt	PROPN
njb-27	82	3	,	,	PUNCT
njb-27	82	4	d4	d4	PROPN
njb-27	82	5	t	t	PROPN
njb-27	82	6	ddi	ddi	PROPN
njb-27	82	7	,	,	PUNCT
njb-27	82	8	abc	abc	PROPN
njb-27	82	9	tnf	tnf	PROPN
njb-27	82	10	k103n	k103n	PROPN
njb-27	82	11	rt	rt	PROPN
njb-27	82	12	efv	efv	PROPN
njb-27	82	13	,	,	PUNCT
njb-27	82	14	nvp	nvp	NOUN
njb-27	82	15	key	key	NOUN
njb-27	82	16	:	:	PUNCT
njb-27	82	17	3tclamivudine	3tclamivudine	NUM
njb-27	82	18	,	,	PUNCT
njb-27	82	19	ftc	ftc	PROPN
njb-27	82	20	-	-	PUNCT
njb-27	82	21	emtricitabine	emtricitabine	PROPN
njb-27	82	22	,	,	PUNCT
njb-27	82	23	aztzidovudine	aztzidovudine	ADJ
njb-27	82	24	,	,	PUNCT
njb-27	82	25	d4tstavudine	d4tstavudine	NOUN
njb-27	82	26	,	,	PUNCT
njb-27	82	27	efv	efv	PROPN
njb-27	82	28	-	-	PUNCT
njb-27	82	29	efavirenz	efavirenz	NOUN
njb-27	82	30	,	,	PUNCT
njb-27	82	31	nvpnevirapine	nvpnevirapine	NOUN
njb-27	82	32	,	,	PUNCT
njb-27	82	33	abcabacavir	abcabacavir	NOUN
njb-27	82	34	,	,	PUNCT
njb-27	82	35	ddi	ddi	PROPN
njb-27	82	36	didanosine	didanosine	PROPN
njb-27	82	37	,	,	PUNCT
njb-27	82	38	tnftenofovir	tnftenofovir	PROPN
njb-27	82	39	nepal	nepal	ADJ
njb-27	82	40	journal	journal	NOUN
njb-27	82	41	of	of	ADP
njb-27	82	42	biotechnology	biotechnology	NOUN
njb-27	82	43	.	.	PUNCT
njb-27	83	1	d	d	X
njb-27	83	2	e	e	PROPN
njb-27	83	3	c	c	PROPN
njb-27	83	4	.	.	PUNCT
njb-27	84	1	2	2	NUM
njb-27	84	2	0	0	NUM
njb-27	84	3	1	1	NUM
njb-27	84	4	6	6	NUM
njb-27	84	5	vol	vol	NOUN
njb-27	84	6	.	.	PROPN
njb-27	85	1	4	4	NUM
njb-27	85	2	,	,	PUNCT
njb-27	85	3	no	no	NOUN
njb-27	85	4	.	.	NOUN
njb-27	85	5	1	1	NUM
njb-27	85	6	:	:	SYM
njb-27	85	7	18	18	NUM
njb-27	85	8	-	-	SYM
njb-27	85	9	25	25	NUM
njb-27	85	10	shrestha	shrestha	NOUN
njb-27	85	11	et	et	X
njb-27	85	12	al	al	PROPN
njb-27	85	13	.	.	PUNCT
njb-27	86	1	©	©	PROPN
njb-27	86	2	njb	njb	PROPN
njb-27	86	3	,	,	PUNCT
njb-27	86	4	biotechnology	biotechnology	NOUN
njb-27	86	5	society	society	NOUN
njb-27	86	6	of	of	ADP
njb-27	86	7	nepal	nepal	ADJ
njb-27	86	8	21	21	NUM
njb-27	86	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	86	10	identification	identification	NOUN
njb-27	86	11	of	of	ADP
njb-27	86	12	env	env	NOUN
njb-27	86	13	v3	v3	PROPN
njb-27	86	14	dna	dna	PROPN
njb-27	86	15	the	the	DET
njb-27	86	16	env	env	NOUN
njb-27	86	17	v3	v3	PROPN
njb-27	86	18	dna	dna	PROPN
njb-27	86	19	sequence	sequence	NOUN
njb-27	86	20	was	be	AUX
njb-27	86	21	analyzed	analyze	VERB
njb-27	86	22	to	to	PART
njb-27	86	23	rule	rule	VERB
njb-27	86	24	out	out	ADP
njb-27	86	25	latent	latent	ADJ
njb-27	86	26	hiv-1	hiv-1	PUNCT
njb-27	86	27	infections	infection	NOUN
njb-27	86	28	.	.	PUNCT
njb-27	87	1	out	out	ADP
njb-27	87	2	of	of	ADP
njb-27	87	3	15	15	NUM
njb-27	87	4	samples	sample	NOUN
njb-27	87	5	amplified	amplify	VERB
njb-27	87	6	for	for	ADP
njb-27	87	7	env	env	NOUN
njb-27	87	8	gene	gene	NOUN
njb-27	87	9	,	,	PUNCT
njb-27	87	10	only	only	ADV
njb-27	87	11	12	12	NUM
njb-27	87	12	of	of	ADP
njb-27	87	13	samples	sample	NOUN
njb-27	87	14	show	show	VERB
njb-27	87	15	positive	positive	ADJ
njb-27	87	16	for	for	ADP
njb-27	87	17	env	env	NOUN
njb-27	87	18	v3	v3	PROPN
njb-27	87	19	dna	dna	PROPN
njb-27	87	20	sequence	sequence	NOUN
njb-27	87	21	by	by	ADP
njb-27	87	22	nested	nested	ADJ
njb-27	87	23	pcr	pcr	PROPN
njb-27	87	24	.	.	PUNCT
njb-27	88	1	the	the	DET
njb-27	88	2	size	size	NOUN
njb-27	88	3	of	of	ADP
njb-27	88	4	the	the	DET
njb-27	88	5	product	product	NOUN
njb-27	88	6	was	be	AUX
njb-27	88	7	335bp	335bp	ADJ
njb-27	88	8	which	which	PRON
njb-27	88	9	was	be	AUX
njb-27	88	10	a	a	DET
njb-27	88	11	band	band	NOUN
njb-27	88	12	of	of	ADP
njb-27	88	13	our	our	PRON
njb-27	88	14	figure	figure	NOUN
njb-27	88	15	1	1	NUM
njb-27	88	16	:	:	PUNCT
njb-27	88	17	nested	nest	VERB
njb-27	88	18	pcr	pcr	NOUN
njb-27	88	19	for	for	ADP
njb-27	88	20	env	env	NOUN
njb-27	88	21	v3	v3	PROPN
njb-27	88	22	dna	dna	PROPN
njb-27	88	23	sequences	sequence	NOUN
njb-27	88	24	.	.	PUNCT
njb-27	89	1	marker	marker	NOUN
njb-27	89	2	(	(	PUNCT
njb-27	89	3	m	m	PROPN
njb-27	89	4	)	)	PUNCT
njb-27	89	5	of	of	ADP
njb-27	89	6	100bp	100bp	PROPN
njb-27	89	7	was	be	AUX
njb-27	89	8	used	use	VERB
njb-27	89	9	to	to	PART
njb-27	89	10	compare	compare	VERB
njb-27	89	11	the	the	DET
njb-27	89	12	molecular	molecular	ADJ
njb-27	89	13	weight	weight	NOUN
njb-27	89	14	of	of	ADP
njb-27	89	15	amplified	amplify	VERB
njb-27	89	16	product	product	NOUN
njb-27	89	17	resolved	resolve	VERB
njb-27	89	18	in	in	ADP
njb-27	89	19	gel	gel	NOUN
njb-27	89	20	of	of	ADP
njb-27	89	21	1.7	1.7	NUM
njb-27	89	22	%	%	NOUN
njb-27	89	23	.	.	PUNCT
njb-27	90	1	a	a	X
njb-27	90	2	)	)	PUNCT
njb-27	90	3	amplified	amplify	VERB
njb-27	90	4	product	product	NOUN
njb-27	90	5	with	with	ADP
njb-27	90	6	band	band	NOUN
njb-27	90	7	of	of	ADP
njb-27	90	8	interest	interest	NOUN
njb-27	90	9	(	(	PUNCT
njb-27	90	10	335bp	335bp	NOUN
njb-27	90	11	)	)	PUNCT
njb-27	90	12	was	be	AUX
njb-27	90	13	visualized	visualize	VERB
njb-27	90	14	in	in	ADP
njb-27	90	15	all	all	DET
njb-27	90	16	lane	lane	NOUN
njb-27	90	17	1	1	NUM
njb-27	90	18	-	-	SYM
njb-27	90	19	6	6	NUM
njb-27	90	20	.	.	PUNCT
njb-27	90	21	b	b	X
njb-27	90	22	)	)	PUNCT
njb-27	90	23	amplified	amplify	VERB
njb-27	90	24	product	product	NOUN
njb-27	90	25	was	be	AUX
njb-27	90	26	observed	observe	VERB
njb-27	90	27	only	only	ADV
njb-27	90	28	in	in	ADP
njb-27	90	29	lane	lane	NOUN
njb-27	90	30	7	7	NUM
njb-27	90	31	,	,	PUNCT
njb-27	90	32	8	8	NUM
njb-27	90	33	,	,	PUNCT
njb-27	90	34	10	10	NUM
njb-27	90	35	,	,	PUNCT
njb-27	90	36	12	12	NUM
njb-27	90	37	but	but	CCONJ
njb-27	90	38	not	not	PART
njb-27	90	39	in	in	ADP
njb-27	90	40	lane	lane	NOUN
njb-27	90	41	9	9	NUM
njb-27	90	42	and	and	CCONJ
njb-27	90	43	11	11	NUM
njb-27	90	44	.	.	PUNCT
njb-27	91	1	gel	gel	NOUN
njb-27	91	2	image	image	NOUN
njb-27	91	3	of	of	ADP
njb-27	91	4	3	3	NUM
njb-27	91	5	positive	positive	ADJ
njb-27	91	6	samples	sample	NOUN
njb-27	91	7	is	be	AUX
njb-27	91	8	not	not	PART
njb-27	91	9	shown	show	VERB
njb-27	91	10	.	.	PUNCT
njb-27	92	1	interest	interest	NOUN
njb-27	92	2	and	and	CCONJ
njb-27	92	3	is	be	AUX
njb-27	92	4	illustrated	illustrate	VERB
njb-27	92	5	in	in	ADP
njb-27	92	6	figure	figure	NOUN
njb-27	92	7	1	1	NUM
njb-27	92	8	(	(	PUNCT
njb-27	92	9	a	a	PROPN
njb-27	92	10	&	&	CCONJ
njb-27	92	11	b	b	PROPN
njb-27	92	12	)	)	PUNCT
njb-27	92	13	.	.	PUNCT
njb-27	93	1	the	the	DET
njb-27	93	2	remaining	remain	VERB
njb-27	93	3	3	3	NUM
njb-27	93	4	samples	sample	NOUN
njb-27	93	5	negative	negative	ADJ
njb-27	93	6	for	for	ADP
njb-27	93	7	the	the	DET
njb-27	93	8	same	same	ADJ
njb-27	93	9	gene	gene	NOUN
njb-27	93	10	was	be	AUX
njb-27	93	11	reamplified	reamplifie	VERB
njb-27	93	12	twice	twice	ADV
njb-27	93	13	showed	show	VERB
njb-27	93	14	the	the	DET
njb-27	93	15	similar	similar	ADJ
njb-27	93	16	results	result	NOUN
njb-27	93	17	.	.	PUNCT
njb-27	94	1	the	the	DET
njb-27	94	2	reason	reason	NOUN
njb-27	94	3	for	for	ADP
njb-27	94	4	env	env	NOUN
njb-27	94	5	gene	gene	NOUN
njb-27	94	6	negative	negative	ADJ
njb-27	94	7	in	in	ADP
njb-27	94	8	those	those	DET
njb-27	94	9	three	three	NUM
njb-27	94	10	samples	sample	NOUN
njb-27	94	11	might	might	AUX
njb-27	94	12	be	be	AUX
njb-27	94	13	due	due	ADJ
njb-27	94	14	to	to	PART
njb-27	94	15	complete	complete	ADJ
njb-27	94	16	elimination	elimination	NOUN
njb-27	94	17	of	of	ADP
njb-27	94	18	proviral	proviral	ADJ
njb-27	94	19	dna	dna	PROPN
njb-27	94	20	or	or	CCONJ
njb-27	94	21	due	due	ADP
njb-27	94	22	to	to	ADP
njb-27	94	23	its	its	PRON
njb-27	94	24	reduction	reduction	NOUN
njb-27	94	25	below	below	ADP
njb-27	94	26	the	the	DET
njb-27	94	27	detection	detection	NOUN
njb-27	94	28	limit	limit	NOUN
njb-27	94	29	after	after	ADP
njb-27	94	30	prolonged	prolonged	ADJ
njb-27	94	31	art	art	NOUN
njb-27	94	32	.	.	PUNCT
njb-27	95	1	m184v	m184v	VERB
njb-27	95	2	mutation	mutation	NOUN
njb-27	95	3	in	in	ADP
njb-27	95	4	hiv-1	hiv-1	PUNCT
njb-27	95	5	rt	rt	PROPN
njb-27	95	6	gene	gene	NOUN
njb-27	95	7	hiv-1	hiv-1	PUNCT
njb-27	95	8	rna	rna	NOUN
njb-27	95	9	was	be	AUX
njb-27	95	10	tested	test	VERB
njb-27	95	11	for	for	ADP
njb-27	95	12	the	the	DET
njb-27	95	13	most	most	ADV
njb-27	95	14	common	common	ADJ
njb-27	95	15	mutation	mutation	NOUN
njb-27	95	16	;	;	PUNCT
njb-27	95	17	m184v	m184v	VERB
njb-27	95	18	which	which	PRON
njb-27	95	19	emerges	emerge	VERB
njb-27	95	20	in	in	ADP
njb-27	95	21	patients	patient	NOUN
njb-27	95	22	using	use	VERB
njb-27	95	23	lamivudine	lamivudine	NOUN
njb-27	95	24	(	(	PUNCT
njb-27	95	25	3tc	3tc	NOUN
njb-27	95	26	)	)	PUNCT
njb-27	95	27	monotherapy	monotherapy	NOUN
njb-27	95	28	or	or	CCONJ
njb-27	95	29	can	can	AUX
njb-27	95	30	be	be	AUX
njb-27	95	31	a	a	DET
njb-27	95	32	phenotypic	phenotypic	ADJ
njb-27	95	33	reversion	reversion	NOUN
njb-27	95	34	of	of	ADP
njb-27	95	35	zidovudine	zidovudine	PROPN
njb-27	95	36	(	(	PUNCT
njb-27	95	37	zdv	zdv	PROPN
njb-27	95	38	)	)	PUNCT
njb-27	95	39	.	.	PUNCT
njb-27	96	1	pcrrfda	pcrrfda	PROPN
njb-27	96	2	molecular	molecular	ADJ
njb-27	96	3	tool	tool	NOUN
njb-27	96	4	was	be	AUX
njb-27	96	5	used	use	VERB
njb-27	96	6	for	for	ADP
njb-27	96	7	testing	test	VERB
njb-27	96	8	the	the	DET
njb-27	96	9	mutation	mutation	NOUN
njb-27	96	10	in	in	ADP
njb-27	96	11	which	which	PRON
njb-27	96	12	gene	gene	NOUN
njb-27	96	13	was	be	AUX
njb-27	96	14	amplified	amplify	VERB
njb-27	96	15	by	by	ADP
njb-27	96	16	nested	nest	VERB
njb-27	96	17	pcr	pcr	NOUN
njb-27	96	18	and	and	CCONJ
njb-27	96	19	further	further	ADJ
njb-27	96	20	final	final	ADJ
njb-27	96	21	product	product	NOUN
njb-27	96	22	was	be	AUX
njb-27	96	23	digested	digest	VERB
njb-27	96	24	with	with	ADP
njb-27	96	25	cviaii	cviaii	PROPN
njb-27	96	26	restriction	restriction	NOUN
njb-27	96	27	endonucleases	endonuclease	NOUN
njb-27	96	28	.	.	PUNCT
njb-27	97	1	in	in	ADP
njb-27	97	2	the	the	DET
njb-27	97	3	present	present	ADJ
njb-27	97	4	study	study	NOUN
njb-27	97	5	,	,	PUNCT
njb-27	97	6	we	we	PRON
njb-27	97	7	tested	test	VERB
njb-27	97	8	m184v	m184v	ADJ
njb-27	97	9	mutation	mutation	NOUN
njb-27	97	10	in	in	ADP
njb-27	97	11	15	15	NUM
njb-27	97	12	samples	sample	NOUN
njb-27	97	13	and	and	CCONJ
njb-27	97	14	all	all	PRON
njb-27	97	15	showed	show	VERB
njb-27	97	16	wildtype	wildtype	ADJ
njb-27	97	17	strain	strain	NOUN
njb-27	97	18	.	.	PUNCT
njb-27	98	1	the	the	DET
njb-27	98	2	wildtype	wildtype	NOUN
njb-27	98	3	strains	strain	NOUN
njb-27	98	4	show	show	VERB
njb-27	98	5	three	three	NUM
njb-27	98	6	fragment	fragment	ADJ
njb-27	98	7	after	after	ADP
njb-27	98	8	digestion	digestion	NOUN
njb-27	98	9	with	with	ADP
njb-27	98	10	band	band	NOUN
njb-27	98	11	size	size	NOUN
njb-27	98	12	of	of	ADP
njb-27	98	13	453bp	453bp	PROPN
njb-27	98	14	,	,	PUNCT
njb-27	98	15	60bp	60bp	NOUN
njb-27	98	16	and	and	CCONJ
njb-27	98	17	168bp	168bp	NOUN
njb-27	98	18	are	be	AUX
njb-27	98	19	susceptible	susceptible	ADJ
njb-27	98	20	to	to	ADP
njb-27	98	21	3tc	3tc	NOUN
njb-27	98	22	while	while	SCONJ
njb-27	98	23	mutant	mutant	ADJ
njb-27	98	24	type	type	NOUN
njb-27	98	25	have	have	VERB
njb-27	98	26	2	2	NUM
njb-27	98	27	bands	band	NOUN
njb-27	98	28	with	with	ADP
njb-27	98	29	size	size	NOUN
njb-27	98	30	of	of	ADP
njb-27	98	31	453bp	453bp	PROPN
njb-27	98	32	and	and	CCONJ
njb-27	98	33	228bp	228bp	PROPN
njb-27	98	34	are	be	AUX
njb-27	98	35	considered	consider	VERB
njb-27	98	36	as	as	ADP
njb-27	98	37	3tc	3tc	ADJ
njb-27	98	38	resistance	resistance	NOUN
njb-27	98	39	which	which	PRON
njb-27	98	40	means	mean	VERB
njb-27	98	41	the	the	DET
njb-27	98	42	m184v	m184v	VERB
njb-27	98	43	resistance	resistance	NOUN
njb-27	98	44	mutation	mutation	NOUN
njb-27	98	45	was	be	AUX
njb-27	98	46	emerged	emerge	VERB
njb-27	98	47	by	by	ADP
njb-27	98	48	modification	modification	NOUN
njb-27	98	49	of	of	ADP
njb-27	98	50	the	the	DET
njb-27	98	51	184	184	NUM
njb-27	98	52	restriction	restriction	NOUN
njb-27	98	53	site	site	NOUN
njb-27	98	54	substituting	substitute	VERB
njb-27	98	55	cviaii	cviaii	PROPN
njb-27	98	56	enzymes	enzyme	NOUN
njb-27	98	57	.	.	PUNCT
njb-27	99	1	the	the	DET
njb-27	99	2	virtual	virtual	ADJ
njb-27	99	3	schematic	schematic	ADJ
njb-27	99	4	illustration	illustration	NOUN
njb-27	99	5	of	of	ADP
njb-27	99	6	nested	nested	ADJ
njb-27	99	7	pcr	pcr	NOUN
njb-27	99	8	and	and	CCONJ
njb-27	99	9	rfda	rfda	NOUN
njb-27	99	10	of	of	ADP
njb-27	99	11	both	both	DET
njb-27	99	12	wild	wild	ADJ
njb-27	99	13	type	type	NOUN
njb-27	99	14	and	and	CCONJ
njb-27	99	15	mutant	mutant	ADJ
njb-27	99	16	type	type	NOUN
njb-27	99	17	is	be	AUX
njb-27	99	18	shown	show	VERB
njb-27	99	19	in	in	ADP
njb-27	99	20	figure	figure	NOUN
njb-27	99	21	2	2	NUM
njb-27	99	22	(	(	PUNCT
njb-27	99	23	a	a	PROPN
njb-27	99	24	&	&	CCONJ
njb-27	99	25	b	b	PROPN
njb-27	99	26	)	)	PUNCT
njb-27	99	27	.	.	PUNCT
njb-27	100	1	discussion	discussion	NOUN
njb-27	100	2	early	early	ADJ
njb-27	100	3	detection	detection	NOUN
njb-27	100	4	of	of	ADP
njb-27	100	5	drug	drug	NOUN
njb-27	100	6	resistance	resistance	NOUN
njb-27	100	7	mutation	mutation	NOUN
njb-27	100	8	in	in	ADP
njb-27	100	9	hiv-1	hiv-1	PUNCT
njb-27	100	10	infected	infected	ADJ
njb-27	100	11	patients	patient	NOUN
njb-27	100	12	in	in	ADP
njb-27	100	13	developing	develop	VERB
njb-27	100	14	countries	country	NOUN
njb-27	100	15	is	be	AUX
njb-27	100	16	a	a	DET
njb-27	100	17	big	big	ADJ
njb-27	100	18	challenge	challenge	NOUN
njb-27	100	19	however	however	ADV
njb-27	100	20	,	,	PUNCT
njb-27	100	21	can	can	AUX
njb-27	100	22	aid	aid	VERB
njb-27	100	23	clinicians	clinician	NOUN
njb-27	100	24	in	in	ADP
njb-27	100	25	making	make	VERB
njb-27	100	26	proper	proper	ADJ
njb-27	100	27	art	art	NOUN
njb-27	100	28	strategy	strategy	NOUN
njb-27	100	29	plans	plan	NOUN
njb-27	100	30	.	.	PUNCT
njb-27	101	1	various	various	ADJ
njb-27	101	2	molecular	molecular	ADJ
njb-27	101	3	tools	tool	NOUN
njb-27	101	4	like	like	ADP
njb-27	101	5	real	real	ADJ
njb-27	101	6	time	time	NOUN
njb-27	101	7	pcr	pcr	NOUN
njb-27	101	8	and	and	CCONJ
njb-27	101	9	sequencing	sequence	VERB
njb-27	101	10	facilities	facility	NOUN
njb-27	101	11	are	be	AUX
njb-27	101	12	still	still	ADV
njb-27	101	13	lacking	lack	VERB
njb-27	101	14	.	.	PUNCT
njb-27	102	1	also	also	ADV
njb-27	102	2	,	,	PUNCT
njb-27	102	3	such	such	ADJ
njb-27	102	4	tools	tool	NOUN
njb-27	102	5	are	be	AUX
njb-27	102	6	expensive	expensive	ADJ
njb-27	102	7	and	and	CCONJ
njb-27	102	8	less	less	ADV
njb-27	102	9	sensitive	sensitive	ADJ
njb-27	102	10	to	to	ADP
njb-27	102	11	minor	minor	ADJ
njb-27	102	12	resistance	resistance	NOUN
njb-27	102	13	variants	variant	NOUN
njb-27	102	14	.	.	PUNCT
njb-27	103	1	the	the	DET
njb-27	103	2	development	development	NOUN
njb-27	103	3	of	of	ADP
njb-27	103	4	cheap	cheap	ADJ
njb-27	103	5	and	and	CCONJ
njb-27	103	6	sensitive	sensitive	ADJ
njb-27	103	7	tools	tool	NOUN
njb-27	103	8	to	to	PART
njb-27	103	9	screen	screen	VERB
njb-27	103	10	resistance	resistance	NOUN
njb-27	103	11	mutation	mutation	NOUN
njb-27	103	12	can	can	AUX
njb-27	103	13	be	be	AUX
njb-27	103	14	a	a	DET
njb-27	103	15	breakthrough	breakthrough	NOUN
njb-27	103	16	in	in	ADP
njb-27	103	17	the	the	DET
njb-27	103	18	field	field	NOUN
njb-27	103	19	of	of	ADP
njb-27	103	20	molecular	molecular	ADJ
njb-27	103	21	biology	biology	NOUN
njb-27	103	22	for	for	ADP
njb-27	103	23	low	low	ADJ
njb-27	103	24	economic	economic	ADJ
njb-27	103	25	countries	country	NOUN
njb-27	103	26	like	like	ADP
njb-27	103	27	nepal	nepal	ADJ
njb-27	103	28	.	.	PUNCT
njb-27	104	1	in	in	ADP
njb-27	104	2	the	the	DET
njb-27	104	3	study	study	NOUN
njb-27	104	4	,	,	PUNCT
njb-27	104	5	we	we	PRON
njb-27	104	6	used	use	VERB
njb-27	104	7	nested	nested	ADJ
njb-27	104	8	pcr	pcr	NOUN
njb-27	104	9	and	and	CCONJ
njb-27	104	10	pcr	pcr	NOUN
njb-27	104	11	-	-	NOUN
njb-27	104	12	rfda	rfda	PROPN
njb-27	104	13	to	to	PART
njb-27	104	14	detect	detect	VERB
njb-27	104	15	hiv-1	hiv-1	PUNCT
njb-27	104	16	infections	infection	NOUN
njb-27	104	17	and	and	CCONJ
njb-27	104	18	screen	screen	NOUN
njb-27	104	19	the	the	DET
njb-27	104	20	prevalence	prevalence	NOUN
njb-27	104	21	of	of	ADP
njb-27	104	22	m184v	m184v	ADJ
njb-27	104	23	mutation	mutation	NOUN
njb-27	104	24	in	in	ADP
njb-27	104	25	hiv-1	hiv-1	PUNCT
njb-27	104	26	patients	patient	NOUN
njb-27	104	27	underwent	undergo	VERB
njb-27	104	28	prolong	prolong	ADJ
njb-27	104	29	art	art	NOUN
njb-27	104	30	.	.	PUNCT
njb-27	105	1	the	the	DET
njb-27	105	2	cheap	cheap	ADJ
njb-27	105	3	and	and	CCONJ
njb-27	105	4	sensitive	sensitive	ADJ
njb-27	105	5	methods	method	NOUN
njb-27	105	6	for	for	ADP
njb-27	105	7	detecting	detect	VERB
njb-27	105	8	primary	primary	ADJ
njb-27	105	9	infection	infection	NOUN
njb-27	105	10	in	in	ADP
njb-27	105	11	infants	infant	NOUN
njb-27	105	12	and	and	CCONJ
njb-27	105	13	latent	latent	ADJ
njb-27	105	14	hiv-1	hiv-1	CCONJ
njb-27	105	15	infection	infection	NOUN
njb-27	105	16	is	be	AUX
njb-27	105	17	to	to	PART
njb-27	105	18	identify	identify	VERB
njb-27	105	19	proviral	proviral	ADJ
njb-27	105	20	dna	dna	PROPN
njb-27	105	21	.	.	PUNCT
njb-27	106	1	the	the	DET
njb-27	106	2	hiv	hiv	PROPN
njb-27	106	3	proviral	proviral	PROPN
njb-27	106	4	dna	dna	PROPN
njb-27	106	5	is	be	AUX
njb-27	106	6	positive	positive	ADJ
njb-27	106	7	after	after	ADP
njb-27	106	8	28	28	NUM
njb-27	106	9	days	day	NOUN
njb-27	106	10	while	while	SCONJ
njb-27	106	11	most	most	ADV
njb-27	106	12	healthy	healthy	ADJ
njb-27	106	13	individuals	individual	NOUN
njb-27	106	14	are	be	AUX
njb-27	106	15	accustomed	accustom	VERB
njb-27	106	16	to	to	ADP
njb-27	106	17	waiting	wait	VERB
njb-27	106	18	3	3	NUM
njb-27	106	19	months	month	NOUN
njb-27	106	20	for	for	ADP
njb-27	106	21	a	a	DET
njb-27	106	22	conclusive	conclusive	ADJ
njb-27	106	23	result	result	NOUN
njb-27	106	24	.	.	PUNCT
njb-27	107	1	we	we	PRON
njb-27	107	2	performed	perform	VERB
njb-27	107	3	nested	nested	ADJ
njb-27	107	4	pcr	pcr	PROPN
njb-27	107	5	to	to	PART
njb-27	107	6	identify	identify	VERB
njb-27	107	7	the	the	DET
njb-27	107	8	env	env	NOUN
njb-27	107	9	v3	v3	PROPN
njb-27	107	10	dna	dna	PROPN
njb-27	107	11	sequences	sequence	NOUN
njb-27	107	12	in	in	ADP
njb-27	107	13	15	15	NUM
njb-27	107	14	samples	sample	NOUN
njb-27	107	15	,	,	PUNCT
njb-27	107	16	out	out	ADP
njb-27	107	17	of	of	ADP
njb-27	107	18	which	which	PRON
njb-27	107	19	12	12	NUM
njb-27	107	20	showed	show	VERB
njb-27	107	21	positive	positive	ADJ
njb-27	107	22	for	for	ADP
njb-27	107	23	proviral	proviral	ADJ
njb-27	107	24	dna	dna	PROPN
njb-27	107	25	.	.	PUNCT
njb-27	108	1	the	the	DET
njb-27	108	2	pcr	pcr	PROPN
njb-27	108	3	amplification	amplification	NOUN
njb-27	108	4	on	on	ADP
njb-27	108	5	3	3	NUM
njb-27	108	6	negative	negative	ADJ
njb-27	108	7	samples	sample	NOUN
njb-27	108	8	was	be	AUX
njb-27	108	9	repeated	repeat	VERB
njb-27	108	10	twice	twice	ADV
njb-27	108	11	with	with	ADP
njb-27	108	12	the	the	DET
njb-27	108	13	same	same	ADJ
njb-27	108	14	primers	primer	NOUN
njb-27	108	15	for	for	ADP
njb-27	108	16	the	the	DET
njb-27	108	17	env	env	NOUN
njb-27	108	18	v3	v3	PROPN
njb-27	108	19	dna	dna	PROPN
njb-27	108	20	but	but	CCONJ
njb-27	108	21	consistently	consistently	ADV
njb-27	108	22	the	the	DET
njb-27	108	23	results	result	NOUN
njb-27	108	24	were	be	AUX
njb-27	108	25	negative	negative	ADJ
njb-27	108	26	.	.	PUNCT
njb-27	109	1	the	the	DET
njb-27	109	2	reason	reason	NOUN
njb-27	109	3	might	might	AUX
njb-27	109	4	be	be	AUX
njb-27	109	5	a	a	DET
njb-27	109	6	low	low	ADJ
njb-27	109	7	copy	copy	NOUN
njb-27	109	8	number	number	NOUN
njb-27	109	9	which	which	PRON
njb-27	109	10	is	be	AUX
njb-27	109	11	below	below	ADP
njb-27	109	12	the	the	DET
njb-27	109	13	detection	detection	NOUN
njb-27	109	14	limit	limit	NOUN
njb-27	109	15	or	or	CCONJ
njb-27	109	16	can	can	AUX
njb-27	109	17	be	be	AUX
njb-27	109	18	complete	complete	ADJ
njb-27	109	19	elimination	elimination	NOUN
njb-27	109	20	of	of	ADP
njb-27	109	21	proviral	proviral	ADJ
njb-27	109	22	dna	dna	NOUN
njb-27	109	23	due	due	ADP
njb-27	109	24	to	to	ADP
njb-27	109	25	prolonged	prolonged	ADJ
njb-27	109	26	art	art	NOUN
njb-27	109	27	.	.	PUNCT
njb-27	110	1	the	the	DET
njb-27	110	2	standard	standard	ADJ
njb-27	110	3	methods	method	NOUN
njb-27	110	4	for	for	ADP
njb-27	110	5	the	the	DET
njb-27	110	6	detection	detection	NOUN
njb-27	110	7	of	of	ADP
njb-27	110	8	hiv-1	hiv-1	PUNCT
njb-27	110	9	proviral	proviral	ADJ
njb-27	110	10	dna	dna	PROPN
njb-27	110	11	are	be	AUX
njb-27	110	12	currently	currently	ADV
njb-27	110	13	lacking	lack	VERB
njb-27	110	14	and	and	CCONJ
njb-27	110	15	several	several	ADJ
njb-27	110	16	discordant	discordant	ADJ
njb-27	110	17	results	result	NOUN
njb-27	110	18	are	be	AUX
njb-27	110	19	still	still	ADV
njb-27	110	20	present	present	ADJ
njb-27	110	21	in	in	ADP
njb-27	110	22	different	different	ADJ
njb-27	110	23	studies	study	NOUN
njb-27	110	24	[	[	X
njb-27	110	25	21	21	NUM
njb-27	110	26	]	]	PUNCT
njb-27	110	27	.	.	PUNCT
njb-27	111	1	in	in	ADP
njb-27	111	2	the	the	DET
njb-27	111	3	present	present	ADJ
njb-27	111	4	study	study	NOUN
njb-27	111	5	,	,	PUNCT
njb-27	111	6	we	we	PRON
njb-27	111	7	did	do	AUX
njb-27	111	8	n’t	not	PART
njb-27	111	9	study	study	VERB
njb-27	111	10	for	for	ADP
njb-27	111	11	the	the	DET
njb-27	111	12	nepal	nepal	ADJ
njb-27	111	13	journal	journal	NOUN
njb-27	111	14	of	of	ADP
njb-27	111	15	biotechnology	biotechnology	NOUN
njb-27	111	16	.	.	PUNCT
njb-27	112	1	d	d	X
njb-27	112	2	e	e	PROPN
njb-27	112	3	c	c	PROPN
njb-27	112	4	.	.	PUNCT
njb-27	113	1	2	2	NUM
njb-27	113	2	0	0	NUM
njb-27	113	3	1	1	NUM
njb-27	113	4	6	6	NUM
njb-27	113	5	vol	vol	NOUN
njb-27	113	6	.	.	PROPN
njb-27	114	1	4	4	NUM
njb-27	114	2	,	,	PUNCT
njb-27	114	3	no	no	NOUN
njb-27	114	4	.	.	NOUN
njb-27	114	5	1	1	NUM
njb-27	114	6	:	:	SYM
njb-27	114	7	18	18	NUM
njb-27	114	8	-	-	SYM
njb-27	114	9	25	25	NUM
njb-27	114	10	shrestha	shrestha	NOUN
njb-27	114	11	et	et	X
njb-27	114	12	al	al	PROPN
njb-27	114	13	.	.	PUNCT
njb-27	115	1	©	©	PROPN
njb-27	115	2	njb	njb	PROPN
njb-27	115	3	,	,	PUNCT
njb-27	115	4	biotechnology	biotechnology	NOUN
njb-27	115	5	society	society	NOUN
njb-27	115	6	of	of	ADP
njb-27	115	7	nepal	nepal	ADJ
njb-27	115	8	22	22	NUM
njb-27	115	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	115	10	figure	figure	NOUN
njb-27	115	11	2	2	NUM
njb-27	115	12	:	:	PUNCT
njb-27	115	13	nested	nest	VERB
njb-27	115	14	pcr	pcr	NOUN
njb-27	115	15	and	and	CCONJ
njb-27	115	16	rfda	rfda	NOUN
njb-27	115	17	for	for	ADP
njb-27	115	18	detection	detection	NOUN
njb-27	115	19	of	of	ADP
njb-27	115	20	m184v	m184v	ADJ
njb-27	115	21	resistance	resistance	NOUN
njb-27	115	22	mutation	mutation	PROPN
njb-27	115	23	.	.	PUNCT
njb-27	116	1	a	a	X
njb-27	116	2	)	)	PUNCT
njb-27	116	3	wildtype	wildtype	ADJ
njb-27	116	4	stain	stain	NOUN
njb-27	116	5	with	with	ADP
njb-27	116	6	three	three	NUM
njb-27	116	7	bands	band	NOUN
njb-27	116	8	of	of	ADP
njb-27	116	9	size	size	NOUN
njb-27	116	10	453bp	453bp	PROPN
njb-27	116	11	,	,	PUNCT
njb-27	116	12	60bp	60bp	PROPN
njb-27	116	13	,	,	PUNCT
njb-27	116	14	168bp	168bp	PROPN
njb-27	116	15	.	.	PUNCT
njb-27	117	1	b	b	X
njb-27	117	2	)	)	PUNCT
njb-27	117	3	mutant	mutant	ADJ
njb-27	117	4	strain	strain	NOUN
njb-27	117	5	with	with	ADP
njb-27	117	6	two	two	NUM
njb-27	117	7	bands	band	NOUN
njb-27	117	8	of	of	ADP
njb-27	117	9	size	size	NOUN
njb-27	117	10	453bp	453bp	PROPN
njb-27	117	11	and	and	CCONJ
njb-27	117	12	228bp	228bp	PROPN
njb-27	117	13	resistance	resistance	NOUN
njb-27	117	14	mutation	mutation	PROPN
njb-27	117	15	in	in	ADP
njb-27	117	16	hiv-1	hiv-1	PUNCT
njb-27	117	17	proviral	proviral	ADJ
njb-27	117	18	dna	dna	PROPN
njb-27	117	19	.	.	PUNCT
njb-27	118	1	however	however	ADV
njb-27	118	2	,	,	PUNCT
njb-27	118	3	the	the	DET
njb-27	118	4	presence	presence	NOUN
njb-27	118	5	of	of	ADP
njb-27	118	6	drug	drug	NOUN
njb-27	118	7	resistance	resistance	NOUN
njb-27	118	8	mutations	mutation	NOUN
njb-27	118	9	in	in	ADP
njb-27	118	10	the	the	DET
njb-27	118	11	reservoir	reservoir	NOUN
njb-27	118	12	of	of	ADP
njb-27	118	13	latent	latent	ADJ
njb-27	118	14	hiv-1	hiv-1	PUNCT
njb-27	118	15	provirus	provirus	NOUN
njb-27	118	16	and	and	CCONJ
njb-27	118	17	their	their	PRON
njb-27	118	18	stability	stability	NOUN
njb-27	118	19	may	may	AUX
njb-27	118	20	impact	impact	VERB
njb-27	118	21	future	future	ADJ
njb-27	118	22	management	management	NOUN
njb-27	118	23	and/or	and/or	CCONJ
njb-27	118	24	treatment	treatment	NOUN
njb-27	118	25	possibilities	possibility	NOUN
njb-27	118	26	.	.	PUNCT
njb-27	119	1	the	the	DET
njb-27	119	2	presence	presence	NOUN
njb-27	119	3	of	of	ADP
njb-27	119	4	latent	latent	ADJ
njb-27	119	5	proviral	proviral	ADJ
njb-27	119	6	dna	dna	NOUN
njb-27	119	7	does	do	AUX
njb-27	119	8	n’t	not	PART
njb-27	119	9	indicate	indicate	VERB
njb-27	119	10	the	the	DET
njb-27	119	11	resistance	resistance	NOUN
njb-27	119	12	to	to	ADP
njb-27	119	13	art	art	NOUN
njb-27	119	14	but	but	CCONJ
njb-27	119	15	the	the	DET
njb-27	119	16	specific	specific	ADJ
njb-27	119	17	mutation	mutation	NOUN
njb-27	119	18	like	like	ADP
njb-27	119	19	m184v	m184v	PROPN
njb-27	119	20	,	,	PUNCT
njb-27	119	21	k65r	k65r	PROPN
njb-27	119	22	,	,	PUNCT
njb-27	119	23	m41l	m41l	NUM
njb-27	119	24	and	and	CCONJ
njb-27	119	25	k103n	k103n	PROPN
njb-27	119	26	etc	etc	X
njb-27	119	27	.	.	X
njb-27	119	28	can	can	AUX
njb-27	119	29	be	be	AUX
njb-27	119	30	detected	detect	VERB
njb-27	119	31	if	if	SCONJ
njb-27	119	32	the	the	DET
njb-27	119	33	similar	similar	ADJ
njb-27	119	34	mutation	mutation	NOUN
njb-27	119	35	is	be	AUX
njb-27	119	36	observed	observe	VERB
njb-27	119	37	in	in	ADP
njb-27	119	38	hiv-1	hiv-1	PUNCT
njb-27	119	39	rna	rna	NOUN
njb-27	119	40	.	.	PUNCT
njb-27	120	1	this	this	PRON
njb-27	120	2	is	be	AUX
njb-27	120	3	due	due	ADJ
njb-27	120	4	to	to	ADP
njb-27	120	5	retention	retention	NOUN
njb-27	120	6	of	of	ADP
njb-27	120	7	mutant	mutant	NOUN
njb-27	120	8	from	from	ADP
njb-27	120	9	hiv-1	hiv-1	PUNCT
njb-27	120	10	rna	rna	NOUN
njb-27	120	11	into	into	ADP
njb-27	120	12	cdna	cdna	PROPN
njb-27	120	13	due	due	ADP
njb-27	120	14	to	to	ADP
njb-27	120	15	long	long	ADJ
njb-27	120	16	term	term	NOUN
njb-27	120	17	suppressive	suppressive	ADJ
njb-27	120	18	art	art	NOUN
njb-27	120	19	that	that	PRON
njb-27	120	20	integrates	integrate	VERB
njb-27	120	21	into	into	ADP
njb-27	120	22	host	host	NOUN
njb-27	120	23	genome	genome	NOUN
njb-27	120	24	.	.	PUNCT
njb-27	121	1	the	the	DET
njb-27	121	2	evolution	evolution	NOUN
njb-27	121	3	of	of	ADP
njb-27	121	4	drug	drug	NOUN
njb-27	121	5	resistance	resistance	NOUN
njb-27	121	6	mutation	mutation	NOUN
njb-27	121	7	in	in	ADP
njb-27	121	8	globally	globally	ADJ
njb-27	121	9	epidemic	epidemic	NOUN
njb-27	121	10	hiv-1	hiv-1	PUNCT
njb-27	121	11	is	be	AUX
njb-27	121	12	due	due	ADJ
njb-27	121	13	to	to	ADP
njb-27	121	14	suboptimal	suboptimal	ADJ
njb-27	121	15	nepal	nepal	ADJ
njb-27	121	16	journal	journal	NOUN
njb-27	121	17	of	of	ADP
njb-27	121	18	biotechnology	biotechnology	NOUN
njb-27	121	19	.	.	PUNCT
njb-27	122	1	d	d	X
njb-27	122	2	e	e	PROPN
njb-27	122	3	c	c	PROPN
njb-27	122	4	.	.	PUNCT
njb-27	123	1	2	2	NUM
njb-27	123	2	0	0	NUM
njb-27	123	3	1	1	NUM
njb-27	123	4	6	6	NUM
njb-27	123	5	vol	vol	NOUN
njb-27	123	6	.	.	PROPN
njb-27	124	1	4	4	NUM
njb-27	124	2	,	,	PUNCT
njb-27	124	3	no	no	NOUN
njb-27	124	4	.	.	NOUN
njb-27	124	5	1	1	NUM
njb-27	124	6	:	:	SYM
njb-27	124	7	18	18	NUM
njb-27	124	8	-	-	SYM
njb-27	124	9	25	25	NUM
njb-27	124	10	shrestha	shrestha	NOUN
njb-27	124	11	et	et	X
njb-27	124	12	al	al	PROPN
njb-27	124	13	.	.	PUNCT
njb-27	125	1	©	©	PROPN
njb-27	125	2	njb	njb	PROPN
njb-27	125	3	,	,	PUNCT
njb-27	125	4	biotechnology	biotechnology	NOUN
njb-27	125	5	society	society	NOUN
njb-27	125	6	of	of	ADP
njb-27	125	7	nepal	nepal	ADJ
njb-27	125	8	23	23	NUM
njb-27	125	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	125	10	treatment	treatment	NOUN
njb-27	125	11	,	,	PUNCT
njb-27	125	12	a	a	DET
njb-27	125	13	point	point	NOUN
njb-27	125	14	mutation	mutation	NOUN
njb-27	125	15	in	in	ADP
njb-27	125	16	viral	viral	ADJ
njb-27	125	17	genome	genome	NOUN
njb-27	125	18	and	and	CCONJ
njb-27	125	19	resistance	resistance	NOUN
njb-27	125	20	variants	variant	NOUN
njb-27	125	21	leads	lead	VERB
njb-27	125	22	to	to	ADP
njb-27	125	23	incomplete	incomplete	ADJ
njb-27	125	24	suppression	suppression	NOUN
njb-27	125	25	of	of	ADP
njb-27	125	26	the	the	DET
njb-27	125	27	viral	viral	ADJ
njb-27	125	28	genome	genome	NOUN
njb-27	125	29	.	.	PUNCT
njb-27	126	1	the	the	DET
njb-27	126	2	development	development	NOUN
njb-27	126	3	of	of	ADP
njb-27	126	4	drug	drug	NOUN
njb-27	126	5	resistance	resistance	NOUN
njb-27	126	6	mutation	mutation	NOUN
njb-27	126	7	threatens	threaten	VERB
njb-27	126	8	the	the	DET
njb-27	126	9	success	success	NOUN
njb-27	126	10	of	of	ADP
njb-27	126	11	the	the	DET
njb-27	126	12	future	future	ADJ
njb-27	126	13	therapy	therapy	NOUN
njb-27	126	14	regimens	regimen	NOUN
njb-27	126	15	.	.	PUNCT
njb-27	127	1	the	the	DET
njb-27	127	2	challenge	challenge	NOUN
njb-27	127	3	in	in	ADP
njb-27	127	4	treatment	treatment	NOUN
njb-27	127	5	of	of	ADP
njb-27	127	6	hiv-1	hiv-1	ADJ
njb-27	127	7	is	be	AUX
njb-27	127	8	associated	associate	VERB
njb-27	127	9	with	with	ADP
njb-27	127	10	the	the	DET
njb-27	127	11	development	development	NOUN
njb-27	127	12	of	of	ADP
njb-27	127	13	drug	drug	NOUN
njb-27	127	14	resistance	resistance	NOUN
njb-27	127	15	mutation	mutation	NOUN
njb-27	127	16	against	against	ADP
njb-27	127	17	antiretroviral	antiretroviral	ADJ
njb-27	127	18	drugs	drug	NOUN
njb-27	127	19	which	which	PRON
njb-27	127	20	can	can	AUX
njb-27	127	21	significantly	significantly	ADV
njb-27	127	22	reduce	reduce	VERB
njb-27	127	23	the	the	DET
njb-27	127	24	viral	viral	ADJ
njb-27	127	25	rna	rna	NOUN
njb-27	127	26	to	to	ADP
njb-27	127	27	undetectable	undetectable	ADJ
njb-27	127	28	levels	level	NOUN
njb-27	127	29	in	in	ADP
njb-27	127	30	plasma	plasma	NOUN
njb-27	127	31	[	[	X
njb-27	127	32	22	22	NUM
njb-27	127	33	]	]	PUNCT
njb-27	127	34	.	.	PUNCT
njb-27	128	1	the	the	DET
njb-27	128	2	various	various	ADJ
njb-27	128	3	resistance	resistance	NOUN
njb-27	128	4	mutation	mutation	NOUN
njb-27	128	5	pattern	pattern	NOUN
njb-27	128	6	has	have	AUX
njb-27	128	7	been	be	AUX
njb-27	128	8	reported	report	VERB
njb-27	128	9	with	with	ADP
njb-27	128	10	majorities	majority	NOUN
njb-27	128	11	in	in	ADP
njb-27	128	12	both	both	DET
njb-27	128	13	nucleoside	nucleoside	NOUN
njb-27	128	14	reverse	reverse	ADJ
njb-27	128	15	transcriptase	transcriptase	NOUN
njb-27	128	16	inhibitors	inhibitor	NOUN
njb-27	128	17	(	(	PUNCT
njb-27	128	18	nrtis	nrtis	PROPN
njb-27	128	19	)	)	PUNCT
njb-27	128	20	and	and	CCONJ
njb-27	128	21	nonnucleoside	nonnucleoside	ADJ
njb-27	128	22	reverse	reverse	ADJ
njb-27	128	23	transcriptase	transcriptase	NOUN
njb-27	128	24	inhibitors	inhibitor	NOUN
njb-27	128	25	(	(	PUNCT
njb-27	128	26	nnrtis	nnrtis	X
njb-27	128	27	)	)	PUNCT
njb-27	128	28	while	while	SCONJ
njb-27	128	29	only	only	ADV
njb-27	128	30	a	a	DET
njb-27	128	31	few	few	ADJ
njb-27	128	32	with	with	ADP
njb-27	128	33	nnrtis	nnrtis	NOUN
njb-27	128	34	and	and	CCONJ
njb-27	128	35	also	also	ADV
njb-27	128	36	in	in	ADP
njb-27	128	37	minor	minor	ADJ
njb-27	128	38	ratio	ratio	NOUN
njb-27	128	39	with	with	ADP
njb-27	128	40	protease	protease	NOUN
njb-27	128	41	inhibitors	inhibitor	NOUN
njb-27	128	42	(	(	PUNCT
njb-27	128	43	pi	pi	NOUN
njb-27	128	44	)	)	PUNCT
njb-27	128	45	and	and	CCONJ
njb-27	128	46	3class	3class	NUM
njb-27	128	47	resistance	resistance	NOUN
njb-27	128	48	(	(	PUNCT
njb-27	128	49	nrtis	nrtis	NOUN
njb-27	128	50	,	,	PUNCT
njb-27	128	51	nnrtis	nnrtis	NOUN
njb-27	128	52	and	and	CCONJ
njb-27	128	53	pis	pis	NOUN
njb-27	128	54	)	)	PUNCT
njb-27	128	55	.	.	PUNCT
njb-27	129	1	the	the	DET
njb-27	129	2	genotyping	genotyping	NOUN
njb-27	129	3	of	of	ADP
njb-27	129	4	the	the	DET
njb-27	129	5	reverse	reverse	ADJ
njb-27	129	6	transcriptase	transcriptase	NOUN
njb-27	129	7	gene	gene	NOUN
njb-27	129	8	sequence	sequence	NOUN
njb-27	129	9	revealed	reveal	VERB
njb-27	129	10	that	that	SCONJ
njb-27	129	11	almost	almost	ADV
njb-27	129	12	90	90	NUM
njb-27	129	13	%	%	NOUN
njb-27	129	14	resistance	resistance	NOUN
njb-27	129	15	mutation	mutation	NOUN
njb-27	129	16	were	be	AUX
njb-27	129	17	m184v	m184v	VERB
njb-27	129	18	[	[	PUNCT
njb-27	129	19	23	23	NUM
njb-27	129	20	]	]	PUNCT
njb-27	129	21	and	and	CCONJ
njb-27	129	22	such	such	ADJ
njb-27	129	23	mutation	mutation	NOUN
njb-27	129	24	emerges	emerge	VERB
njb-27	129	25	in	in	ADP
njb-27	129	26	patients	patient	NOUN
njb-27	129	27	receiving	receive	VERB
njb-27	129	28	lamivudine	lamivudine	NOUN
njb-27	129	29	(	(	PUNCT
njb-27	129	30	3tc	3tc	NOUN
njb-27	129	31	)	)	PUNCT
njb-27	129	32	therapy	therapy	NOUN
njb-27	129	33	,	,	PUNCT
njb-27	129	34	but	but	CCONJ
njb-27	129	35	also	also	ADV
njb-27	129	36	it	it	PRON
njb-27	129	37	could	could	AUX
njb-27	129	38	be	be	AUX
njb-27	129	39	associated	associate	VERB
njb-27	129	40	with	with	ADP
njb-27	129	41	phenotypic	phenotypic	ADJ
njb-27	129	42	reversion	reversion	NOUN
njb-27	129	43	of	of	ADP
njb-27	129	44	zidovudine	zidovudine	PROPN
njb-27	129	45	(	(	PUNCT
njb-27	129	46	zdv	zdv	PROPN
njb-27	129	47	)	)	PUNCT
njb-27	129	48	resistance	resistance	NOUN
njb-27	130	1	[	[	PUNCT
njb-27	130	2	24	24	NUM
njb-27	130	3	]	]	PUNCT
njb-27	130	4	.	.	PUNCT
njb-27	131	1	in	in	ADP
njb-27	131	2	the	the	DET
njb-27	131	3	present	present	ADJ
njb-27	131	4	study	study	NOUN
njb-27	131	5	,	,	PUNCT
njb-27	131	6	we	we	PRON
njb-27	131	7	screened	screen	VERB
njb-27	131	8	for	for	ADP
njb-27	131	9	m184v	m184v	ADJ
njb-27	131	10	resistance	resistance	NOUN
njb-27	131	11	mutation	mutation	NOUN
njb-27	131	12	in	in	ADP
njb-27	131	13	hiv-1	hiv-1	PUNCT
njb-27	131	14	infected	infect	VERB
njb-27	131	15	patients	patient	NOUN
njb-27	131	16	receiving	receive	VERB
njb-27	131	17	3tc	3tc	NOUN
njb-27	131	18	in	in	ADP
njb-27	131	19	combination	combination	NOUN
njb-27	131	20	by	by	ADP
njb-27	131	21	pcrrfda	pcrrfda	PROPN
njb-27	131	22	methods	method	NOUN
njb-27	131	23	.	.	PUNCT
njb-27	132	1	the	the	DET
njb-27	132	2	only	only	ADJ
njb-27	132	3	wild	wild	ADJ
njb-27	132	4	type	type	NOUN
njb-27	132	5	strain	strain	NOUN
njb-27	132	6	was	be	AUX
njb-27	132	7	found	find	VERB
njb-27	132	8	in	in	ADP
njb-27	132	9	all	all	DET
njb-27	132	10	the	the	DET
njb-27	132	11	sample	sample	NOUN
njb-27	132	12	analyzed	analyze	VERB
njb-27	132	13	which	which	PRON
njb-27	132	14	means	mean	VERB
njb-27	132	15	the	the	DET
njb-27	132	16	m184v	m184v	ADJ
njb-27	132	17	mutation	mutation	NOUN
njb-27	132	18	was	be	AUX
njb-27	132	19	negative	negative	ADJ
njb-27	132	20	.	.	PUNCT
njb-27	133	1	our	our	PRON
njb-27	133	2	results	result	NOUN
njb-27	133	3	completely	completely	ADV
njb-27	133	4	contradict	contradict	VERB
njb-27	133	5	the	the	DET
njb-27	133	6	other	other	ADJ
njb-27	133	7	reports	report	NOUN
njb-27	133	8	on	on	ADP
njb-27	133	9	m184v	m184v	PROPN
njb-27	133	10	.	.	PUNCT
njb-27	134	1	in	in	ADP
njb-27	134	2	the	the	DET
njb-27	134	3	study	study	NOUN
njb-27	134	4	though	though	SCONJ
njb-27	134	5	phenotypic	phenotypic	ADJ
njb-27	134	6	resistance	resistance	NOUN
njb-27	134	7	and	and	CCONJ
njb-27	134	8	high	high	ADJ
njb-27	134	9	viral	viral	ADJ
njb-27	134	10	load	load	NOUN
njb-27	134	11	were	be	AUX
njb-27	134	12	included	include	VERB
njb-27	134	13	,	,	PUNCT
njb-27	134	14	m184v	m184v	VERB
njb-27	134	15	mutation	mutation	NOUN
njb-27	134	16	was	be	AUX
njb-27	134	17	not	not	PART
njb-27	134	18	detected	detect	VERB
njb-27	134	19	which	which	PRON
njb-27	134	20	might	might	AUX
njb-27	134	21	be	be	AUX
njb-27	134	22	due	due	ADJ
njb-27	134	23	to	to	ADP
njb-27	134	24	numerous	numerous	ADJ
njb-27	134	25	reasons	reason	NOUN
njb-27	134	26	like	like	ADP
njb-27	134	27	1	1	NUM
njb-27	134	28	)	)	PUNCT
njb-27	134	29	duration	duration	NOUN
njb-27	134	30	of	of	ADP
njb-27	134	31	3tc	3tc	ADJ
njb-27	134	32	art	art	NOUN
njb-27	134	33	,	,	PUNCT
njb-27	134	34	2	2	NUM
njb-27	134	35	)	)	PUNCT
njb-27	134	36	possibilities	possibility	NOUN
njb-27	134	37	of	of	ADP
njb-27	134	38	other	other	ADJ
njb-27	134	39	mutation	mutation	NOUN
njb-27	134	40	like	like	ADP
njb-27	134	41	m184i	m184i	PROPN
njb-27	134	42	,	,	PUNCT
njb-27	134	43	k65r	k65r	PROPN
njb-27	134	44	,	,	PUNCT
njb-27	134	45	etc	etc	X
njb-27	134	46	3	3	X
njb-27	134	47	)	)	PUNCT
njb-27	134	48	change	change	NOUN
njb-27	134	49	in	in	ADP
njb-27	134	50	drugs	drug	NOUN
njb-27	134	51	4	4	NUM
njb-27	134	52	)	)	PUNCT
njb-27	134	53	less	less	ADV
njb-27	134	54	likely	likely	ADJ
njb-27	134	55	to	to	PART
njb-27	134	56	be	be	AUX
njb-27	134	57	technical	technical	ADJ
njb-27	134	58	error	error	NOUN
njb-27	134	59	.	.	PUNCT
njb-27	135	1	the	the	DET
njb-27	135	2	commonly	commonly	ADV
njb-27	135	3	used	use	VERB
njb-27	135	4	drugs	drug	NOUN
njb-27	135	5	by	by	ADP
njb-27	135	6	the	the	DET
njb-27	135	7	hiv-1	hiv-1	PUNCT
njb-27	135	8	infected	infect	VERB
njb-27	135	9	patients	patient	NOUN
njb-27	135	10	in	in	ADP
njb-27	135	11	nepal	nepal	ADJ
njb-27	135	12	are	be	AUX
njb-27	135	13	azt	azt	PROPN
njb-27	135	14	,	,	PUNCT
njb-27	135	15	3tc	3tc	NOUN
njb-27	135	16	,	,	PUNCT
njb-27	135	17	efv	efv	NOUN
njb-27	135	18	and	and	CCONJ
njb-27	135	19	nfv	nfv	INTJ
njb-27	135	20	and	and	CCONJ
njb-27	135	21	is	be	AUX
njb-27	135	22	shown	show	VERB
njb-27	135	23	in	in	ADP
njb-27	135	24	table	table	NOUN
njb-27	135	25	1	1	NUM
njb-27	135	26	.	.	PUNCT
njb-27	136	1	the	the	DET
njb-27	136	2	high	high	ADJ
njb-27	136	3	level	level	NOUN
njb-27	136	4	resistance	resistance	NOUN
njb-27	136	5	to	to	ADP
njb-27	136	6	3tc	3tc	NOUN
njb-27	136	7	associated	associate	VERB
njb-27	136	8	with	with	ADP
njb-27	136	9	m184v	m184v	ADJ
njb-27	136	10	mutation	mutation	NOUN
njb-27	136	11	is	be	AUX
njb-27	136	12	also	also	ADV
njb-27	136	13	resistance	resistance	NOUN
njb-27	136	14	to	to	ADP
njb-27	136	15	other	other	ADJ
njb-27	136	16	drugs	drug	NOUN
njb-27	136	17	like	like	ADP
njb-27	136	18	ftc	ftc	PROPN
njb-27	136	19	,	,	PUNCT
njb-27	136	20	abc	abc	PROPN
njb-27	136	21	and	and	CCONJ
njb-27	136	22	ddi	ddi	PROPN
njb-27	136	23	.	.	PUNCT
njb-27	137	1	in	in	ADP
njb-27	137	2	addition	addition	NOUN
njb-27	137	3	to	to	ADP
njb-27	137	4	this	this	PRON
njb-27	137	5	,	,	PUNCT
njb-27	137	6	resistance	resistance	NOUN
njb-27	137	7	to	to	ADP
njb-27	137	8	3tc	3tc	NOUN
njb-27	137	9	is	be	AUX
njb-27	137	10	also	also	ADV
njb-27	137	11	associated	associate	VERB
njb-27	137	12	with	with	ADP
njb-27	137	13	k65r	k65r	PRON
njb-27	137	14	mutation	mutation	NOUN
njb-27	137	15	and	and	CCONJ
njb-27	137	16	its	its	PRON
njb-27	137	17	variant	variant	ADJ
njb-27	137	18	forms	form	NOUN
njb-27	137	19	but	but	CCONJ
njb-27	137	20	the	the	DET
njb-27	137	21	level	level	NOUN
njb-27	137	22	of	of	ADP
njb-27	137	23	resistance	resistance	NOUN
njb-27	137	24	may	may	AUX
njb-27	137	25	vary	vary	VERB
njb-27	137	26	from	from	ADP
njb-27	137	27	high	high	ADJ
njb-27	137	28	-	-	PUNCT
njb-27	137	29	intermediate	intermediate	ADJ
njb-27	137	30	-	-	PUNCT
njb-27	137	31	low	low	ADJ
njb-27	137	32	.	.	PUNCT
njb-27	138	1	the	the	DET
njb-27	138	2	most	most	ADV
njb-27	138	3	common	common	ADJ
njb-27	138	4	rt	rt	PROPN
njb-27	138	5	gene	gene	NOUN
njb-27	138	6	mutation	mutation	NOUN
njb-27	138	7	and	and	CCONJ
njb-27	138	8	specific	specific	ADJ
njb-27	138	9	drug	drug	NOUN
njb-27	138	10	resistance	resistance	NOUN
njb-27	138	11	is	be	AUX
njb-27	138	12	shown	show	VERB
njb-27	138	13	in	in	ADP
njb-27	138	14	table	table	NOUN
njb-27	138	15	2	2	NUM
njb-27	138	16	.	.	PUNCT
njb-27	139	1	there	there	PRON
njb-27	139	2	are	be	VERB
njb-27	139	3	several	several	ADJ
njb-27	139	4	mutations	mutation	NOUN
njb-27	139	5	in	in	ADP
njb-27	139	6	genes	gene	NOUN
njb-27	139	7	of	of	ADP
njb-27	139	8	hiv-1	hiv-1	ADV
njb-27	139	9	associated	associate	VERB
njb-27	139	10	with	with	ADP
njb-27	139	11	resistance	resistance	NOUN
njb-27	139	12	to	to	ADP
njb-27	139	13	specific	specific	ADJ
njb-27	139	14	drugs	drug	NOUN
njb-27	139	15	[	[	PUNCT
njb-27	139	16	25	25	NUM
njb-27	139	17	]	]	PUNCT
njb-27	139	18	.	.	PUNCT
njb-27	140	1	the	the	DET
njb-27	140	2	m184v	m184v	ADJ
njb-27	140	3	mutation	mutation	NOUN
njb-27	140	4	was	be	AUX
njb-27	140	5	detected	detect	VERB
njb-27	140	6	in	in	ADP
njb-27	140	7	lesser	less	ADJ
njb-27	140	8	than	than	ADP
njb-27	140	9	10	10	NUM
njb-27	140	10	%	%	NOUN
njb-27	140	11	by	by	ADP
njb-27	140	12	allele	allele	PROPN
njb-27	140	13	specific	specific	ADJ
njb-27	140	14	pcr	pcr	NOUN
njb-27	140	15	but	but	CCONJ
njb-27	140	16	was	be	AUX
njb-27	140	17	consistently	consistently	ADV
njb-27	140	18	negative	negative	ADJ
njb-27	140	19	by	by	ADP
njb-27	140	20	standard	standard	ADJ
njb-27	140	21	genotyping	genotyping	NOUN
njb-27	140	22	[	[	PUNCT
njb-27	140	23	26	26	NUM
njb-27	140	24	]	]	PUNCT
njb-27	140	25	while	while	SCONJ
njb-27	140	26	the	the	DET
njb-27	140	27	ratio	ratio	NOUN
njb-27	140	28	of	of	ADP
njb-27	140	29	mutant	mutant	ADJ
njb-27	140	30	and	and	CCONJ
njb-27	140	31	wild	wild	ADJ
njb-27	140	32	type	type	NOUN
njb-27	140	33	is	be	AUX
njb-27	140	34	equal	equal	ADJ
njb-27	140	35	to	to	ADP
njb-27	140	36	50:50	50:50	NUM
njb-27	140	37	reported	report	VERB
njb-27	140	38	by	by	ADP
njb-27	140	39	almost	almost	ADV
njb-27	140	40	half	half	NOUN
njb-27	140	41	of	of	ADP
njb-27	140	42	the	the	DET
njb-27	140	43	laboratories	laboratory	NOUN
njb-27	140	44	[	[	X
njb-27	140	45	27	27	NUM
njb-27	140	46	]	]	PUNCT
njb-27	140	47	.	.	PUNCT
njb-27	141	1	the	the	DET
njb-27	141	2	prevalence	prevalence	NOUN
njb-27	141	3	of	of	ADP
njb-27	141	4	the	the	DET
njb-27	141	5	m184v	m184v	ADJ
njb-27	141	6	mutation	mutation	NOUN
njb-27	141	7	is	be	AUX
njb-27	141	8	notably	notably	ADV
njb-27	141	9	higher	high	ADJ
njb-27	141	10	than	than	ADP
njb-27	141	11	that	that	PRON
njb-27	141	12	of	of	ADP
njb-27	141	13	other	other	ADJ
njb-27	141	14	mutation	mutation	NOUN
njb-27	141	15	[	[	PUNCT
njb-27	141	16	28	28	NUM
njb-27	141	17	-	-	SYM
njb-27	141	18	30	30	NUM
njb-27	141	19	]	]	PUNCT
njb-27	141	20	and	and	CCONJ
njb-27	141	21	is	be	AUX
njb-27	141	22	significantly	significantly	ADV
njb-27	141	23	associated	associate	VERB
njb-27	141	24	with	with	ADP
njb-27	141	25	3tc	3tc	NOUN
njb-27	142	1	[	[	X
njb-27	142	2	31	31	NUM
njb-27	142	3	]	]	PUNCT
njb-27	142	4	.	.	PUNCT
njb-27	143	1	the	the	DET
njb-27	143	2	early	early	ADJ
njb-27	143	3	detection	detection	NOUN
njb-27	143	4	of	of	ADP
njb-27	143	5	resistance	resistance	NOUN
njb-27	143	6	mutation	mutation	NOUN
njb-27	143	7	in	in	ADP
njb-27	143	8	hiv-1	hiv-1	PUNCT
njb-27	143	9	infected	infected	ADJ
njb-27	143	10	patients	patient	NOUN
njb-27	143	11	would	would	AUX
njb-27	143	12	help	help	VERB
njb-27	143	13	to	to	PART
njb-27	143	14	change	change	VERB
njb-27	143	15	the	the	DET
njb-27	143	16	treatment	treatment	NOUN
njb-27	143	17	regimens	regimen	NOUN
njb-27	143	18	susceptible	susceptible	ADJ
njb-27	143	19	to	to	ADP
njb-27	143	20	both	both	CCONJ
njb-27	143	21	proviral	proviral	ADJ
njb-27	143	22	dna	dna	NOUN
njb-27	143	23	and	and	CCONJ
njb-27	143	24	viral	viral	ADJ
njb-27	143	25	rna	rna	NOUN
njb-27	143	26	and	and	CCONJ
njb-27	143	27	control	control	NOUN
njb-27	143	28	measures	measure	NOUN
njb-27	143	29	can	can	AUX
njb-27	143	30	be	be	AUX
njb-27	143	31	taken	take	VERB
njb-27	143	32	to	to	PART
njb-27	143	33	minimize	minimize	VERB
njb-27	143	34	the	the	DET
njb-27	143	35	transmission	transmission	NOUN
njb-27	143	36	of	of	ADP
njb-27	143	37	resistant	resistant	ADJ
njb-27	143	38	variants	variant	NOUN
njb-27	143	39	.	.	PUNCT
njb-27	144	1	an	an	DET
njb-27	144	2	understanding	understanding	NOUN
njb-27	144	3	of	of	ADP
njb-27	144	4	the	the	DET
njb-27	144	5	molecular	molecular	ADJ
njb-27	144	6	mechanism	mechanism	NOUN
njb-27	144	7	of	of	ADP
njb-27	144	8	drug	drug	NOUN
njb-27	144	9	resistance	resistance	NOUN
njb-27	144	10	will	will	AUX
njb-27	144	11	enable	enable	VERB
njb-27	144	12	us	we	PRON
njb-27	144	13	to	to	PART
njb-27	144	14	develop	develop	VERB
njb-27	144	15	improved	improved	ADJ
njb-27	144	16	tools	tool	NOUN
njb-27	144	17	for	for	ADP
njb-27	144	18	resistance	resistance	NOUN
njb-27	144	19	screening	screening	NOUN
njb-27	144	20	.	.	PUNCT
njb-27	145	1	conclusion	conclusion	NOUN
njb-27	145	2	in	in	ADP
njb-27	145	3	the	the	DET
njb-27	145	4	present	present	ADJ
njb-27	145	5	study	study	NOUN
njb-27	145	6	,	,	PUNCT
njb-27	145	7	we	we	PRON
njb-27	145	8	set	set	VERB
njb-27	145	9	out	out	ADP
njb-27	145	10	to	to	PART
njb-27	145	11	identify	identify	VERB
njb-27	145	12	the	the	DET
njb-27	145	13	hiv1	hiv1	PROPN
njb-27	145	14	latent	latent	ADJ
njb-27	145	15	infections	infection	NOUN
njb-27	145	16	by	by	ADP
njb-27	145	17	detecting	detect	VERB
njb-27	145	18	env	env	NOUN
njb-27	145	19	v3	v3	PROPN
njb-27	145	20	dna	dna	PROPN
njb-27	145	21	sequences	sequence	NOUN
njb-27	145	22	using	use	VERB
njb-27	145	23	nested	nest	VERB
njb-27	145	24	pcr	pcr	PROPN
njb-27	145	25	.	.	PUNCT
njb-27	146	1	in	in	ADP
njb-27	146	2	addition	addition	NOUN
njb-27	146	3	to	to	ADP
njb-27	146	4	this	this	PRON
njb-27	146	5	,	,	PUNCT
njb-27	146	6	the	the	DET
njb-27	146	7	m184v	m184v	ADJ
njb-27	146	8	resistance	resistance	NOUN
njb-27	146	9	mutation	mutation	NOUN
njb-27	146	10	was	be	AUX
njb-27	146	11	not	not	PART
njb-27	146	12	observed	observe	VERB
njb-27	146	13	in	in	ADP
njb-27	146	14	the	the	DET
njb-27	146	15	samples	sample	NOUN
njb-27	146	16	analyzed	analyze	VERB
njb-27	146	17	thus	thus	ADV
njb-27	146	18	indicating	indicate	VERB
njb-27	146	19	as	as	ADP
njb-27	146	20	wild	wild	ADJ
njb-27	146	21	type	type	NOUN
njb-27	146	22	strain	strain	NOUN
njb-27	146	23	.	.	PUNCT
njb-27	147	1	also	also	ADV
njb-27	147	2	,	,	PUNCT
njb-27	147	3	we	we	PRON
njb-27	147	4	optimized	optimize	VERB
njb-27	147	5	the	the	DET
njb-27	147	6	pcr	pcr	PROPN
njb-27	147	7	-	-	PUNCT
njb-27	147	8	rfda	rfda	PROPN
njb-27	147	9	protocol	protocol	NOUN
njb-27	147	10	using	use	VERB
njb-27	147	11	cviaii	cviaii	PROPN
njb-27	147	12	restriction	restriction	NOUN
njb-27	147	13	enzymes	enzyme	NOUN
njb-27	147	14	for	for	ADP
njb-27	147	15	the	the	DET
njb-27	147	16	hiv-1	hiv-1	PUNCT
njb-27	147	17	rt	rt	PROPN
njb-27	147	18	strains	strain	NOUN
njb-27	147	19	for	for	ADP
njb-27	147	20	mutation	mutation	NOUN
njb-27	147	21	testing	testing	NOUN
njb-27	147	22	.	.	PUNCT
njb-27	148	1	this	this	DET
njb-27	148	2	strategy	strategy	NOUN
njb-27	148	3	was	be	AUX
njb-27	148	4	meant	mean	VERB
njb-27	148	5	to	to	PART
njb-27	148	6	enhance	enhance	VERB
njb-27	148	7	assay	assay	NOUN
njb-27	148	8	discrimination	discrimination	NOUN
njb-27	148	9	between	between	ADP
njb-27	148	10	the	the	DET
njb-27	148	11	specific	specific	ADJ
njb-27	148	12	drug	drug	NOUN
njb-27	148	13	resistance	resistance	NOUN
njb-27	148	14	mutation	mutation	NOUN
njb-27	148	15	(	(	PUNCT
njb-27	148	16	mutant	mutant	ADJ
njb-27	148	17	allele	allele	PROPN
njb-27	148	18	)	)	PUNCT
njb-27	148	19	and	and	CCONJ
njb-27	148	20	its	its	PRON
njb-27	148	21	wild	wild	ADJ
njb-27	148	22	type	type	NOUN
njb-27	148	23	(	(	PUNCT
njb-27	148	24	wild	wild	ADJ
njb-27	148	25	type	type	NOUN
njb-27	148	26	allele	allele	PROPN
njb-27	148	27	)	)	PUNCT
njb-27	148	28	using	use	VERB
njb-27	148	29	nested	nested	ADJ
njb-27	148	30	primers	primer	NOUN
njb-27	148	31	and	and	CCONJ
njb-27	148	32	cviaii	cviaii	PROPN
njb-27	148	33	restriction	restriction	NOUN
njb-27	148	34	enzymes	enzyme	NOUN
njb-27	148	35	.	.	PUNCT
njb-27	149	1	declaration	declaration	NOUN
njb-27	149	2	of	of	ADP
njb-27	149	3	interests	interest	NOUN
njb-27	149	4	the	the	DET
njb-27	149	5	authors	author	NOUN
njb-27	149	6	declare	declare	VERB
njb-27	149	7	that	that	SCONJ
njb-27	149	8	they	they	PRON
njb-27	149	9	have	have	VERB
njb-27	149	10	no	no	DET
njb-27	149	11	competing	compete	VERB
njb-27	149	12	interests	interest	NOUN
njb-27	149	13	.	.	PUNCT
njb-27	150	1	authors	author	NOUN
njb-27	150	2	’	’	PART
njb-27	150	3	contributions	contribution	NOUN
njb-27	150	4	rupendra	rupendra	NOUN
njb-27	150	5	came	come	VERB
njb-27	150	6	up	up	ADP
njb-27	150	7	with	with	ADP
njb-27	150	8	the	the	DET
njb-27	150	9	study	study	NOUN
njb-27	150	10	,	,	PUNCT
njb-27	150	11	frame	frame	NOUN
njb-27	150	12	experimental	experimental	ADJ
njb-27	150	13	work	work	NOUN
njb-27	150	14	and	and	CCONJ
njb-27	150	15	prepared	prepared	ADJ
njb-27	150	16	manuscript	manuscript	NOUN
njb-27	150	17	.	.	PUNCT
njb-27	151	1	all	all	DET
njb-27	151	2	authors	author	NOUN
njb-27	151	3	have	have	AUX
njb-27	151	4	equally	equally	ADV
njb-27	151	5	involved	involve	VERB
njb-27	151	6	in	in	ADP
njb-27	151	7	completing	complete	VERB
njb-27	151	8	the	the	DET
njb-27	151	9	research	research	NOUN
njb-27	151	10	experiment	experiment	NOUN
njb-27	151	11	and	and	CCONJ
njb-27	151	12	data	datum	NOUN
njb-27	151	13	compiling	compile	VERB
njb-27	151	14	.	.	PUNCT
njb-27	152	1	all	all	DET
njb-27	152	2	authors	author	NOUN
njb-27	152	3	read	read	VERB
njb-27	152	4	and	and	CCONJ
njb-27	152	5	approved	approve	VERB
njb-27	152	6	the	the	DET
njb-27	152	7	final	final	ADJ
njb-27	152	8	manuscript	manuscript	NOUN
njb-27	152	9	for	for	ADP
njb-27	152	10	publication	publication	NOUN
njb-27	152	11	.	.	PUNCT
njb-27	153	1	acknowledgement	acknowledgement	VERB
njb-27	153	2	the	the	DET
njb-27	153	3	authors	author	NOUN
njb-27	153	4	would	would	AUX
njb-27	153	5	like	like	VERB
njb-27	153	6	to	to	PART
njb-27	153	7	thank	thank	VERB
njb-27	153	8	the	the	DET
njb-27	153	9	nobel	nobel	PROPN
njb-27	153	10	college	college	PROPN
njb-27	153	11	for	for	ADP
njb-27	153	12	funding	fund	VERB
njb-27	153	13	the	the	DET
njb-27	153	14	projects	project	NOUN
njb-27	153	15	and	and	CCONJ
njb-27	153	16	center	center	NOUN
njb-27	153	17	for	for	ADP
njb-27	153	18	molecular	molecular	ADJ
njb-27	153	19	dynamics	dynamic	NOUN
njb-27	153	20	nepal	nepal	ADJ
njb-27	153	21	(	(	PUNCT
njb-27	153	22	cmdn	cmdn	PROPN
njb-27	153	23	)	)	PUNCT
njb-27	153	24	for	for	ADP
njb-27	153	25	providing	provide	VERB
njb-27	153	26	all	all	DET
njb-27	153	27	the	the	DET
njb-27	153	28	facilities	facility	NOUN
njb-27	153	29	to	to	PART
njb-27	153	30	perform	perform	VERB
njb-27	153	31	the	the	DET
njb-27	153	32	research	research	NOUN
njb-27	153	33	experiment	experiment	NOUN
njb-27	153	34	.	.	PUNCT
njb-27	154	1	we	we	PRON
njb-27	154	2	also	also	ADV
njb-27	154	3	like	like	VERB
njb-27	154	4	to	to	PART
njb-27	154	5	thank	thank	VERB
njb-27	154	6	dr	dr	PROPN
njb-27	154	7	.	.	PROPN
njb-27	154	8	sameer	sameer	PROPN
njb-27	154	9	m.	m.	PROPN
njb-27	154	10	dixit	dixit	PROPN
njb-27	154	11	,	,	PUNCT
njb-27	154	12	bhavesh	bhavesh	PROPN
njb-27	154	13	mishra	mishra	PROPN
njb-27	154	14	,	,	PUNCT
njb-27	154	15	raunak	raunak	PROPN
njb-27	154	16	shrestha	shrestha	PROPN
njb-27	154	17	,	,	PUNCT
njb-27	154	18	sulochana	sulochana	PROPN
njb-27	154	19	manandhar	manandhar	NOUN
njb-27	154	20	,	,	PUNCT
njb-27	154	21	and	and	CCONJ
njb-27	154	22	prajwal	prajwal	NOUN
njb-27	154	23	rajbhandari	rajbhandari	PROPN
njb-27	154	24	for	for	ADP
njb-27	154	25	their	their	PRON
njb-27	154	26	valuable	valuable	ADJ
njb-27	154	27	discussion	discussion	NOUN
njb-27	154	28	and	and	CCONJ
njb-27	154	29	extensive	extensive	ADJ
njb-27	154	30	support	support	NOUN
njb-27	154	31	to	to	PART
njb-27	154	32	make	make	VERB
njb-27	154	33	this	this	DET
njb-27	154	34	work	work	NOUN
njb-27	154	35	done	do	VERB
njb-27	154	36	.	.	PUNCT
njb-27	155	1	nepal	nepal	ADJ
njb-27	155	2	journal	journal	PROPN
njb-27	155	3	of	of	ADP
njb-27	155	4	biotechnology	biotechnology	NOUN
njb-27	155	5	.	.	PUNCT
njb-27	156	1	d	d	X
njb-27	156	2	e	e	PROPN
njb-27	156	3	c	c	PROPN
njb-27	156	4	.	.	PUNCT
njb-27	157	1	2	2	NUM
njb-27	157	2	0	0	NUM
njb-27	157	3	1	1	NUM
njb-27	157	4	6	6	NUM
njb-27	157	5	vol	vol	NOUN
njb-27	157	6	.	.	PROPN
njb-27	158	1	4	4	NUM
njb-27	158	2	,	,	PUNCT
njb-27	158	3	no	no	NOUN
njb-27	158	4	.	.	NOUN
njb-27	158	5	1	1	NUM
njb-27	158	6	:	:	SYM
njb-27	158	7	18	18	NUM
njb-27	158	8	-	-	SYM
njb-27	158	9	25	25	NUM
njb-27	158	10	shrestha	shrestha	NOUN
njb-27	158	11	et	et	X
njb-27	158	12	al	al	PROPN
njb-27	158	13	.	.	PUNCT
njb-27	159	1	©	©	PROPN
njb-27	159	2	njb	njb	PROPN
njb-27	159	3	,	,	PUNCT
njb-27	159	4	biotechnology	biotechnology	NOUN
njb-27	159	5	society	society	NOUN
njb-27	159	6	of	of	ADP
njb-27	159	7	nepal	nepal	ADJ
njb-27	159	8	24	24	NUM
njb-27	159	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	ADJ
njb-27	159	10	references	reference	NOUN
njb-27	159	11	1	1	NUM
njb-27	159	12	.	.	PUNCT
njb-27	160	1	global	global	ADJ
njb-27	160	2	aids	aids	PROPN
njb-27	160	3	update	update	VERB
njb-27	160	4	:	:	PUNCT
njb-27	160	5	unaids	unaid	NOUN
njb-27	160	6	report	report	NOUN
njb-27	160	7	.	.	PUNCT
njb-27	161	1	geneva	geneva	PROPN
njb-27	161	2	;	;	PUNCT
njb-27	161	3	2016	2016	NUM
njb-27	161	4	.	.	PUNCT
njb-27	162	1	2	2	X
njb-27	162	2	.	.	NOUN
njb-27	162	3	country	country	NOUN
njb-27	162	4	progress	progress	NOUN
njb-27	162	5	report	report	NOUN
njb-27	162	6	:	:	PUNCT
njb-27	162	7	national	national	PROPN
njb-27	162	8	centre	centre	PROPN
njb-27	162	9	for	for	ADP
njb-27	162	10	aids	aids	PROPN
njb-27	162	11	and	and	CCONJ
njb-27	162	12	std	std	PROPN
njb-27	162	13	control	control	PROPN
njb-27	162	14	(	(	PUNCT
njb-27	162	15	ncasc	ncasc	PROPN
njb-27	162	16	)	)	PUNCT
njb-27	162	17	.	.	PUNCT
njb-27	163	1	nepal	nepal	ADJ
njb-27	163	2	;	;	PUNCT
njb-27	163	3	2015	2015	NUM
njb-27	163	4	.	.	PUNCT
njb-27	164	1	3	3	X
njb-27	164	2	.	.	PUNCT
njb-27	164	3	finzi	finzi	PROPN
njb-27	164	4	d	d	PROPN
njb-27	164	5	,	,	PUNCT
njb-27	164	6	hermankova	hermankova	PROPN
njb-27	164	7	m	m	PROPN
njb-27	164	8	,	,	PUNCT
njb-27	164	9	pierson	pierson	PROPN
njb-27	164	10	t	t	PROPN
njb-27	164	11	,	,	PUNCT
njb-27	164	12	carruth	carruth	PROPN
njb-27	164	13	lm	lm	PROPN
njb-27	164	14	,	,	PUNCT
njb-27	164	15	buck	buck	PROPN
njb-27	164	16	c	c	PROPN
njb-27	164	17	,	,	PUNCT
njb-27	164	18	chaisson	chaisson	PROPN
njb-27	164	19	re	re	PROPN
njb-27	164	20	,	,	PUNCT
njb-27	164	21	quinn	quinn	PROPN
njb-27	164	22	tc	tc	PROPN
njb-27	164	23	,	,	PUNCT
njb-27	164	24	chadwick	chadwick	PROPN
njb-27	164	25	k	k	PROPN
njb-27	164	26	,	,	PUNCT
njb-27	164	27	margolick	margolick	PROPN
njb-27	164	28	j	j	PROPN
njb-27	164	29	,	,	PUNCT
njb-27	164	30	brookmeyer	brookmeyer	PROPN
njb-27	164	31	r	r	PROPN
njb-27	164	32	,	,	PUNCT
njb-27	164	33	gallant	gallant	PROPN
njb-27	164	34	j	j	PROPN
njb-27	164	35	,	,	PUNCT
njb-27	164	36	markowitz	markowitz	PROPN
njb-27	164	37	m	m	PROPN
njb-27	164	38	,	,	PUNCT
njb-27	164	39	ho	ho	PROPN
njb-27	164	40	dd	dd	PROPN
njb-27	164	41	,	,	PUNCT
njb-27	164	42	richman	richman	PROPN
njb-27	164	43	dd	dd	NOUN
njb-27	164	44	,	,	PUNCT
njb-27	164	45	siliciano	siliciano	PROPN
njb-27	164	46	rf	rf	NOUN
njb-27	164	47	:	:	PUNCT
njb-27	164	48	identification	identification	NOUN
njb-27	164	49	of	of	ADP
njb-27	164	50	a	a	DET
njb-27	164	51	reservoir	reservoir	NOUN
njb-27	164	52	for	for	ADP
njb-27	164	53	hiv-1	hiv-1	PUNCT
njb-27	164	54	in	in	ADP
njb-27	164	55	patients	patient	NOUN
njb-27	164	56	on	on	ADP
njb-27	164	57	highly	highly	ADV
njb-27	164	58	active	active	ADJ
njb-27	164	59	antiretroviral	antiretroviral	ADJ
njb-27	164	60	therapy	therapy	NOUN
njb-27	164	61	.	.	PUNCT
njb-27	165	1	science	science	NOUN
njb-27	165	2	1997	1997	NUM
njb-27	165	3	,	,	PUNCT
njb-27	165	4	278(5341	278(5341	NUM
njb-27	165	5	):	):	PUNCT
njb-27	165	6	1295	1295	NUM
njb-27	165	7	-	-	SYM
njb-27	165	8	1300	1300	NUM
njb-27	165	9	.	.	NUM
njb-27	165	10	4	4	X
njb-27	165	11	.	.	PUNCT
njb-27	166	1	siliciano	siliciano	PROPN
njb-27	166	2	jd	jd	PROPN
njb-27	166	3	,	,	PUNCT
njb-27	166	4	kajdas	kajdas	PROPN
njb-27	166	5	j	j	PROPN
njb-27	166	6	,	,	PUNCT
njb-27	166	7	finzi	finzi	PROPN
njb-27	166	8	d	d	PROPN
njb-27	166	9	,	,	PUNCT
njb-27	166	10	quinn	quinn	PROPN
njb-27	166	11	tc	tc	PROPN
njb-27	166	12	,	,	PUNCT
njb-27	166	13	chadwick	chadwick	PROPN
njb-27	166	14	k	k	PROPN
njb-27	166	15	,	,	PUNCT
njb-27	166	16	margolick	margolick	PROPN
njb-27	166	17	jb	jb	PROPN
njb-27	166	18	,	,	PUNCT
njb-27	166	19	kovacs	kovacs	PROPN
njb-27	166	20	c	c	PROPN
njb-27	166	21	,	,	PUNCT
njb-27	166	22	gange	gange	PROPN
njb-27	166	23	sj	sj	PROPN
njb-27	166	24	,	,	PUNCT
njb-27	166	25	siliciano	siliciano	PROPN
njb-27	166	26	rf	rf	PROPN
njb-27	166	27	:	:	PUNCT
njb-27	166	28	long	long	ADJ
njb-27	166	29	-	-	PUNCT
njb-27	166	30	term	term	NOUN
njb-27	166	31	follow	follow	VERB
njb-27	166	32	-	-	PUNCT
njb-27	166	33	up	up	ADP
njb-27	166	34	studies	study	NOUN
njb-27	166	35	confirm	confirm	VERB
njb-27	166	36	the	the	DET
njb-27	166	37	stability	stability	NOUN
njb-27	166	38	of	of	ADP
njb-27	166	39	the	the	DET
njb-27	166	40	latent	latent	ADJ
njb-27	166	41	reservoir	reservoir	NOUN
njb-27	166	42	for	for	ADP
njb-27	166	43	hiv-1	hiv-1	CCONJ
njb-27	166	44	in	in	ADP
njb-27	166	45	resting	rest	VERB
njb-27	166	46	cd4	cd4	PROPN
njb-27	166	47	+	+	SYM
njb-27	166	48	t	t	NOUN
njb-27	166	49	cells	cell	NOUN
njb-27	166	50	.	.	PUNCT
njb-27	167	1	nature	nature	PROPN
njb-27	167	2	medicine	medicine	PROPN
njb-27	167	3	2003	2003	NUM
njb-27	167	4	,	,	PUNCT
njb-27	167	5	9(6	9(6	NUM
njb-27	167	6	):	):	PUNCT
njb-27	167	7	727	727	NUM
njb-27	167	8	-	-	SYM
njb-27	167	9	728	728	NUM
njb-27	167	10	.	.	PROPN
njb-27	167	11	5	5	NUM
njb-27	167	12	.	.	X
njb-27	168	1	levy	levy	PROPN
njb-27	168	2	ja	ja	PROPN
njb-27	168	3	,	,	PUNCT
njb-27	168	4	hoffman	hoffman	NOUN
njb-27	168	5	ad	ad	NOUN
njb-27	168	6	,	,	PUNCT
njb-27	168	7	kramer	kramer	PROPN
njb-27	168	8	sm	sm	PROPN
njb-27	168	9	,	,	PUNCT
njb-27	168	10	landis	landis	PROPN
njb-27	168	11	ja	ja	PROPN
njb-27	168	12	,	,	PUNCT
njb-27	168	13	shimabukuro	shimabukuro	PROPN
njb-27	168	14	jm	jm	PROPN
njb-27	168	15	,	,	PUNCT
njb-27	168	16	oshiro	oshiro	PROPN
njb-27	168	17	ls	l	VERB
njb-27	168	18	:	:	PUNCT
njb-27	168	19	isolation	isolation	NOUN
njb-27	168	20	of	of	ADP
njb-27	168	21	lymphocytopathic	lymphocytopathic	ADJ
njb-27	168	22	retroviruses	retrovirus	NOUN
njb-27	168	23	from	from	ADP
njb-27	168	24	san	san	PROPN
njb-27	168	25	francisco	francisco	PROPN
njb-27	168	26	patients	patient	NOUN
njb-27	168	27	with	with	ADP
njb-27	168	28	aids	aid	NOUN
njb-27	168	29	.	.	PUNCT
njb-27	169	1	science	science	NOUN
njb-27	169	2	1984	1984	NUM
njb-27	169	3	,	,	PUNCT
njb-27	169	4	225(4664	225(4664	NUM
njb-27	169	5	):	):	PUNCT
njb-27	169	6	840	840	NUM
njb-27	169	7	-	-	SYM
njb-27	169	8	842	842	NUM
njb-27	169	9	.	.	NOUN
njb-27	169	10	6	6	NUM
njb-27	169	11	.	.	PUNCT
njb-27	170	1	ho	ho	PROPN
njb-27	170	2	dd	dd	PROPN
njb-27	170	3	,	,	PUNCT
njb-27	170	4	neumann	neumann	PROPN
njb-27	170	5	au	au	PROPN
njb-27	170	6	,	,	PUNCT
njb-27	170	7	perelson	perelson	PROPN
njb-27	170	8	as	as	ADP
njb-27	170	9	,	,	PUNCT
njb-27	170	10	chen	chen	PROPN
njb-27	170	11	w	w	PROPN
njb-27	170	12	,	,	PUNCT
njb-27	170	13	leonard	leonard	PROPN
njb-27	170	14	jm	jm	PROPN
njb-27	170	15	,	,	PUNCT
njb-27	170	16	markowitz	markowitz	PROPN
njb-27	170	17	m	m	PROPN
njb-27	170	18	:	:	PUNCT
njb-27	170	19	rapid	rapid	ADJ
njb-27	170	20	turnover	turnover	NOUN
njb-27	170	21	of	of	ADP
njb-27	170	22	plasma	plasma	NOUN
njb-27	170	23	virions	virion	NOUN
njb-27	170	24	and	and	CCONJ
njb-27	170	25	cd4	cd4	ADP
njb-27	170	26	lymphocytes	lymphocyte	NOUN
njb-27	170	27	in	in	ADP
njb-27	170	28	hiv-1	hiv-1	PUNCT
njb-27	170	29	infection	infection	NOUN
njb-27	170	30	.	.	PUNCT
njb-27	171	1	nature	nature	NOUN
njb-27	171	2	1995	1995	NUM
njb-27	171	3	,	,	PUNCT
njb-27	171	4	373(6510	373(6510	NUM
njb-27	171	5	):	):	PUNCT
njb-27	171	6	123	123	NUM
njb-27	171	7	-	-	SYM
njb-27	171	8	126	126	NUM
njb-27	171	9	.	.	PUNCT
njb-27	171	10	7	7	NUM
njb-27	171	11	.	.	PROPN
njb-27	171	12	roberts	roberts	PROPN
njb-27	171	13	jd	jd	PROPN
njb-27	171	14	,	,	PUNCT
njb-27	171	15	bebenek	bebenek	PROPN
njb-27	171	16	k	k	PROPN
njb-27	171	17	,	,	PUNCT
njb-27	171	18	kunkel	kunkel	PROPN
njb-27	171	19	ta	ta	PROPN
njb-27	171	20	:	:	PUNCT
njb-27	171	21	the	the	DET
njb-27	171	22	accuracy	accuracy	NOUN
njb-27	171	23	of	of	ADP
njb-27	171	24	reverse	reverse	ADJ
njb-27	171	25	transcriptase	transcriptase	NOUN
njb-27	171	26	from	from	ADP
njb-27	171	27	hiv-1	hiv-1	X
njb-27	171	28	.	.	PUNCT
njb-27	172	1	science	science	NOUN
njb-27	172	2	1988	1988	NUM
njb-27	172	3	,	,	PUNCT
njb-27	172	4	242(4882	242(4882	NUM
njb-27	172	5	):	):	PUNCT
njb-27	172	6	1171	1171	NUM
njb-27	172	7	-	-	SYM
njb-27	172	8	1173	1173	NUM
njb-27	172	9	.	.	PUNCT
njb-27	172	10	8	8	NUM
njb-27	172	11	.	.	PUNCT
njb-27	173	1	preston	preston	PROPN
njb-27	173	2	bd	bd	PROPN
njb-27	173	3	,	,	PUNCT
njb-27	173	4	poiesz	poiesz	PROPN
njb-27	173	5	bj	bj	PROPN
njb-27	173	6	,	,	PUNCT
njb-27	173	7	loeb	loeb	PROPN
njb-27	173	8	la	la	PROPN
njb-27	173	9	:	:	PUNCT
njb-27	173	10	fidelity	fidelity	PROPN
njb-27	173	11	of	of	ADP
njb-27	173	12	hiv-1	hiv-1	PUNCT
njb-27	173	13	reverse	reverse	ADJ
njb-27	173	14	transcriptase	transcriptase	NOUN
njb-27	173	15	.	.	PUNCT
njb-27	174	1	science	science	NOUN
njb-27	174	2	1988	1988	NUM
njb-27	174	3	,	,	PUNCT
njb-27	174	4	242(4882	242(4882	NUM
njb-27	174	5	):	):	PUNCT
njb-27	174	6	11681171	11681171	NUM
njb-27	174	7	.	.	PUNCT
njb-27	175	1	9	9	X
njb-27	175	2	.	.	X
njb-27	175	3	chew	chew	PROPN
njb-27	175	4	cb	cb	PROPN
njb-27	175	5	,	,	PUNCT
njb-27	175	6	potter	potter	NOUN
njb-27	175	7	sj	sj	PROPN
njb-27	175	8	,	,	PUNCT
njb-27	175	9	wang	wang	PROPN
njb-27	175	10	b	b	PROPN
njb-27	175	11	,	,	PUNCT
njb-27	175	12	wang	wang	PROPN
njb-27	175	13	ym	ym	PROPN
njb-27	175	14	,	,	PUNCT
njb-27	175	15	shaw	shaw	PROPN
njb-27	175	16	co	co	PROPN
njb-27	175	17	,	,	PUNCT
njb-27	175	18	dwyer	dwyer	PROPN
njb-27	175	19	de	de	PROPN
njb-27	175	20	,	,	PUNCT
njb-27	175	21	saksena	saksena	PROPN
njb-27	175	22	nk	nk	PROPN
njb-27	175	23	:	:	PUNCT
njb-27	175	24	assessment	assessment	NOUN
njb-27	175	25	of	of	ADP
njb-27	175	26	drug	drug	NOUN
njb-27	175	27	resistance	resistance	NOUN
njb-27	175	28	mutations	mutation	NOUN
njb-27	175	29	in	in	ADP
njb-27	175	30	plasma	plasma	NOUN
njb-27	175	31	and	and	CCONJ
njb-27	175	32	peripheral	peripheral	ADJ
njb-27	175	33	blood	blood	NOUN
njb-27	175	34	mononuclear	mononuclear	ADJ
njb-27	175	35	cells	cell	NOUN
njb-27	175	36	at	at	ADP
njb-27	175	37	different	different	ADJ
njb-27	175	38	plasma	plasma	NOUN
njb-27	175	39	viral	viral	ADJ
njb-27	175	40	loads	load	NOUN
njb-27	175	41	in	in	ADP
njb-27	175	42	patients	patient	NOUN
njb-27	175	43	receiving	receive	VERB
njb-27	175	44	haart	haart	PROPN
njb-27	175	45	.	.	PUNCT
njb-27	176	1	j.	j.	PROPN
njb-27	176	2	of	of	ADP
njb-27	176	3	clin	clin	PROPN
njb-27	176	4	virol	virol	PROPN
njb-27	176	5	2005	2005	NUM
njb-27	176	6	,	,	PUNCT
njb-27	176	7	33(3	33(3	NUM
njb-27	176	8	):	):	PUNCT
njb-27	176	9	206	206	NUM
njb-27	176	10	-	-	SYM
njb-27	176	11	216	216	NUM
njb-27	176	12	.	.	PUNCT
njb-27	177	1	10	10	NUM
njb-27	177	2	.	.	PUNCT
njb-27	178	1	hirsch	hirsch	PROPN
njb-27	178	2	ms	ms	PROPN
njb-27	178	3	,	,	PUNCT
njb-27	178	4	conway	conway	PROPN
njb-27	178	5	b	b	PROPN
njb-27	178	6	,	,	PUNCT
njb-27	178	7	d'aquila	d'aquila	PROPN
njb-27	178	8	rt	rt	PROPN
njb-27	178	9	,	,	PUNCT
njb-27	178	10	johnson	johnson	PROPN
njb-27	178	11	va	va	PROPN
njb-27	178	12	,	,	PUNCT
njb-27	178	13	brun	brun	ADJ
njb-27	178	14	-	-	PUNCT
njb-27	178	15	vezinet	vezinet	NOUN
njb-27	178	16	f	f	PROPN
njb-27	178	17	,	,	PUNCT
njb-27	178	18	clotet	clotet	PROPN
njb-27	178	19	b	b	PROPN
njb-27	178	20	,	,	PUNCT
njb-27	178	21	demeter	demeter	PROPN
njb-27	178	22	lm	lm	PROPN
njb-27	178	23	,	,	PUNCT
njb-27	178	24	hammer	hammer	PROPN
njb-27	178	25	sm	sm	PROPN
njb-27	178	26	,	,	PUNCT
njb-27	178	27	jacobsen	jacobsen	PROPN
njb-27	178	28	dm	dm	PROPN
njb-27	178	29	,	,	PUNCT
njb-27	178	30	kuritzkes	kuritzkes	PROPN
njb-27	178	31	dr	dr	PROPN
njb-27	178	32	,	,	PUNCT
njb-27	178	33	loveday	loveday	PROPN
njb-27	178	34	c	c	PROPN
njb-27	178	35	,	,	PUNCT
njb-27	178	36	mellors	mellors	PROPN
njb-27	178	37	jw	jw	PROPN
njb-27	178	38	,	,	PUNCT
njb-27	178	39	vella	vella	PROPN
njb-27	178	40	s	s	PROPN
njb-27	178	41	,	,	PUNCT
njb-27	178	42	richman	richman	NOUN
njb-27	178	43	dd	dd	NOUN
njb-27	178	44	:	:	PUNCT
njb-27	178	45	antiretroviral	antiretroviral	ADJ
njb-27	178	46	drug	drug	NOUN
njb-27	178	47	resistance	resistance	NOUN
njb-27	178	48	testing	testing	NOUN
njb-27	178	49	in	in	ADP
njb-27	178	50	adults	adult	NOUN
njb-27	178	51	with	with	ADP
njb-27	178	52	hiv	hiv	PROPN
njb-27	178	53	infection	infection	NOUN
njb-27	178	54	:	:	PUNCT
njb-27	178	55	implications	implication	NOUN
njb-27	178	56	for	for	ADP
njb-27	178	57	clinical	clinical	ADJ
njb-27	178	58	management	management	NOUN
njb-27	178	59	.	.	PUNCT
njb-27	179	1	international	international	PROPN
njb-27	179	2	aids	aids	PROPN
njb-27	179	3	society	society	PROPN
njb-27	179	4	--	--	PUNCT
njb-27	179	5	usa	usa	PROPN
njb-27	179	6	panel	panel	PROPN
njb-27	179	7	.	.	PUNCT
njb-27	180	1	jama	jama	NOUN
njb-27	180	2	1998	1998	NUM
njb-27	180	3	,	,	PUNCT
njb-27	180	4	279(24	279(24	NUM
njb-27	180	5	):	):	PUNCT
njb-27	180	6	1984	1984	NUM
njb-27	180	7	-	-	SYM
njb-27	180	8	1991	1991	NUM
njb-27	180	9	.	.	PUNCT
njb-27	181	1	11	11	NUM
njb-27	181	2	.	.	PUNCT
njb-27	181	3	yerly	yerly	PROPN
njb-27	181	4	s	s	PROPN
njb-27	181	5	,	,	PUNCT
njb-27	181	6	rakik	rakik	VERB
njb-27	181	7	a	a	DET
njb-27	181	8	,	,	PUNCT
njb-27	181	9	kinloch	kinloch	NOUN
njb-27	181	10	-	-	PUNCT
njb-27	181	11	de	de	ADJ
njb-27	181	12	-	-	PUNCT
njb-27	181	13	loes	loe	NOUN
njb-27	181	14	s	s	PROPN
njb-27	181	15	,	,	PUNCT
njb-27	181	16	erb	erb	PROPN
njb-27	181	17	p	p	PROPN
njb-27	181	18	,	,	PUNCT
njb-27	181	19	vernazza	vernazza	PROPN
njb-27	181	20	p	p	PROPN
njb-27	181	21	,	,	PUNCT
njb-27	181	22	hirschel	hirschel	PROPN
njb-27	181	23	b	b	PROPN
njb-27	181	24	,	,	PUNCT
njb-27	181	25	perrin	perrin	PROPN
njb-27	181	26	l	l	PROPN
njb-27	181	27	:	:	PUNCT
njb-27	182	1	[	[	X
njb-27	182	2	prevalence	prevalence	NOUN
njb-27	182	3	of	of	ADP
njb-27	182	4	transmission	transmission	NOUN
njb-27	182	5	of	of	ADP
njb-27	182	6	zidovudine	zidovudine	NOUN
njb-27	182	7	-	-	PUNCT
njb-27	182	8	resistant	resistant	ADJ
njb-27	182	9	viruses	virus	NOUN
njb-27	182	10	in	in	ADP
njb-27	182	11	switzerland	switzerland	PROPN
njb-27	182	12	.	.	PUNCT
njb-27	183	1	l'etude	l'etude	PROPN
njb-27	183	2	suisse	suisse	X
njb-27	183	3	de	de	X
njb-27	183	4	cohorte	cohorte	PROPN
njb-27	183	5	vih	vih	PROPN
njb-27	183	6	]	]	PUNCT
njb-27	183	7	.	.	PUNCT
njb-27	184	1	schweiz	schweiz	PROPN
njb-27	184	2	med	med	PROPN
njb-27	184	3	wochenschr	wochenschr	PROPN
njb-27	184	4	1996	1996	NUM
njb-27	184	5	,	,	PUNCT
njb-27	184	6	126(43	126(43	NUM
njb-27	184	7	):	):	PUNCT
njb-27	184	8	1845	1845	NUM
njb-27	184	9	-	-	SYM
njb-27	184	10	1848	1848	NUM
njb-27	184	11	.	.	PUNCT
njb-27	185	1	12	12	NUM
njb-27	185	2	.	.	PUNCT
njb-27	185	3	hecht	hecht	PROPN
njb-27	185	4	fm	fm	PROPN
njb-27	185	5	,	,	PUNCT
njb-27	185	6	grant	grant	PROPN
njb-27	185	7	rm	rm	PROPN
njb-27	185	8	,	,	PUNCT
njb-27	185	9	petropoulos	petropoulos	PROPN
njb-27	185	10	cj	cj	PROPN
njb-27	185	11	,	,	PUNCT
njb-27	185	12	dillon	dillon	PROPN
njb-27	185	13	b	b	PROPN
njb-27	185	14	,	,	PUNCT
njb-27	185	15	chesney	chesney	PROPN
njb-27	185	16	ma	ma	PROPN
njb-27	185	17	,	,	PUNCT
njb-27	185	18	tian	tian	PROPN
njb-27	185	19	h	h	PROPN
njb-27	185	20	,	,	PUNCT
njb-27	185	21	hellmann	hellmann	PROPN
njb-27	185	22	ns	ns	PROPN
njb-27	185	23	,	,	PUNCT
njb-27	185	24	bandrapalli	bandrapalli	PROPN
njb-27	185	25	ni	ni	PROPN
njb-27	185	26	,	,	PUNCT
njb-27	185	27	digilio	digilio	PROPN
njb-27	185	28	l	l	PROPN
njb-27	185	29	,	,	PUNCT
njb-27	185	30	branson	branson	PROPN
njb-27	185	31	b	b	PROPN
njb-27	185	32	,	,	PUNCT
njb-27	185	33	kahn	kahn	PROPN
njb-27	185	34	jo	jo	PROPN
njb-27	185	35	:	:	PUNCT
njb-27	185	36	sexual	sexual	ADJ
njb-27	185	37	transmission	transmission	NOUN
njb-27	185	38	of	of	ADP
njb-27	185	39	an	an	DET
njb-27	185	40	hiv-1	hiv-1	PUNCT
njb-27	185	41	variant	variant	NOUN
njb-27	185	42	resistant	resistant	ADJ
njb-27	185	43	to	to	ADP
njb-27	185	44	multiple	multiple	ADJ
njb-27	185	45	reverse	reverse	NOUN
njb-27	185	46	-	-	PUNCT
njb-27	185	47	transcriptase	transcriptase	NOUN
njb-27	185	48	and	and	CCONJ
njb-27	185	49	protease	protease	NOUN
njb-27	185	50	inhibitors	inhibitor	NOUN
njb-27	185	51	.	.	PUNCT
njb-27	186	1	n	n	ADV
njb-27	186	2	engl	engl	PROPN
njb-27	186	3	j	j	PROPN
njb-27	186	4	of	of	ADP
njb-27	186	5	med	med	PROPN
njb-27	186	6	1998	1998	NUM
njb-27	186	7	,	,	PUNCT
njb-27	186	8	339(5	339(5	NUM
njb-27	186	9	):	):	PUNCT
njb-27	186	10	307	307	NUM
njb-27	186	11	-	-	SYM
njb-27	186	12	311	311	NUM
njb-27	186	13	.	.	NUM
njb-27	186	14	13	13	NUM
njb-27	186	15	.	.	PUNCT
njb-27	187	1	boucher	boucher	NOUN
njb-27	187	2	ca	can	AUX
njb-27	187	3	,	,	PUNCT
njb-27	187	4	cammack	cammack	PROPN
njb-27	187	5	n	n	PROPN
njb-27	187	6	,	,	PUNCT
njb-27	187	7	schipper	schipper	PROPN
njb-27	187	8	p	p	PROPN
njb-27	187	9	,	,	PUNCT
njb-27	187	10	schuurman	schuurman	PROPN
njb-27	187	11	r	r	PROPN
njb-27	187	12	,	,	PUNCT
njb-27	187	13	rouse	rouse	VERB
njb-27	187	14	p	p	PROPN
njb-27	187	15	,	,	PUNCT
njb-27	187	16	wainberg	wainberg	PROPN
njb-27	187	17	ma	ma	PROPN
njb-27	187	18	,	,	PUNCT
njb-27	187	19	cameron	cameron	PROPN
njb-27	187	20	jm	jm	PROPN
njb-27	187	21	:	:	PUNCT
njb-27	187	22	highlevel	highlevel	NOUN
njb-27	187	23	resistance	resistance	NOUN
njb-27	187	24	to	to	ADP
njb-27	187	25	(	(	PUNCT
njb-27	187	26	-	-	PUNCT
njb-27	187	27	)	)	PUNCT
njb-27	187	28	enantiomeric	enantiomeric	NOUN
njb-27	187	29	2'-deoxy-3'thiacytidine	2'-deoxy-3'thiacytidine	PROPN
njb-27	187	30	in	in	ADP
njb-27	187	31	vitro	vitro	X
njb-27	187	32	is	be	AUX
njb-27	187	33	due	due	ADJ
njb-27	187	34	to	to	ADP
njb-27	187	35	one	one	NUM
njb-27	187	36	amino	amino	ADJ
njb-27	187	37	acid	acid	NOUN
njb-27	187	38	substitution	substitution	NOUN
njb-27	187	39	in	in	ADP
njb-27	187	40	the	the	DET
njb-27	187	41	catalytic	catalytic	ADJ
njb-27	187	42	site	site	NOUN
njb-27	187	43	of	of	ADP
njb-27	187	44	human	human	ADJ
njb-27	187	45	immunodeficiency	immunodeficiency	NOUN
njb-27	187	46	virus	virus	NOUN
njb-27	187	47	type	type	NOUN
njb-27	187	48	1	1	NUM
njb-27	187	49	reverse	reverse	ADJ
njb-27	187	50	transcriptase	transcriptase	NOUN
njb-27	187	51	.	.	PUNCT
njb-27	188	1	antimicrobial	antimicrobial	ADJ
njb-27	188	2	agents	agent	NOUN
njb-27	188	3	and	and	CCONJ
njb-27	188	4	chemotherapy	chemotherapy	NOUN
njb-27	188	5	1993	1993	NUM
njb-27	188	6	,	,	PUNCT
njb-27	188	7	37(10	37(10	NUM
njb-27	188	8	):	):	PUNCT
njb-27	188	9	2231	2231	PROPN
njb-27	188	10	-	-	SYM
njb-27	188	11	2234	2234	NUM
njb-27	188	12	.	.	PUNCT
njb-27	188	13	14	14	NUM
njb-27	188	14	.	.	PUNCT
njb-27	189	1	back	back	ADV
njb-27	189	2	nk	nk	INTJ
njb-27	189	3	,	,	PUNCT
njb-27	189	4	nijhuis	nijhuis	PROPN
njb-27	189	5	m	m	PROPN
njb-27	189	6	,	,	PUNCT
njb-27	189	7	keulen	keulen	PROPN
njb-27	189	8	w	w	PROPN
njb-27	189	9	,	,	PUNCT
njb-27	189	10	boucher	boucher	ADJ
njb-27	189	11	ca	can	AUX
njb-27	189	12	,	,	PUNCT
njb-27	189	13	oude	oude	VERB
njb-27	189	14	essink	essink	PROPN
njb-27	189	15	bo	bo	PROPN
njb-27	189	16	,	,	PUNCT
njb-27	189	17	van	van	PROPN
njb-27	189	18	kuilenburg	kuilenburg	PROPN
njb-27	189	19	ab	ab	PROPN
njb-27	189	20	,	,	PUNCT
njb-27	189	21	van	van	PROPN
njb-27	189	22	gennip	gennip	PROPN
njb-27	189	23	ah	ah	INTJ
njb-27	189	24	,	,	PUNCT
njb-27	189	25	berkhout	berkhout	PROPN
njb-27	189	26	b	b	NOUN
njb-27	189	27	:	:	PUNCT
njb-27	189	28	reduced	reduce	VERB
njb-27	189	29	replication	replication	NOUN
njb-27	189	30	of	of	ADP
njb-27	189	31	3tc	3tc	NOUN
njb-27	189	32	-	-	PUNCT
njb-27	189	33	resistant	resistant	ADJ
njb-27	189	34	hiv-1	hiv-1	PUNCT
njb-27	189	35	variants	variant	NOUN
njb-27	189	36	in	in	ADP
njb-27	189	37	primary	primary	ADJ
njb-27	189	38	cells	cell	NOUN
njb-27	189	39	due	due	ADP
njb-27	189	40	to	to	ADP
njb-27	189	41	a	a	DET
njb-27	189	42	processivity	processivity	NOUN
njb-27	189	43	defect	defect	NOUN
njb-27	189	44	of	of	ADP
njb-27	189	45	the	the	DET
njb-27	189	46	reverse	reverse	ADJ
njb-27	189	47	transcriptase	transcriptase	NOUN
njb-27	189	48	enzyme	enzyme	NOUN
njb-27	189	49	.	.	PUNCT
njb-27	190	1	the	the	DET
njb-27	190	2	embo	embo	ADJ
njb-27	190	3	journal	journal	NOUN
njb-27	190	4	1996	1996	NUM
njb-27	190	5	,	,	PUNCT
njb-27	190	6	15(15	15(15	NUM
njb-27	190	7	):	):	PUNCT
njb-27	190	8	4040	4040	NUM
njb-27	190	9	-	-	SYM
njb-27	190	10	4049	4049	NUM
njb-27	190	11	.	.	PUNCT
njb-27	191	1	15	15	X
njb-27	191	2	.	.	PUNCT
njb-27	191	3	larder	lard	ADJ
njb-27	191	4	ba	ba	PROPN
njb-27	191	5	,	,	PUNCT
njb-27	191	6	kemp	kemp	PROPN
njb-27	191	7	sd	sd	PROPN
njb-27	191	8	,	,	PUNCT
njb-27	191	9	harrigan	harrigan	PROPN
njb-27	191	10	pr	pr	PROPN
njb-27	191	11	:	:	PUNCT
njb-27	191	12	potential	potential	ADJ
njb-27	191	13	mechanism	mechanism	NOUN
njb-27	191	14	for	for	ADP
njb-27	191	15	sustained	sustained	ADJ
njb-27	191	16	antiretroviral	antiretroviral	ADJ
njb-27	191	17	efficacy	efficacy	NOUN
njb-27	191	18	of	of	ADP
njb-27	191	19	azt-3tc	azt-3tc	ADJ
njb-27	191	20	combination	combination	NOUN
njb-27	191	21	therapy	therapy	NOUN
njb-27	191	22	.	.	PUNCT
njb-27	192	1	science	science	NOUN
njb-27	192	2	1995	1995	NUM
njb-27	192	3	,	,	PUNCT
njb-27	192	4	269(5224	269(5224	NUM
njb-27	192	5	):	):	PUNCT
njb-27	192	6	696	696	NUM
njb-27	192	7	-	-	SYM
njb-27	192	8	699	699	NUM
njb-27	192	9	.	.	NUM
njb-27	192	10	16	16	NUM
njb-27	192	11	.	.	PUNCT
njb-27	193	1	keulen	keulen	PROPN
njb-27	193	2	w	w	PROPN
njb-27	193	3	,	,	PUNCT
njb-27	193	4	back	back	ADV
njb-27	193	5	nk	nk	NOUN
njb-27	193	6	,	,	PUNCT
njb-27	193	7	van	van	PROPN
njb-27	193	8	wijk	wijk	PROPN
njb-27	193	9	a	a	DET
njb-27	193	10	,	,	PUNCT
njb-27	193	11	boucher	boucher	NOUN
njb-27	193	12	ca	can	AUX
njb-27	193	13	,	,	PUNCT
njb-27	193	14	berkhout	berkhout	PROPN
njb-27	193	15	b.	b.	PROPN
njb-27	193	16	initial	initial	ADJ
njb-27	193	17	appearance	appearance	NOUN
njb-27	193	18	of	of	ADP
njb-27	193	19	the	the	DET
njb-27	193	20	184ile	184ile	NUM
njb-27	193	21	variant	variant	NOUN
njb-27	193	22	in	in	ADP
njb-27	193	23	lamivudine	lamivudine	NOUN
njb-27	193	24	-	-	PUNCT
njb-27	193	25	treated	treat	VERB
njb-27	193	26	patients	patient	NOUN
njb-27	193	27	is	be	AUX
njb-27	193	28	caused	cause	VERB
njb-27	193	29	by	by	ADP
njb-27	193	30	the	the	DET
njb-27	193	31	mutational	mutational	ADJ
njb-27	193	32	bias	bias	NOUN
njb-27	193	33	of	of	ADP
njb-27	193	34	human	human	ADJ
njb-27	193	35	immunodeficiency	immunodeficiency	NOUN
njb-27	193	36	virus	virus	NOUN
njb-27	193	37	type	type	NOUN
njb-27	193	38	1	1	NUM
njb-27	193	39	reverse	reverse	ADJ
njb-27	193	40	transcriptase	transcriptase	NOUN
njb-27	193	41	.	.	PUNCT
njb-27	194	1	j	j	PROPN
njb-27	194	2	virol	virol	PROPN
njb-27	194	3	1997	1997	NUM
njb-27	194	4	,	,	PUNCT
njb-27	194	5	71(4	71(4	NUM
njb-27	194	6	):	):	PUNCT
njb-27	194	7	3346	3346	NUM
njb-27	194	8	-	-	SYM
njb-27	194	9	3350	3350	NUM
njb-27	194	10	.	.	PUNCT
njb-27	194	11	17	17	NUM
njb-27	194	12	.	.	PUNCT
njb-27	195	1	cheynier	cheyni	ADJ
njb-27	195	2	r	r	PROPN
njb-27	195	3	,	,	PUNCT
njb-27	195	4	gratton	gratton	PROPN
njb-27	195	5	s	s	PROPN
njb-27	195	6	,	,	PUNCT
njb-27	195	7	vartanian	vartanian	PROPN
njb-27	195	8	jp	jp	PROPN
njb-27	195	9	,	,	PUNCT
njb-27	195	10	meyerhans	meyerhans	PROPN
njb-27	195	11	a	a	PROPN
njb-27	195	12	,	,	PUNCT
njb-27	195	13	wain	wain	PROPN
njb-27	195	14	-	-	PUNCT
njb-27	195	15	hobson	hobson	PROPN
njb-27	195	16	s	s	PROPN
njb-27	195	17	:	:	PUNCT
njb-27	195	18	g	g	PROPN
njb-27	195	19	--	--	PUNCT
njb-27	195	20	>	>	X
njb-27	195	21	a	a	DET
njb-27	195	22	hypermutation	hypermutation	NOUN
njb-27	195	23	does	do	AUX
njb-27	195	24	not	not	PART
njb-27	195	25	result	result	VERB
njb-27	195	26	from	from	ADP
njb-27	195	27	polymerase	polymerase	NOUN
njb-27	195	28	chain	chain	NOUN
njb-27	195	29	reaction	reaction	NOUN
njb-27	195	30	.	.	PUNCT
njb-27	196	1	aids	aid	VERB
njb-27	196	2	research	research	NOUN
njb-27	196	3	and	and	CCONJ
njb-27	196	4	human	human	ADJ
njb-27	196	5	retroviruses	retrovirus	NOUN
njb-27	196	6	1997	1997	NUM
njb-27	196	7	,	,	PUNCT
njb-27	196	8	13(12	13(12	NUM
njb-27	196	9	):	):	PUNCT
njb-27	196	10	985986	985986	NUM
njb-27	196	11	.	.	PUNCT
njb-27	196	12	18	18	NUM
njb-27	196	13	.	.	PUNCT
njb-27	197	1	gunther	gunther	PROPN
njb-27	197	2	s	s	PROPN
njb-27	197	3	,	,	PUNCT
njb-27	197	4	sommer	sommer	PROPN
njb-27	197	5	g	g	PROPN
njb-27	197	6	,	,	PUNCT
njb-27	197	7	plikat	plikat	PROPN
njb-27	197	8	u	u	PROPN
njb-27	197	9	,	,	PUNCT
njb-27	197	10	iwanska	iwanska	PROPN
njb-27	197	11	a	a	PROPN
njb-27	197	12	,	,	PUNCT
njb-27	197	13	wainhobson	wainhobson	PROPN
njb-27	197	14	s	s	PROPN
njb-27	197	15	,	,	PUNCT
njb-27	197	16	will	will	AUX
njb-27	197	17	h	h	PROPN
njb-27	197	18	,	,	PUNCT
njb-27	197	19	meyerhans	meyerhans	PROPN
njb-27	197	20	a	a	DET
njb-27	197	21	:	:	PUNCT
njb-27	197	22	naturally	naturally	ADV
njb-27	197	23	occurring	occur	VERB
njb-27	197	24	hepatitis	hepatitis	PROPN
njb-27	197	25	b	b	PROPN
njb-27	197	26	virus	virus	NOUN
njb-27	197	27	genomes	genome	VERB
njb-27	197	28	bearing	bear	VERB
njb-27	197	29	the	the	DET
njb-27	197	30	hallmarks	hallmark	NOUN
njb-27	197	31	of	of	ADP
njb-27	197	32	retroviral	retroviral	ADJ
njb-27	197	33	g-->a	g-->a	PROPN
njb-27	197	34	hypermutation	hypermutation	NOUN
njb-27	197	35	.	.	PUNCT
njb-27	198	1	virology	virology	NOUN
njb-27	198	2	1997	1997	NUM
njb-27	198	3	,	,	PUNCT
njb-27	198	4	235(1	235(1	NUM
njb-27	198	5	):	):	PUNCT
njb-27	198	6	104	104	NUM
njb-27	198	7	-	-	SYM
njb-27	198	8	108	108	NUM
njb-27	198	9	.	.	NUM
njb-27	198	10	19	19	NUM
njb-27	198	11	.	.	PUNCT
njb-27	199	1	khan	khan	PROPN
njb-27	199	2	s	s	PROPN
njb-27	199	3	,	,	PUNCT
njb-27	199	4	rai	rai	PROPN
njb-27	199	5	ma	ma	PROPN
njb-27	199	6	,	,	PUNCT
njb-27	199	7	khanani	khanani	PROPN
njb-27	199	8	mr	mr	PROPN
njb-27	199	9	,	,	PUNCT
njb-27	199	10	khan	khan	PROPN
njb-27	199	11	mn	mn	PROPN
njb-27	199	12	,	,	PUNCT
njb-27	199	13	ali	ali	PROPN
njb-27	199	14	sh	sh	PROPN
njb-27	199	15	:	:	PUNCT
njb-27	199	16	hiv-1	hiv-1	PUNCT
njb-27	199	17	subtype	subtype	VERB
njb-27	199	18	a	a	DET
njb-27	199	19	infection	infection	NOUN
njb-27	199	20	in	in	ADP
njb-27	199	21	a	a	DET
njb-27	199	22	community	community	NOUN
njb-27	199	23	of	of	ADP
njb-27	199	24	intravenous	intravenous	ADJ
njb-27	199	25	drug	drug	NOUN
njb-27	199	26	users	user	NOUN
njb-27	199	27	in	in	ADP
njb-27	199	28	pakistan	pakistan	PROPN
njb-27	199	29	.	.	PUNCT
njb-27	200	1	bmc	bmc	PROPN
njb-27	200	2	infectious	infectious	ADJ
njb-27	200	3	diseases	disease	NOUN
njb-27	200	4	2006	2006	NUM
njb-27	200	5	,	,	PUNCT
njb-27	200	6	6	6	NUM
njb-27	200	7	:	:	SYM
njb-27	200	8	164	164	NUM
njb-27	200	9	.	.	X
njb-27	200	10	20	20	NUM
njb-27	200	11	.	.	PUNCT
njb-27	201	1	yerly	yerly	PROPN
njb-27	201	2	s	s	PROPN
njb-27	201	3	,	,	PUNCT
njb-27	201	4	kaiser	kaiser	PROPN
njb-27	201	5	l	l	PROPN
njb-27	201	6	,	,	PUNCT
njb-27	201	7	race	race	NOUN
njb-27	201	8	e	e	NOUN
njb-27	201	9	,	,	PUNCT
njb-27	201	10	bru	bru	PROPN
njb-27	201	11	jp	jp	PROPN
njb-27	201	12	,	,	PUNCT
njb-27	201	13	clavel	clavel	PROPN
njb-27	201	14	f	f	PROPN
njb-27	201	15	,	,	PUNCT
njb-27	201	16	perrin	perrin	PROPN
njb-27	201	17	l	l	PROPN
njb-27	201	18	:	:	PUNCT
njb-27	201	19	transmission	transmission	NOUN
njb-27	201	20	of	of	ADP
njb-27	201	21	antiretroviral	antiretroviral	ADJ
njb-27	201	22	-	-	PUNCT
njb-27	201	23	drug	drug	NOUN
njb-27	201	24	-	-	PUNCT
njb-27	201	25	resistant	resistant	ADJ
njb-27	201	26	hiv-1	hiv-1	PUNCT
njb-27	201	27	variants	variant	NOUN
njb-27	201	28	.	.	PUNCT
njb-27	202	1	lancet	lancet	PROPN
njb-27	202	2	1999	1999	PROPN
njb-27	202	3	,	,	PUNCT
njb-27	202	4	354(9180	354(9180	NUM
njb-27	202	5	):	):	PUNCT
njb-27	202	6	729	729	NUM
njb-27	202	7	-	-	SYM
njb-27	202	8	733	733	NUM
njb-27	202	9	.	.	PROPN
njb-27	202	10	21	21	NUM
njb-27	202	11	.	.	PUNCT
njb-27	203	1	jangam	jangam	PROPN
njb-27	203	2	sr	sr	PROPN
njb-27	203	3	,	,	PUNCT
njb-27	203	4	yamada	yamada	PROPN
njb-27	203	5	dh	dh	PROPN
njb-27	203	6	,	,	PUNCT
njb-27	203	7	mcfall	mcfall	PROPN
njb-27	203	8	sm	sm	PROPN
njb-27	203	9	,	,	PUNCT
njb-27	203	10	kelso	kelso	PROPN
njb-27	203	11	dm	dm	PROPN
njb-27	203	12	:	:	PUNCT
njb-27	203	13	rapid	rapid	ADJ
njb-27	203	14	,	,	PUNCT
njb-27	203	15	point	point	NOUN
njb-27	203	16	-	-	PUNCT
njb-27	203	17	of	of	ADP
njb-27	203	18	-	-	PUNCT
njb-27	203	19	care	care	NOUN
njb-27	203	20	extraction	extraction	NOUN
njb-27	203	21	of	of	ADP
njb-27	203	22	human	human	ADJ
njb-27	203	23	immunodeficiency	immunodeficiency	NOUN
njb-27	203	24	virus	virus	NOUN
njb-27	203	25	type	type	NOUN
njb-27	203	26	1	1	NUM
njb-27	203	27	proviral	proviral	ADJ
njb-27	203	28	dna	dna	NOUN
njb-27	203	29	from	from	ADP
njb-27	203	30	whole	whole	ADJ
njb-27	203	31	blood	blood	NOUN
njb-27	203	32	for	for	ADP
njb-27	203	33	detection	detection	NOUN
njb-27	203	34	by	by	ADP
njb-27	203	35	real	real	ADJ
njb-27	203	36	-	-	PUNCT
njb-27	203	37	time	time	NOUN
njb-27	203	38	pcr	pcr	NOUN
njb-27	203	39	.	.	PUNCT
njb-27	204	1	j	j	PROPN
njb-27	204	2	clin	clin	PROPN
njb-27	204	3	microbiol	microbiol	PROPN
njb-27	204	4	2009	2009	NUM
njb-27	204	5	,	,	PUNCT
njb-27	204	6	47(8	47(8	NUM
njb-27	204	7	):	):	PUNCT
njb-27	204	8	2363	2363	NUM
njb-27	204	9	-	-	SYM
njb-27	204	10	2368	2368	NUM
njb-27	204	11	.	.	PUNCT
njb-27	205	1	22	22	NUM
njb-27	205	2	.	.	PUNCT
njb-27	205	3	de	de	X
njb-27	205	4	rossi	rossi	X
njb-27	205	5	a	a	DET
njb-27	205	6	,	,	PUNCT
njb-27	205	7	zanchetta	zanchetta	PROPN
njb-27	205	8	m	m	PROPN
njb-27	205	9	,	,	PUNCT
njb-27	205	10	vitone	vitone	PROPN
njb-27	205	11	f	f	PROPN
njb-27	205	12	,	,	PUNCT
njb-27	205	13	antonelli	antonelli	PROPN
njb-27	205	14	g	g	PROPN
njb-27	205	15	,	,	PUNCT
njb-27	205	16	bagnarelli	bagnarelli	PROPN
njb-27	205	17	p	p	PROPN
njb-27	205	18	,	,	PUNCT
njb-27	205	19	buonaguro	buonaguro	PROPN
njb-27	205	20	l	l	PROPN
njb-27	205	21	,	,	PUNCT
njb-27	205	22	capobianchi	capobianchi	PROPN
njb-27	205	23	mr	mr	PROPN
njb-27	205	24	,	,	PUNCT
njb-27	205	25	clementi	clementi	PROPN
njb-27	205	26	m	m	PROPN
njb-27	205	27	,	,	PUNCT
njb-27	205	28	abbate	abbate	ADJ
njb-27	205	29	i	i	PROPN
njb-27	205	30	,	,	PUNCT
njb-27	205	31	canducci	canducci	PROPN
njb-27	205	32	f	f	PROPN
njb-27	205	33	,	,	PUNCT
njb-27	205	34	monachetti	monachetti	PROPN
njb-27	205	35	a	a	PROPN
njb-27	205	36	,	,	PUNCT
njb-27	205	37	riva	riva	PROPN
njb-27	205	38	e	e	NOUN
njb-27	205	39	,	,	PUNCT
njb-27	205	40	rozera	rozera	PROPN
njb-27	205	41	g	g	PROPN
njb-27	205	42	,	,	PUNCT
njb-27	205	43	scagnolari	scagnolari	PROPN
njb-27	205	44	c	c	PROPN
njb-27	205	45	,	,	PUNCT
njb-27	205	46	tagliamonte	tagliamonte	PROPN
njb-27	205	47	m	m	PROPN
njb-27	205	48	,	,	PUNCT
njb-27	205	49	re	re	ADP
njb-27	205	50	mc	mc	PROPN
njb-27	205	51	:	:	PUNCT
njb-27	205	52	quantitative	quantitative	ADJ
njb-27	205	53	hiv-1	hiv-1	ADV
njb-27	205	54	proviral	proviral	ADJ
njb-27	205	55	dna	dna	PROPN
njb-27	205	56	detection	detection	NOUN
njb-27	205	57	:	:	PUNCT
njb-27	205	58	a	a	DET
njb-27	205	59	multicentre	multicentre	NOUN
njb-27	205	60	analysis	analysis	NOUN
njb-27	205	61	.	.	PUNCT
njb-27	206	1	the	the	DET
njb-27	206	2	new	new	ADJ
njb-27	206	3	microbiologica	microbiologica	PROPN
njb-27	206	4	2010	2010	NUM
njb-27	206	5	,	,	PUNCT
njb-27	206	6	33(4	33(4	NUM
njb-27	206	7	):	):	PUNCT
njb-27	206	8	293	293	NUM
njb-27	206	9	-	-	SYM
njb-27	206	10	302	302	NUM
njb-27	206	11	.	.	NUM
njb-27	206	12	23	23	NUM
njb-27	206	13	.	.	PUNCT
njb-27	207	1	kandathil	kandathil	PROPN
njb-27	207	2	aj	aj	PROPN
njb-27	207	3	,	,	PUNCT
njb-27	207	4	kannangai	kannangai	PROPN
njb-27	207	5	r	r	PROPN
njb-27	207	6	,	,	PUNCT
njb-27	207	7	verghese	verghese	PROPN
njb-27	207	8	vp	vp	PROPN
njb-27	207	9	,	,	PUNCT
njb-27	207	10	pulimood	pulimood	PROPN
njb-27	207	11	sa	sa	PROPN
njb-27	207	12	,	,	PUNCT
njb-27	207	13	rupali	rupali	PROPN
njb-27	207	14	p	p	PROPN
njb-27	207	15	,	,	PUNCT
njb-27	207	16	sridharan	sridharan	PROPN
njb-27	207	17	g	g	PROPN
njb-27	207	18	,	,	PUNCT
njb-27	207	19	grant	grant	PROPN
njb-27	207	20	p	p	PROPN
njb-27	207	21	,	,	PUNCT
njb-27	207	22	pillay	pillay	PROPN
njb-27	207	23	d	d	PROPN
njb-27	207	24	,	,	PUNCT
njb-27	207	25	abraham	abraham	PROPN
njb-27	207	26	oc	oc	PROPN
njb-27	207	27	:	:	PUNCT
njb-27	207	28	drug	drug	NOUN
njb-27	207	29	resistant	resistant	ADJ
njb-27	207	30	mutations	mutation	NOUN
njb-27	207	31	detected	detect	VERB
njb-27	207	32	by	by	ADP
njb-27	207	33	genotypic	genotypic	ADJ
njb-27	207	34	drug	drug	NOUN
njb-27	207	35	resistance	resistance	NOUN
njb-27	207	36	testing	testing	NOUN
njb-27	207	37	in	in	ADP
njb-27	207	38	patients	patient	NOUN
njb-27	207	39	failing	fail	VERB
njb-27	207	40	therapy	therapy	NOUN
njb-27	207	41	in	in	ADP
njb-27	207	42	clade	clade	NOUN
njb-27	207	43	c	c	PROPN
njb-27	207	44	hiv-1	hiv-1	PUNCT
njb-27	207	45	infected	infect	VERB
njb-27	207	46	individuals	individual	NOUN
njb-27	207	47	from	from	ADP
njb-27	207	48	india	india	PROPN
njb-27	207	49	.	.	PUNCT
njb-27	208	1	ind	ind	PROPN
njb-27	208	2	j	j	PROPN
njb-27	208	3	med	med	PROPN
njb-27	208	4	microbio	microbio	PROPN
njb-27	208	5	2009	2009	NUM
njb-27	208	6	,	,	PUNCT
njb-27	208	7	27(3	27(3	NUM
njb-27	208	8	):	):	PUNCT
njb-27	208	9	231	231	NUM
njb-27	208	10	-	-	SYM
njb-27	208	11	236	236	NUM
njb-27	208	12	.	.	PROPN
njb-27	208	13	24	24	NUM
njb-27	208	14	.	.	PUNCT
njb-27	209	1	miller	miller	PROPN
njb-27	209	2	v	v	PROPN
njb-27	209	3	,	,	PUNCT
njb-27	209	4	phillips	phillip	VERB
njb-27	209	5	a	a	PRON
njb-27	209	6	,	,	PUNCT
njb-27	209	7	rottmann	rottmann	PROPN
njb-27	209	8	c	c	PROPN
njb-27	209	9	,	,	PUNCT
njb-27	209	10	staszewski	staszewski	PROPN
njb-27	209	11	s	s	PROPN
njb-27	209	12	,	,	PUNCT
njb-27	209	13	pauwels	pauwels	PROPN
njb-27	209	14	r	r	PROPN
njb-27	209	15	,	,	PUNCT
njb-27	209	16	hertogs	hertog	VERB
njb-27	209	17	k	k	PROPN
njb-27	209	18	,	,	PUNCT
njb-27	209	19	de	de	PROPN
njb-27	209	20	bethune	bethune	PROPN
njb-27	209	21	mp	mp	PROPN
njb-27	209	22	,	,	PUNCT
njb-27	209	23	kemp	kemp	PROPN
njb-27	209	24	sd	sd	PROPN
njb-27	209	25	,	,	PUNCT
njb-27	209	26	bloor	bloor	PROPN
njb-27	209	27	s	s	PROPN
njb-27	209	28	,	,	PUNCT
njb-27	209	29	harrigan	harrigan	PROPN
njb-27	209	30	pr	pr	PROPN
njb-27	209	31	,	,	PUNCT
njb-27	209	32	larder	lard	ADJ
njb-27	209	33	ba	ba	PROPN
njb-27	209	34	:	:	PUNCT
njb-27	209	35	dual	dual	ADJ
njb-27	209	36	resistance	resistance	NOUN
njb-27	209	37	to	to	ADP
njb-27	209	38	zidovudine	zidovudine	PROPN
njb-27	209	39	and	and	CCONJ
njb-27	209	40	lamivudine	lamivudine	NOUN
njb-27	209	41	in	in	ADP
njb-27	209	42	patients	patient	NOUN
njb-27	209	43	treated	treat	VERB
njb-27	209	44	with	with	ADP
njb-27	209	45	zidovudine	zidovudine	NOUN
njb-27	209	46	-	-	PUNCT
njb-27	209	47	lamivudine	lamivudine	NOUN
njb-27	209	48	combination	combination	NOUN
njb-27	209	49	therapy	therapy	NOUN
njb-27	209	50	:	:	PUNCT
njb-27	209	51	association	association	NOUN
njb-27	209	52	with	with	ADP
njb-27	209	53	therapy	therapy	NOUN
njb-27	209	54	failure	failure	NOUN
njb-27	209	55	.	.	PUNCT
njb-27	210	1	the	the	DET
njb-27	210	2	journal	journal	NOUN
njb-27	210	3	of	of	ADP
njb-27	210	4	infectious	infectious	ADJ
njb-27	210	5	diseases	disease	NOUN
njb-27	210	6	1998	1998	NUM
njb-27	210	7	,	,	PUNCT
njb-27	210	8	177(6	177(6	NUM
njb-27	210	9	):	):	PUNCT
njb-27	210	10	1521	1521	NUM
njb-27	210	11	-	-	SYM
njb-27	210	12	1532	1532	NUM
njb-27	210	13	.	.	PUNCT
njb-27	211	1	nepal	nepal	ADJ
njb-27	211	2	journal	journal	PROPN
njb-27	211	3	of	of	ADP
njb-27	211	4	biotechnology	biotechnology	NOUN
njb-27	211	5	.	.	PUNCT
njb-27	212	1	d	d	X
njb-27	212	2	e	e	PROPN
njb-27	212	3	c	c	PROPN
njb-27	212	4	.	.	PUNCT
njb-27	213	1	2	2	NUM
njb-27	213	2	0	0	NUM
njb-27	213	3	1	1	NUM
njb-27	213	4	6	6	NUM
njb-27	213	5	vol	vol	NOUN
njb-27	213	6	.	.	PROPN
njb-27	214	1	4	4	NUM
njb-27	214	2	,	,	PUNCT
njb-27	214	3	no	no	NOUN
njb-27	214	4	.	.	NOUN
njb-27	214	5	1	1	NUM
njb-27	214	6	:	:	SYM
njb-27	214	7	18	18	NUM
njb-27	214	8	-	-	SYM
njb-27	214	9	25	25	NUM
njb-27	214	10	shrestha	shrestha	NOUN
njb-27	214	11	et	et	X
njb-27	214	12	al	al	PROPN
njb-27	214	13	.	.	PUNCT
njb-27	215	1	©	©	PROPN
njb-27	215	2	njb	njb	PROPN
njb-27	215	3	,	,	PUNCT
njb-27	215	4	biotechnology	biotechnology	NOUN
njb-27	215	5	society	society	NOUN
njb-27	215	6	of	of	ADP
njb-27	215	7	nepal	nepal	ADJ
njb-27	215	8	25	25	NUM
njb-27	215	9	nepjol.info/index.php/njb	nepjol.info/index.php/njb	PROPN
njb-27	215	10	25	25	NUM
njb-27	215	11	.	.	PUNCT
njb-27	216	1	wensing	wense	VERB
njb-27	216	2	am	am	PROPN
njb-27	216	3	,	,	PUNCT
njb-27	216	4	calvez	calvez	PROPN
njb-27	216	5	v	v	PROPN
njb-27	216	6	,	,	PUNCT
njb-27	216	7	günthard	günthard	PROPN
njb-27	216	8	hf	hf	PROPN
njb-27	216	9	,	,	PUNCT
njb-27	216	10	johnson	johnson	PROPN
njb-27	216	11	va	va	PROPN
njb-27	216	12	,	,	PUNCT
njb-27	216	13	paredes	parede	VERB
njb-27	216	14	r	r	PROPN
njb-27	216	15	,	,	PUNCT
njb-27	216	16	pillay	pillay	NOUN
njb-27	216	17	d	d	PROPN
njb-27	216	18	,	,	PUNCT
njb-27	216	19	shafer	shafer	NOUN
njb-27	216	20	rw	rw	NOUN
njb-27	216	21	,	,	PUNCT
njb-27	216	22	richman	richman	NOUN
njb-27	216	23	dd	dd	NOUN
njb-27	216	24	:	:	PUNCT
njb-27	216	25	2014	2014	NUM
njb-27	216	26	update	update	NOUN
njb-27	216	27	of	of	ADP
njb-27	216	28	the	the	DET
njb-27	216	29	drug	drug	NOUN
njb-27	216	30	resistance	resistance	NOUN
njb-27	216	31	mutations	mutation	NOUN
njb-27	216	32	in	in	ADP
njb-27	216	33	hiv-1	hiv-1	SYM
njb-27	216	34	.	.	NUM
njb-27	216	35	topics	topic	NOUN
njb-27	216	36	in	in	ADP
njb-27	216	37	antiviral	antiviral	ADJ
njb-27	216	38	medicine	medicine	NOUN
njb-27	216	39	2014	2014	NUM
njb-27	216	40	,	,	PUNCT
njb-27	216	41	22(3	22(3	NUM
njb-27	216	42	):	):	PUNCT
njb-27	216	43	642650	642650	NUM
njb-27	216	44	.	.	PUNCT
njb-27	217	1	26	26	NUM
njb-27	217	2	.	.	PUNCT
njb-27	218	1	paredes	parede	VERB
njb-27	218	2	r	r	PROPN
njb-27	218	3	,	,	PUNCT
njb-27	218	4	marconi	marconi	PROPN
njb-27	218	5	vc	vc	PROPN
njb-27	218	6	,	,	PUNCT
njb-27	218	7	campbell	campbell	PROPN
njb-27	218	8	tb	tb	PROPN
njb-27	218	9	,	,	PUNCT
njb-27	218	10	kuritzkes	kuritzkes	PROPN
njb-27	218	11	dr	dr	PROPN
njb-27	218	12	:	:	PUNCT
njb-27	218	13	systematic	systematic	ADJ
njb-27	218	14	evaluation	evaluation	NOUN
njb-27	218	15	of	of	ADP
njb-27	218	16	allele	allele	PROPN
njb-27	218	17	-	-	PUNCT
njb-27	218	18	specific	specific	ADJ
njb-27	218	19	realtime	realtime	ADJ
njb-27	218	20	pcr	pcr	NOUN
njb-27	218	21	for	for	ADP
njb-27	218	22	the	the	DET
njb-27	218	23	detection	detection	NOUN
njb-27	218	24	of	of	ADP
njb-27	218	25	minor	minor	ADJ
njb-27	218	26	hiv-1	hiv-1	PUNCT
njb-27	218	27	variants	variant	NOUN
njb-27	218	28	with	with	ADP
njb-27	218	29	pol	pol	NOUN
njb-27	218	30	and	and	CCONJ
njb-27	218	31	env	env	NOUN
njb-27	218	32	resistance	resistance	NOUN
njb-27	218	33	mutations	mutation	NOUN
njb-27	218	34	.	.	PUNCT
njb-27	219	1	journal	journal	NOUN
njb-27	219	2	of	of	ADP
njb-27	219	3	virological	virological	ADJ
njb-27	219	4	methods	method	NOUN
njb-27	219	5	2007	2007	NUM
njb-27	219	6	,	,	PUNCT
njb-27	219	7	146(1	146(1	NUM
njb-27	219	8	-	-	SYM
njb-27	219	9	2	2	NUM
njb-27	219	10	):	):	PUNCT
njb-27	219	11	136	136	NUM
njb-27	219	12	-	-	SYM
njb-27	219	13	146	146	NUM
njb-27	219	14	.	.	NUM
njb-27	219	15	27	27	NUM
njb-27	219	16	.	.	PUNCT
njb-27	220	1	frater	frater	PROPN
njb-27	220	2	aj	aj	PROPN
njb-27	220	3	,	,	PUNCT
njb-27	220	4	dunn	dunn	PROPN
njb-27	220	5	dt	dt	PROPN
njb-27	220	6	,	,	PUNCT
njb-27	220	7	beardall	beardall	PROPN
njb-27	220	8	aj	aj	PROPN
njb-27	220	9	,	,	PUNCT
njb-27	220	10	ariyoshi	ariyoshi	PROPN
njb-27	220	11	k	k	PROPN
njb-27	220	12	,	,	PUNCT
njb-27	220	13	clarke	clarke	PROPN
njb-27	220	14	jr	jr	PROPN
njb-27	220	15	,	,	PUNCT
njb-27	220	16	mcclure	mcclure	PROPN
njb-27	220	17	mo	mo	PROPN
njb-27	220	18	,	,	PUNCT
njb-27	220	19	weber	weber	PROPN
njb-27	220	20	jn	jn	PROPN
njb-27	220	21	:	:	PUNCT
njb-27	220	22	comparative	comparative	ADJ
njb-27	220	23	response	response	NOUN
njb-27	220	24	of	of	ADP
njb-27	220	25	african	african	ADJ
njb-27	220	26	hiv-1	hiv-1	CCONJ
njb-27	220	27	-	-	PUNCT
njb-27	220	28	infected	infect	VERB
njb-27	220	29	individuals	individual	NOUN
njb-27	220	30	to	to	ADP
njb-27	220	31	highly	highly	ADV
njb-27	220	32	active	active	ADJ
njb-27	220	33	antiretroviral	antiretroviral	ADJ
njb-27	220	34	therapy	therapy	NOUN
njb-27	220	35	.	.	PUNCT
njb-27	221	1	aids	aids	PROPN
njb-27	221	2	2002	2002	NUM
njb-27	221	3	,	,	PUNCT
njb-27	221	4	16(8	16(8	NUM
njb-27	221	5	):	):	PUNCT
njb-27	221	6	1139	1139	NUM
njb-27	221	7	-	-	SYM
njb-27	221	8	1146	1146	NUM
njb-27	221	9	.	.	PUNCT
njb-27	222	1	28	28	NUM
njb-27	222	2	.	.	PUNCT
njb-27	223	1	delaunay	delaunay	PROPN
njb-27	223	2	c	c	PROPN
njb-27	223	3	,	,	PUNCT
njb-27	223	4	brun	brun	ADJ
njb-27	223	5	-	-	PUNCT
njb-27	223	6	vézinet	vézinet	PROPN
njb-27	223	7	f	f	PROPN
njb-27	223	8	,	,	PUNCT
njb-27	223	9	landman	landman	PROPN
njb-27	223	10	r	r	PROPN
njb-27	223	11	,	,	PUNCT
njb-27	223	12	collin	collin	PROPN
njb-27	223	13	g	g	NOUN
njb-27	223	14	,	,	PUNCT
njb-27	223	15	peytavin	peytavin	PROPN
njb-27	223	16	g	g	PROPN
njb-27	223	17	,	,	PUNCT
njb-27	223	18	trylesinski	trylesinski	VERB
njb-27	223	19	a	a	PRON
njb-27	223	20	,	,	PUNCT
njb-27	223	21	flandre	flandre	PROPN
njb-27	223	22	p	p	PROPN
njb-27	223	23	,	,	PUNCT
njb-27	223	24	miller	miller	PROPN
njb-27	223	25	m	m	PROPN
njb-27	223	26	,	,	PUNCT
njb-27	223	27	descamps	descamps	PROPN
njb-27	223	28	d	d	PROPN
njb-27	223	29	:	:	PUNCT
njb-27	223	30	comparative	comparative	ADJ
njb-27	223	31	selection	selection	NOUN
njb-27	223	32	of	of	ADP
njb-27	223	33	the	the	DET
njb-27	223	34	k65r	k65r	NOUN
njb-27	223	35	and	and	CCONJ
njb-27	223	36	m184v	m184v	PROPN
njb-27	223	37	/	/	SYM
njb-27	223	38	i	i	PRON
njb-27	223	39	mutations	mutation	NOUN
njb-27	223	40	in	in	ADP
njb-27	223	41	human	human	ADJ
njb-27	223	42	immunodeficiency	immunodeficiency	NOUN
njb-27	223	43	virus	virus	NOUN
njb-27	223	44	type	type	NOUN
njb-27	223	45	1	1	NUM
njb-27	223	46	-	-	PUNCT
njb-27	223	47	infected	infect	VERB
njb-27	223	48	patients	patient	NOUN
njb-27	223	49	enrolled	enrol	VERB
njb-27	223	50	in	in	ADP
njb-27	223	51	a	a	DET
njb-27	223	52	trial	trial	NOUN
njb-27	223	53	of	of	ADP
njb-27	223	54	first	first	ADJ
njb-27	223	55	-	-	PUNCT
njb-27	223	56	line	line	NOUN
njb-27	223	57	triplenucleoside	triplenucleoside	NOUN
njb-27	223	58	analog	analog	NOUN
njb-27	223	59	therapy	therapy	NOUN
njb-27	223	60	(	(	PUNCT
njb-27	223	61	tonus	tonus	NOUN
njb-27	223	62	imea	imea	PROPN
njb-27	223	63	021	021	NUM
njb-27	223	64	)	)	PUNCT
njb-27	223	65	.	.	PUNCT
njb-27	224	1	journal	journal	NOUN
njb-27	224	2	of	of	ADP
njb-27	224	3	virology	virology	NOUN
njb-27	224	4	2005	2005	NUM
njb-27	224	5	,	,	PUNCT
njb-27	224	6	79:9572	79:9572	NUM
njb-27	224	7	-	-	PUNCT
njb-27	224	8	9578	9578	NUM
njb-27	224	9	.	.	PUNCT
njb-27	224	10	29	29	NUM
njb-27	224	11	.	.	PUNCT
njb-27	225	1	hira	hira	PROPN
njb-27	225	2	sk	sk	PROPN
njb-27	225	3	,	,	PUNCT
njb-27	225	4	panchal	panchal	PROPN
njb-27	225	5	k	k	PROPN
njb-27	225	6	,	,	PUNCT
njb-27	225	7	parmar	parmar	PROPN
njb-27	225	8	pa	pa	PROPN
njb-27	225	9	,	,	PUNCT
njb-27	225	10	bhatia	bhatia	PROPN
njb-27	225	11	vp	vp	PROPN
njb-27	225	12	:	:	PUNCT
njb-27	225	13	high	high	ADJ
njb-27	225	14	resistance	resistance	NOUN
njb-27	225	15	to	to	ADP
njb-27	225	16	antiretroviral	antiretroviral	ADJ
njb-27	225	17	drugs	drug	NOUN
njb-27	225	18	:	:	PUNCT
njb-27	225	19	the	the	DET
njb-27	225	20	indian	indian	ADJ
njb-27	225	21	experience	experience	NOUN
njb-27	225	22	.	.	PUNCT
njb-27	226	1	international	international	ADJ
njb-27	226	2	journal	journal	PROPN
njb-27	226	3	of	of	ADP
njb-27	226	4	std	std	PROPN
njb-27	226	5	&	&	CCONJ
njb-27	226	6	aids	aids	PROPN
njb-27	226	7	2004	2004	NUM
njb-27	226	8	,	,	PUNCT
njb-27	226	9	15(3	15(3	NUM
njb-27	226	10	):	):	PUNCT
njb-27	226	11	173	173	NUM
njb-27	226	12	-	-	SYM
njb-27	226	13	177	177	NUM
njb-27	226	14	.	.	NUM
njb-27	226	15	30	30	NUM
njb-27	226	16	.	.	PUNCT
njb-27	227	1	sen	sen	PROPN
njb-27	227	2	s	s	PROPN
njb-27	227	3	,	,	PUNCT
njb-27	227	4	tripathy	tripathy	PROPN
njb-27	227	5	sp	sp	PROPN
njb-27	227	6	,	,	PUNCT
njb-27	227	7	patil	patil	PROPN
njb-27	227	8	aa	aa	PROPN
njb-27	227	9	,	,	PUNCT
njb-27	227	10	chimanpure	chimanpure	PROPN
njb-27	227	11	vm	vm	PROPN
njb-27	227	12	,	,	PUNCT
njb-27	227	13	paranjape	paranjape	NOUN
njb-27	227	14	rs	rs	PROPN
njb-27	227	15	:	:	PUNCT
njb-27	227	16	high	high	ADJ
njb-27	227	17	prevalence	prevalence	NOUN
njb-27	227	18	of	of	ADP
njb-27	227	19	human	human	ADJ
njb-27	227	20	immunodeficiency	immunodeficiency	NOUN
njb-27	227	21	virus	virus	NOUN
njb-27	227	22	type	type	NOUN
njb-27	227	23	1	1	NUM
njb-27	227	24	drug	drug	NOUN
njb-27	227	25	resistance	resistance	NOUN
njb-27	227	26	mutations	mutation	NOUN
njb-27	227	27	in	in	ADP
njb-27	227	28	antiretroviral	antiretroviral	ADJ
njb-27	227	29	treatmentexperienced	treatmentexperience	VERB
njb-27	227	30	patients	patient	NOUN
njb-27	227	31	from	from	ADP
njb-27	227	32	pune	pune	PROPN
njb-27	227	33	,	,	PUNCT
njb-27	227	34	india	india	PROPN
njb-27	227	35	.	.	PUNCT
njb-27	228	1	aids	aids	PROPN
njb-27	228	2	research	research	NOUN
njb-27	228	3	and	and	CCONJ
njb-27	228	4	human	human	ADJ
njb-27	228	5	retroviruses	retrovirus	NOUN
njb-27	228	6	2007	2007	NUM
njb-27	228	7	,	,	PUNCT
njb-27	228	8	23(10	23(10	NUM
njb-27	228	9	):	):	PUNCT
njb-27	228	10	13031308	13031308	NUM
njb-27	228	11	.	.	PUNCT
njb-27	229	1	31	31	NUM
njb-27	229	2	.	.	PUNCT
njb-27	229	3	zaccarelli	zaccarelli	PROPN
njb-27	229	4	m	m	PROPN
njb-27	229	5	,	,	PUNCT
njb-27	229	6	perno	perno	NOUN
njb-27	229	7	cf	cf	INTJ
njb-27	229	8	,	,	PUNCT
njb-27	229	9	forbici	forbici	PROPN
njb-27	229	10	f	f	PROPN
njb-27	229	11	,	,	PUNCT
njb-27	229	12	cingolani	cingolani	PROPN
njb-27	229	13	a	a	PROPN
njb-27	229	14	,	,	PUNCT
njb-27	229	15	liuzzi	liuzzi	PROPN
njb-27	229	16	g	g	PROPN
njb-27	229	17	,	,	PUNCT
njb-27	229	18	bertoli	bertoli	PROPN
njb-27	229	19	a	a	PROPN
njb-27	229	20	,	,	PUNCT
njb-27	229	21	trotta	trotta	PROPN
njb-27	229	22	mp	mp	PROPN
njb-27	229	23	,	,	PUNCT
njb-27	229	24	bellocchi	bellocchi	PROPN
njb-27	229	25	mc	mc	PROPN
njb-27	229	26	,	,	PUNCT
njb-27	229	27	di	di	PROPN
njb-27	229	28	giambenedetto	giambenedetto	PROPN
njb-27	229	29	s	s	PROPN
njb-27	229	30	,	,	PUNCT
njb-27	229	31	tozzi	tozzi	PROPN
njb-27	229	32	v	v	PROPN
njb-27	229	33	,	,	PUNCT
njb-27	229	34	gori	gori	PROPN
njb-27	229	35	c	c	PROPN
njb-27	229	36	,	,	PUNCT
njb-27	229	37	d'arrigo	d'arrigo	PROPN
njb-27	229	38	r	r	PROPN
njb-27	229	39	,	,	PUNCT
njb-27	229	40	de	de	PROPN
njb-27	229	41	longis	longis	PROPN
njb-27	229	42	p	p	PROPN
njb-27	229	43	,	,	PUNCT
njb-27	229	44	noto	noto	PROPN
njb-27	229	45	p	p	PROPN
njb-27	229	46	,	,	PUNCT
njb-27	229	47	girardi	girardi	PROPN
njb-27	229	48	e	e	PROPN
njb-27	229	49	,	,	PUNCT
njb-27	229	50	de	de	PROPN
njb-27	229	51	luca	luca	PROPN
njb-27	229	52	a	a	PROPN
njb-27	229	53	,	,	PUNCT
njb-27	229	54	antinori	antinori	NOUN
njb-27	229	55	a	a	PRON
njb-27	229	56	:	:	PUNCT
njb-27	229	57	using	use	VERB
njb-27	229	58	a	a	DET
njb-27	229	59	database	database	NOUN
njb-27	229	60	of	of	ADP
njb-27	229	61	hiv	hiv	PROPN
njb-27	229	62	patients	patient	NOUN
njb-27	229	63	undergoing	undergo	VERB
njb-27	229	64	genotypic	genotypic	NOUN
njb-27	229	65	resistance	resistance	NOUN
njb-27	229	66	test	test	NOUN
njb-27	229	67	after	after	SCONJ
njb-27	229	68	haart	haart	PROPN
njb-27	229	69	failure	failure	NOUN
njb-27	229	70	to	to	PART
njb-27	229	71	understand	understand	VERB
njb-27	229	72	the	the	DET
njb-27	229	73	dynamics	dynamic	NOUN
njb-27	229	74	of	of	ADP
njb-27	229	75	m184v	m184v	ADJ
njb-27	229	76	mutation	mutation	NOUN
njb-27	229	77	.	.	PUNCT
njb-27	230	1	antiviral	antiviral	ADJ
njb-27	230	2	therapy	therapy	PROPN
njb-27	230	3	2003	2003	NUM
njb-27	230	4	,	,	PUNCT
njb-27	230	5	8(1	8(1	NUM
njb-27	230	6	):	):	PUNCT
njb-27	230	7	51	51	NUM
njb-27	230	8	-	-	SYM
njb-27	230	9	56	56	NUM
njb-27	230	10	.	.	PUNCT